Reactivities of biologically active small molecules: Kinetic assessment of electrophilic enones and characterization of a photoactive phosphoantigen probe by Enzinger, Monika
Reactivities of biologically active small molecules:                             
Kinetic assessment of electrophilic enones and characterization of 
a photoactive phosphoantigen probe 
 
 
Zur Erlangung des 
DOKTORGRADES DER NATURWISSENSCHAFTEN 
(Dr. rer. nat.) 
der Fakultät für Chemie und Pharmazie  
der Universität Regensburg 
 
DISSERTATION 
vorgelegt von Monika Enzinger 
aus Regensburg 
Mai 2019 
  
 
II 
Die vorliegende Arbeit wurde unter der Leitung von PD Dr. Sabine Amslinger in der Zeit von 
November 2014 bis April 2019 angefertigt. 
Promotionsgesuch eingereicht am: 03.05.2019 
 
  
 
III 
Eidesstattliche Erklärung 
 
Ich erkläre hiermit an Eides statt, dass ich die vorliegende Arbeit ohne unzulässige Hilfe 
Dritter und ohne Benutzung anderer als der angegebenen Hilfsmittel angefertigt habe. Die 
aus anderen Quellen direkt oder indirekt übernommenen Daten und Konzepte sind unter 
Angabe des Literaturzitats gekennzeichnet. 
 
 
 
__________________________________ 
Monika Enzinger 
  
 
IV 
Content 
ABBREVIATIONS VI 
A ELECTROPHILES OF THE ENONE-TYPE AND THE INVESTIGATION OF THEIR 
REACTIVITY AND BIOLOGICAL ACTIVITY 1 
A 1 Introduction 1 
A 1.1 Signal transduction pathways and their role in inflammation 1 
A 1.2 Enones as electrophilic, covalently binding inflammation mediators 3 
A 1.3 In-vitro cell assays to determine the toxicity and anti-inflammatory activity of compounds 6 
A 1.4 General methodological access to kinetic measurements for the determination of the reactivity 
of compounds 8 
A 1.5 The Kinetic Thiol Assay for electrophiles and its application in the determination of the reactivity 
of chalcone derivatives 10 
A 1.6 α-X-Hydroxychalcones (α-X-HCs) 14 
A 1.7 Synthesis of oxadiazoline enones (OXEs): a library of new electrophilic substances with an enone 
unit 16 
A 1.8 Synthesis of further electrophiles in the Amslinger work group 22 
A 1.9 Further development of the kinetic thiol assay towards the investigation of colorless 
electrophiles 25 
A 1.10    Aim of the present work 29 
A 2 Results and Discussion I: Synthesis, kinetic and biological evaluation of oxadiazoline enones 
(OXEs): a library of new anti-inflammatory electrophilic compounds 31 
A 2.1 Synthesis 32 
A 2.2 UV-Vis spectral properties of OXEs and OXE analogues 37 
A 2.3 Kinetic evaluation of OXE and OXE analogues 40 
A 2.4 Biological evaluation of the OXE and OXE analogues substance library 56 
A 3 Results and Discussion II: Reactivity assessment of further electrophiles by the kinetic thiol assay
 63 
A 3.1 Reactivity modification of phenylacrylamide derivatives as reactive units in drug development 63 
A 3.2 Juglone and juglone derivatives and their reactivity towards cysteamine 66 
A 3.3 α-Nitro-hydroxychalcone (α-NO2-HC) as part of the α-X-hydroxychalcone (α-X-HC) substance 
library 75 
A 4 Results and Discussion III: Investigations for a further development of the kinetic thiol assay 
towards the use of colorless enones as test substances 79 
A 4.1 Syntheses 79 
A 4.2 Fluorescence investigations of Michael addition reactions 85 
A 5 Summary of Chapter A 88 
A 6 Experimental 90 
 
V 
A 6.1 General synthesis information 90 
A 6.2 Syntheses of OXEs, OXE analogues and their precursors 90 
A 6.3 Synthesis of NO2-flavanone and precursors 99 
A 6.4 Synthesis of fluorescent aromatic thiol dyes 102 
A 6.5 Kinetic evaluation of electrophiles 108 
A 6.6 In-vitro cell assays 111 
B CHARACTERIZATION OF A NEW PHOTOACTIVE PROTEIN PROBE FOR THE 
LABELING OF BTN3A4 113 
B 1 Introduction 113 
B 1.1 The immune modulator role of HMBPP 113 
B 1.2 BioBP-HMBPP as a new photoactive protein probe for the labeling of BTN3A4 115 
B 1.3 Aim of this work 116 
B 2 Results and Discussion 117 
B 2.1 Photochemical and UV-Vis evaluation, handling of proteins and probe solutions 117 
B 2.2 Stimulation of γδ T cells by BioBP-HMBPP (103) 120 
B 2.3 Labeling of the B30.2 domain of the protein BTN3A1 by BioBP-HMBPP (103) in the absence and 
presence of HMBPP (102) 123 
B 2.4 Labeling of a BTN3A1-B30.2 charge transfer mutant 128 
B 2.5 Determination of labeling efficiency by BioBP-HMBPP 129 
B 3 Summary of Chapter B 130 
B 4 Experimental 131 
B 4.1 General information 131 
B 4.2 Photochemical labeling of proteins with BioBP-HMBPP and Western Blot analysis of biotinylated 
proteins 131 
C LITERATURE 133 
D APPENDIX 139 
D 1 NMR spectra of synthesized compounds 139 
D 2 Pre-kinetic UV-Vis spectra of OXEs 162 
D 3 Additional figures for the kinetic evaluation of OXEs and OXE analogues 167 
D 4 LC-MS data of juglone derivatives in kinetic assay buffer 177 
D 5 Additional figures for protein labeling experiments 190 
D 6 PhD thesis figures Fehler! Textmarke nicht definiert. 
  
VI 
Abbreviations 
15d-PGJ2    15-Deoxy-Δ12,14-prostaglandine J2 
A     Absorbance 
α-X-TMC    α-X-Substituted 2’,3,4’,4-tetramethoxychalcones 
α-X-HC    α-X-Substituted 2’-hydroxy, 3,4’,4-trimethoxychalcones 
B30.2    Domain of the protein BTN3A1 
BioBP-HMBPP    Biotin-Benzophenone-HMBPP 
BP-HMBPP    (E)-4-((4-Benzoyl-benzoyl)oxy)-3-methylbut-2-en-1-yl  
      diphosphate, Benzo-Phenone-HMBPP 
BSA     Bovine serum albumin 
BTN3A1     Butyrophilin 3A1 
CPS      Counts per second 
c     Concentration [mol/l], [M] 
CD69    Cluster of differentiation 69 
CDCl3    Deuterated chloroform 
COX-2    Cyclooxygenase 2 
CuI3    Cullin 3 
δ     Chemical shift 
DCM    Dichloromethane 
DCY    Dansyl cysteamine 
DCYA    Dansyl cysteamine assay 
DIPEA    Diisopropylethylamine 
DMAPP    Dimethylallyl diphosphate (formerly: pyrophosphate) 
DMF    Dimethylformamide 
DMSO/DMSO-d6    Dimethyl sulfoxide/deuterated dimethyl sulfoxide 
DOXP    1-Deoxy-D-xylulose 5-phosphate 
E     Electrophile 
EC50    Effective concentration 
EGFR    Epidermal growth factor receptor 
EDTA    Ethylendiamintetraacetic acid 
EG     Ethylene glycol 
EGF    Epidermal growth factor 
EI-MS    Electron impact mass spectrometry 
ESI-MS    Electronspray ionization mass spectrometry 
EtOAc    Ethyl acetate 
EtOH    Ethanol 
eq.     Equivalents 
  
VII 
FITR    Fourier-transform infrared spectroscopy 
FPPS    Farnesyl diphosphate synthase 
GSH    Glutathione 
HEPES    4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid 
HMBPP    (E)-4-Hydroxy-3-methylbut-2-enyl diphosphate 
HO-1    Heme oxygenase 1 
HOAc    Acetic acid 
HRPO    Horseradish peroxidase 
HTS     High throughput screening 
HV     High vacuum 
Hz     Hertz 
IκBα    Inhibitory κB-protein α 
IC50/IC20    Inhibitory concentration  
IKK     Inhibitory κB-protein kinase 
IL     Interleukin 
iNOS    Inducible NO-Synthase 
IPP     Isopentenyl diphosphate 
IR     Infrared 
k     Reaction rate constant 
Keap1    Kelch-like ECH-associated protein 1 
λ     Wavelength  
LC-MS    Liquid chromatography Mass spectrometry 
LPS     Lipopolysaccharide 
LR-MS    Low-resolution Mass spectrometry 
M     Molar mass [g/mol] 
[value] M    Concentration [mol/l] 
m/z     Mass per charge number 
mCPBA    Metachloroperbenzoic acid 
Me     Methyl 
MeO    Methoxy 
MeOH    Methanol 
MS     Mass spectrometry 
MSTI    (E)-2-(4-Mercaptostyryl)-1,3,3-trimethyl-3H-indol-1-ium 
     iodide  
MTT    3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  
     bromide 
NBD    7-Nitrobenzo[c][1,2,5]-oxadiazol-4-thiol 
n-BuLi    n-Buthyllithium 
  
VIII 
NED    N-(1-Naphthyl)ethylenediamine 
NF-κB    Nuclear factor kappa-light-chain-enhancer of activated B  
     cells 
nm     Nanometer 
NMR    Nuclear magnetic resonance-spectroscopy 
Nrf2    Nuclear factor-erythroid-2-related factor 
NOS    NO-synthase 
OXAc    Acyl-substituted oxadiazoline 
OXCE    Oxadiazoline cyclohexane enone 
OXE    Oxadiazoline enone 
OXEp    Oxadiazoline epoxide 
OXTE    Oxadiazol thioester 
PAg     Phosphoantigen 
PBMCs    Peripheral blood mononuclear cells 
PBS     Phosphate-buffered saline 
p-BZ-C-C5-OPP    (E)-4-((4-Benzoyl-benzoyl)oxy)-3-methylbut-2-en-1-yl  
     diphosphate 
Ponceau S    3-Hydroxy-4-(2-sulfo-4-[4-sulfophenylazo]phenylazo)-2,7- 
     naphthalenedisulfonic acid sodium salt 
PP     Diphosphate 
ppm    Parts per million 
PVDF    Polyvinylidene difluoride 
Rf     Retention factor 
RPMI medium    Roswell Park Memorial Institute medium 
rt     Room temperature 
SD     Standard deviation 
SDS-PAGE    Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
T cell    Thymus-derived lymphocyte 
TBS-T    Tris-buffered saline with 0.1% Tween 
TCR     T cell receptor 
TFA     Trifluoroacetic acid 
TLC     Thin layer chromatography 
TMC    Tetramethoxychalcone 
TNF    Tumor necrosis factor 
Tris-HCl    Tris(hydroxymethyl)aminomethane 
UV-VIS    Ultraviolet-visible-light-spectroscopy 
v     Reaction rate 
Electrophiles of the enone-type and the investigation of their reactivity and biological activity 
1 
A Electrophiles of the enone-type and the investigation of 
their reactivity and biological activity 
A 1 Introduction 
A 1.1 Signal transduction pathways and their role in inflammation 
The biochemical reaction of organisms to external stimuli of all kinds is controlled by a 
complex signal transduction network in which biomolecules interact extra- and intracellu-
larly. If a cell is activated from the outside by the binding of a signal molecule to a mem-
brane receptor, this is the beginning of a multitude of possible intracellular information 
transmission pathways. Numerous proteins regulate gene expression and subsequent pro-
duction of proteins and enzymes via signaling cascades (Figure 1). 
 
Figure 1: Principle of intracellular signal cascades under the influence of external stimuli. 
Inflammation is a well-studied biochemical process as it is the cause and/or symptom of 
many diseases. Various signal transduction pathways have been identified as mechanisms 
for the development of inflammation, for example the NF-κB pathway. NF-κB (nuclear fac-
tor kappa-B) is a transcription factor that, when bound to its target structures on the DNA, 
triggers the biosynthesis of pro-inflammatory proteins[1] such as TNF (tumor necrosis fac-
tors), COX-2 (cyclooxygenase 2) and iNOS (inducible nitrite oxide synthase). In the cytosol, 
NF-κB is present in its inactive form, bound to the inhibitor protein IκBα (inhibitory κB pro-
tein α). External stimuli activate protein kinases such as IKK (inhibitory κB protein kinase) 
that phosphorylate the inhibitor protein, which leads to its ubiquitination and degradation 
and activates NF-κB by release (Figure 2).[2] 
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Figure 2: Schematic mechanism of the NF-κB signal transduction pathway. NF-κB: nuclear factor kappa B, IKK: 
IκB kinase, IκBα: kappa-B inhibitor, Ub-Ub-Ub: ubiquitination, iNOS: inducible NO synthase. 
One of the pro-inflammatory enzymes produced by the influence of NF-κB is iNOS. This 
enzyme is one of three NOS isoforms, heme dioxygenases that cause the conversion of L-
arginine to citrulline and the gaseous signaling molecule nitric oxide, NO[3] (see Scheme 
1A). NO in general has multiple functions in the human body, depending on its concentra-
tion and the tissue of release. For example, in the nerval system and in endothelia it is 
synthesized by nNOS (neuronal NOS) and eNOS (endothelial NOS), respectively, and acts as 
a neurotransmitter, causing for example vaso- and bronchodilatation in the latter. These 
functions are regulated in such way that NO is present in low concentrations and its activity 
is short-lasting.[4] 
However, this is different in iNOS-containing cells. INOS is found in the cytosol of macro-
phages[5] in a basic amount, but its synthesis is up-regulated by external stimuli such as 
bacterial lipopolysaccharides (LPS) or pro-inflammatory cytokines (e.g. TNF and interleu-
kins, ILs) in inflamed tissues, tumor tissue or by microbial infections via the NF-κB pathway 
as described in Figure 2. Here, NO acts as an important mediator of inflammation and un-
specific immune response by different mechanisms of action, depending on its chemical 
form, summarized in Scheme 1B.[4] NO can directly act as ligand to metal ions in cofactors, 
such as iron in heme proteins, and coordination leads to increased activation or inhibition 
of those enzymes. Furthermore, NO is oxidized by oxygen O2 to NO+, the nitrosyl cation, 
which is able to react with nucleophiles in amino acid residues of enzymes, transcription 
factors and ion channels. In fact this leads to the nitrosylation of cysteine thiols, which 
modifies the activity of these proteins.[6] Then, NO reacts also very quickly with the super-
oxide radical anion O2-, which leads to the formation of ONOO-, peroxonitrite. This high-
potency cellular toxin performs nitration and oxidation in biomolecules, leading to protein 
de-functionalization, DNA damage and strand breaks[7] or peroxidation of lipids[8] and caus-
ing overall necrosis and apoptosis.[9] 
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Scheme 1: A: Biosynthesis of NO by iNOS; B: effects of NO towards biomolecules in immune response and as 
a trigger of inflammation. 
Based on these descriptions, one can imagine that, despite the positive role of NO in the 
fight against infections and tumors, uncontrolled overexpression of iNOS and subsequent 
increased NO synthesis also damages healthy cells, leading to several diseases described as 
NO-induced via the NF-κB pathway.[10] [11] Asthma, arthritis and various forms of bowel dis-
eases (intestinal inflammation) are amongst them. These pathological mechanisms raise 
the question which biochemical measures can be taken to intervene in the development of 
inflammation. If these biochemical connections are known, the course of associated dis-
eases can be influenced. 
A 1.2 Enones as electrophilic, covalently binding inflammation mediators 
For pharmacologically active substances it is possible to intervene at certain points of signal 
transduction by covalent or non-covalent binding. If these biologically active compounds 
are electrophiles, covalent binding plays a particularly important role as they can react with 
biomolecular nucleophiles. These interactions can for example influence the activity of pro-
teins in general and enzymes in particular, leading to a positive influence on many diseases. 
This has been well investigated and proven for a large number of biologically active elec-
trophilic natural compounds of various chemical structures and target proteins.[12] 
Cysteine residues on the surface of proteins are an important target. The nucleophilic prop-
erties of their terminal thiol group (sulfhydryl group) enable them to form covalent bonds 
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with electrophilic compounds. Organic molecules that have a carbonyl function in the im-
mediate vicinity of a carbon-carbon double bond (α,β-unsaturated carbonyl function) are 
such electrophiles and are called enones or Michael acceptors. Depending on their reactiv-
ity, they can react on their electrophilic β-position with thiol groups in a Michael addition[13] 
(Scheme 2), the organic reaction type first described by Arthur Michael.[14] 
 
Scheme 2: Michael addition of a pharmacologically active α,β-unsaturated carbonyl compound (enone, Mi-
chael acceptor) to the thiol group of a cysteine in a protein. 
Enones can be divided into different substance classes due to their different structure 
and/or function.[12, 15] Some natural products are given as examples in Figure 3. 
 
Figure 3: Examples of natural products with α,β-unsaturated carbonyl function.[12, 15] 
In the literature, anti-inflammatory, antimicrobial, neuroprotective and antiproliferative 
properties based on their Michael acceptor activity are described for some of these com-
pounds.[13, 15-16] However, depending on their structure, other chemical properties of the 
substances, radical scavenging properties, isomerization at the double bond or oxidation 
and reduction can also be the reason for their biological activity.[13] 
The mechanism of the anti-inflammatory effect of electrophiles and enones in particular 
by reacting with surface thiols of proteins can be explained by two major signaling path-
ways. On the one hand, they can inhibit the NF-κB signal transduction pathway at multiple 
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points. As shown in Figure 4A, enones can react with surface thiols of IKK, IκBα or NF-κB 
itself. This causes protein alkylation, which inactivates them. Thus, the transcription of pro-
inflammatory genes is inhibited by direct deactivation or prevention of activation of NF-
κB.[2] Some natural products such as polyphenols and terpenes are NF-κB inhibitors,[17] for 
example curcumin (1, Figure 3) from Curcuma longa, CAPE (6) from Apis mellifera or gallo-
catechins from Camellia sinensis, just to name a few. On the other hand, enone electro-
philes can trigger the synthesis of anti-inflammatory enzymes by activating the Nrf2 path-
way (Figure 4B). Nrf2 (nuclear factor-erythroid-2-related factor) is a transcription factor, 
which is inactive by the binding to a complex of the two inhibitor proteins Keap1 (Kelch-
like ECH-associated protein 1) and CuI3 (cullin 3). More precisely, Keap1 and Cul3 binding 
leads to ubiquitination and degradation of Nrf2. If cysteines of Keap1 are oxidized to disul-
fides or alkylated by electrophiles, Nrf2 is released and activated.[18] By binding to its DNA 
targets, Nrf2 triggers an increased synthesis of anti-inflammatory proteins, including heme 
oxygenase 1 (HO-1).[19] Various enones have been described to inactivate Keap1 by Michael 
addition on surface thiols.[20] 
 
Figure 4: Mechanisms of the anti-inflammatory activity of α,β-unsaturated carbonyl compounds. A: Inhibition 
of the NF-κB pathway. E: enone, NF-κB: nuclear factor kappa B, IKK: IκB kinase, IκBα: kappa B inhibitor. B: 
Mechanism of the Keap1-Nrf2 signal transduction pathway. E: enone, Keap1: Kelch-like ECH-associated pro-
tein 1, CuI3: cullin 3, Nrf2: nuclear factor-erythoid-2-related factor 2, HO-1: heme oxygenase 1. 
Thus, all natural substances, but also synthetically altered derivatives and completely syn-
thetically produced substances with α,β-unsaturated carbonyl functions possess the po-
tential to have an anti-inflammatory effect. However, in the search for new drugs from 
nature or in synthetic drug development, the therapeutic index (or ratio) that describes the 
relationship between efficiency and toxicity must always be taken into account. Electro-
philic active substances in particular are known for causing toxicity besides their pharma-
cological potency.[21] This is due to their more or less high reactivity at the electrophilic site, 
with which they can also bind to non-target biomolecules in a non-specific way. As a coun-
termeasure, cells have developed detoxification systems that can mitigate or eliminate 
toxic effects of highly reactive substances. Electrophiles in particular can react with the 
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cellular detoxification agent glutathione (GSH, 7, Scheme 3), which is intracellularly present 
in high concentration (1-10 mM[22]). GSH is a tripeptide with a cysteine thiol functionality 
that is reactive towards electrophilic carbons of cell toxins.[23] 
 
Scheme 3: Structure of glutathione (7) and its reaction with electrophiles (E). 
In order to face the problem of the right balance between activity and toxicity, synthetic-
organic drug research often uses substance libraries, which are identical in essential struc-
tural elements, but whose properties can be modulated by further building blocks and/or 
substituents of different kinds. Since the intensity of the biological effect also depends on 
the reactivity of enones at the β-position of their double bond, reactivity and reaction rate 
play an important role in these investigations. By combining a pharmacologically active 
core structure with reactivity-varying substituents and building blocks, it is possible to fine-
tune the reactivity and therefore also influence biological activity and selectivity. Further-
more, determining the reactivity of new electrophiles can be a tool in the search for new 
potential pharmacological agents. 
A 1.3 In-vitro cell assays to determine the toxicity and anti-inflammatory 
activity of compounds 
Cell viability 
The standard procedure performed in in-vitro assays is the following: first, the cell toxicity 
of substances has to be evaluated in a cell viability assay. Toxicity is characterized by IC 
values (inhibitory concentration) expressing the percentage of non-surviving cells after in-
cubation with the corresponding concentration of the test compound. Most important are 
the IC50, which is the general value for the toxicity of the test substance, and the IC20, the 
so-called toxicity limit. With >80% cell survival rate, the latter concentrations of test com-
pounds are generally considered as non-toxic for the specific cell line and are used in fol-
low-up activity assays. In this work, the so-called MTT cell viability assay[24] was performed 
to determine the toxicity of substances. This is a quantitative, colorimetric assay in 96 well 
plate format, which was performed on the murine macrophages cell line RAW264.7. After 
the incubation of cells together with the test compounds at physiological conditions, MTT 
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(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide, 8) is added. Only living cells 
with active metabolism are able to reduce this yellow tetrazolium salt to the purple form-
azan dye 9 (Scheme 4). The absorbance of 9 can be measured by UV-Vis spectroscopy at 
560 nm and is a direct measure for the percentage of surviving cells. 
 
Scheme 4: Colorimetric reaction of MTT (8) to the formazan dye 9 in the MTT cell viability assay. 
Anti-inflammatory activity 
After non-toxic concentrations are determined, the main activity assay can be performed. 
In this work, the anti-inflammatory activity of the test substances is determined by their 
ability to suppress the NO synthesis caused by an iNOS up-regulation as described in chap-
ter A 1.1. Murine RAW264.7 macrophages are used due to their ability to synthesize iNOS. 
LPS is added to induce inflammation in the cells, which are incubated together with the test 
compounds. The resulting NO, quickly transformed into NO2- (Scheme 1), is detected in the 
cell culture medium by the colorimetric Griess reaction (Scheme 5). 
 
Scheme 5: Colorimetric reaction in the iNOS assay to detect NO via diazotation and coupling to a diazo dye. 
Under acidic conditions, sulfanilamide (10) reacts with NO2- by diazotation to the diazonium 
cation 11, then couples to N-(1-naphthyl)ethylenediamine (12), which forms the pink azo 
dye 13. The absorbance measured at 560 nm is inversely proportional to the inhibition of 
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NO production and is compared to those of cells in absence of the test compound. A high 
ability to inhibit NO production is thus associated with anti-inflammatory properties.[25] 
A 1.4 General methodological access to kinetic measurements for the 
determination of the reactivity of compounds  
In chemical reactions, the reaction order describes the type and number of individual mol-
ecules that react with each other to form a certain number of product molecules. The re-
action rate of the bimolecular reaction  
𝐸𝑛𝑜𝑛𝑒 + 𝑇ℎ𝑖𝑜𝑙 ⇌ 𝑀𝑖𝑐ℎ𝑎𝑒𝑙 − 𝑎𝑑𝑑𝑢𝑐𝑡 
depends linearly on the concentration of the two educts enone and thiol, which each con-
tribute to the reaction with first order. Thus, the reaction follows a second order kinetics. 
Since the data for these mathematical thermae are difficult to access experimentally, ki-
netics research often uses the simplification of pseudo-first order kinetics. The principle is 
the presence of one reaction component in excess so that its concentration does not 
change significantly during reaction. The reaction rate still depends on the concentrations 
of both reaction partners, but the concentration of the excess component can be neglected 
mathematically. Experimental data of pseudo-first order reactions can be mathematically 
treated like those of first order reactions. In experiments, the time-dependent concentra-
tion change of the reaction participant in the low concentration is measured by monitoring 
the change of analytical properties, for example pressure, conductivity or spectroscopic 
parameters. The parameter used for the characterization of the reactivity, the reaction rate 
constant k, can be determined from a first order reaction with the rate law equation ( 1 ), 
where v is the reaction rate and k is the reaction rate constant. If ( 1 ) is resolved, an expo-
nential function ( 2 ) is obtained with c(A) being the low-concentration starting material 
and c(A0) its initial concentration. 
 𝑣 = −
𝑑𝑐(𝐴)
𝑑𝑡
= 𝑘 ∗ 𝑐(𝐴) ( 1 ) 
 𝑐(𝐴) = 𝑐(𝐴0) ∗ 𝑒
−𝑘𝑡 ( 2 ) 
After the adjusting of the reaction equilibrium, k is obtained from the slope of ( 2 ) after 
linearization or by a curve fit of ( 2 ) with function ( 3 ) alternatively. 
 𝐴𝑡 = 𝐴0 − 𝑒
−𝑘𝑜𝑏𝑠𝑡+𝑐 ( 3 ) 
In the Arrhenius equation ( 4 ) 
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 𝑘 = 𝐴 ∗ 𝑒−𝐸𝑎∗𝑅𝑇 ( 4 ) 
it becomes clear that k depends on the temperature. Therefore, in kinetic experiments, the 
temperature must always be taken into account and specified. Usually 25 °C is used. 
There are numerous reported measurement methods to get access to the reactivity of com-
pounds. A non-quantitative NMR assay was published in 2011 to identify which natural 
products with enone functionality are Michael acceptors towards cysteamine in DMSO-d6 
by observing the enone signals in the 1H NMR spectrum.[26] Also, considering that thia-Mi-
chael additions require polar solvents, reversibility of those reactions could be investigated 
with a 1:20 dilution in CDCl3. Another work group used LC-MS and NMR measurements to 
follow the reaction of various electrophiles, including enamides, towards glutathione 7 
(Scheme 3) under pseudo-first order conditions.[27] Based on the time-dependent data, the 
kinetic rate constants kpseudo-1 were calculated and compared. A similar LC-MS method was 
developed to investigate the structure-activity-reactivity relationship of new covalent 
EGFR-2 inhibitors.[28] These methods are technically relatively complex, more or less expen-
sive and not available in every work group as they require highly developed devices. How-
ever, simple and fast methods that use spectroscopic measurements are also available.  
For example, the amount of the unreacted thiol of the Michael reaction can be indirectly 
determined by adding Ellman’s reagent (14) (5,5’-dithiobis-2-nitrobenzoic acid). Since the 
late 1950s, this method has been used for the determination of low amounts of thiols in 
biochemical solutions.[29] Reagent 14 forms a mixed disulfide 15 with free or unreacted thi-
ols R-SH, respectively, releasing 16 which is present as an anion in buffers with a pH > 7 
(Scheme 6). The absorbance of 16 can be read out at 412 nm and is inversely proportional 
to c(R-SH). For example, this method was used under second order conditions to establish 
the reactivity-bioactivity relationship for a set of Nrf2 inhibitors[30] or to compare predicted 
kinetic data with experimental data of GSH (7) to Michael-type acceptors.[31]  
 
Scheme 6: Principle of the determination of free thiols by the use of Ellmann’s reagent. 
Even simpler is the direct and permanent monitoring by the absorbance decrease of the 
test compounds during the reaction. This technique was used for example by Dinkova-
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Kostova et al to determine k2 rate constants under pseudo-first order conditions for the 
reaction of electrophiles to various simple thiols, including GSH and mercaptoethanol, in a 
mixture of Tris-HCl buffer pH 7.4 and acetonitrile.[32]  
In this specific project, chalcone derivatives were the compounds of interest. Their reactiv-
ity and anti-inflammatory activity were determined and evaluated. A new easy-to-use 96-
well UV-Vis assay has been tailored to the new class of compounds by adapting and opti-
mizing the solvent system and measurement conditions. 
A 1.5 The Kinetic Thiol Assay for electrophiles and its application in the 
determination of the reactivity of chalcone derivatives 
Chalcones are aromatic compounds with two aromatic units A and B, which are connected 
via an α,β-unsaturated carbonyl unit and belong to the natural compounds class of flavo-
noids. Due to their electrophilic nature, they possess anti-inflammatory and anticancero-
genic properties, among others, by alkylation and inhibition of proteins involved in the NF-
κB pathway.[33] The unsubstituted chalcone diphenyl-prop-2-ene-1-one (17, Figure 5) has 
numerous hydroxy-, alkoxy and glycosyl derivatives, which occur in a great variety of plants, 
fruits and vegetables as well as spices.[33] These are also biosynthetic precursors of fla-
vanones and other cyclic flavonoids.[34] One project already published concerning electro-
philes of the enone-type in the working group Amslinger was the synthesis, characteriza-
tion and reactivity evaluation of chalcones and their fully synthetic derivatives as depicted 
in Figure 5.[35] [36] 
 
Figure 5: Basic structure chalcone 7 and synthetically varied derivatives studied in the work group of PD Dr. 
Sabine Amslinger. α-X-TMCs: R1,2,3,4 = OCH3; X = H, CH3, CF3, CN, NO2, COOH, COOEt, F, Cl, Br, I, Ph, p-H3CO-
Ar, p-NO2-Ar; α-H chalcone derivatives: R1,2,3,4 = OH, OCH3, OiPr; X = H. Members of the work group of PD Dr. 
Sabine Amslinger contributing to this project were: Nafisah Al-Rifai (PhD thesis, 2013) and Hannelore Rücker 
(PhD thesis, 2014). 
Substituents were introduced to the aromatic rings (hydroxy and alkoxy groups, α-H chal-
cones[35]) and moreover the enone α-position of tetramethoxychalcone was varied with 
electron-withdrawing and electron-pushing functional groups X (α-X-tetramethoxychal-
cones, α-X-TMCs) to investigate their influence on the electrophilicity.[36] In order to 
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estimate the reactivity of chalcones with regard to their electrophilicity at the β position of 
their enone system towards thiol nucleophiles, a kinetic assay using UV-Vis detection in 96 
well plate format was developed.[35] In this assay, cysteamine (18, Figure 6) is used as model 
compound, imitating cysteine residues in biomolecules. The reaction with cysteamine in-
terrupts the chalcone chromophore between 300 and 450 nm and the yellow absorbance 
band disappears in the spectrum. This absorbance decrease is recorded time-dependently 
at a suitable wavelength whereby the decreasing exponential functions ( 2 ) are obtained. 
Figure 6 shows as example the absorbance spectra of α-H-tetramethoxychalcone (α-H-
TMC) measured at ten-minute intervals after addition of a 60-fold excess of cysteamine as 
well as the kinetic absorbance decrease obtained. 
 
Figure 6: Principle of the kinetic thiol assay for the Michael addition of cysteamine to chalcones using the 
example of α-H-TMC. A: Reaction equation; B: Time-dependent UV-Vis spectra with and without cysteamine 
at 25 °C; C: Kinetic progress of the reaction with 60-fold thiol, measurement at 360 nm.[35] 
This reaction follows a second order kinetic with the rate constant k2 (5). 
 −
𝑑𝑐(𝑐ℎ𝑎𝑙𝑐𝑜𝑛𝑒)
𝑑𝑡
= 𝑘2 ∗ 𝑐(𝑐ℎ𝑎𝑙𝑐𝑜𝑛𝑒) ∗ 𝑐(𝑐𝑦𝑠𝑡𝑒𝑎𝑚𝑖𝑛𝑒) ( 5 ) 
Due to the excess of cysteamine, a reaction kinetics of pseudo-first order with kobs as 
pseudo-first order rate constant can be assumed ( 6 ), ( 7 ). 
 
𝑐(𝑐𝑦𝑠𝑡𝑒𝑎𝑚𝑖𝑛𝑒) ≫ 𝑐(𝑐ℎ𝑎𝑙𝑐𝑜𝑛𝑒) 
→ 𝑐(𝑐𝑦𝑠𝑡𝑒𝑎𝑚𝑖𝑛𝑒) = 𝑐𝑜𝑛𝑠𝑡. = 𝑐(𝑐𝑦𝑠𝑡𝑒𝑎𝑚𝑖𝑛𝑒)0 
( 6 ) 
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 −
𝑑𝑐(𝑐ℎ𝑎𝑙𝑐𝑜𝑛𝑒)
𝑑𝑡
= 𝑘2 ∗ 𝑐(𝑐𝑦𝑠𝑡𝑒𝑎𝑚𝑖𝑛𝑒)  
 −
𝑑𝑐(𝑐ℎ𝑎𝑙𝑐𝑜𝑛𝑒)
𝑑𝑡
= 𝑘𝑜𝑏𝑠 ∗ 𝑐(𝑐ℎ𝑎𝑙𝑐𝑜𝑛𝑒) ( 7 ) 
The obtained e-functions are mathematically fitted with the program Origin according to a 
decreasing first order exponential function, thus eliminating the need for linearization. 
From these mathematical equations ( 3 ) the kobs values for all thiol concentrations can be 
read out. It must be considered that Michael additions are reversible, thus equilibrium re-
actions and therefore the reaction must be monitored until the equilibrium is achieved. 
The excess cysteamine concentration determines the associated kobs value, the reaction 
rate for each cysteamine concentration, which describes the net effect of the forward and 
backward reactions. From the linear ratio of different excess thiol concentrations to their 
corresponding kobs values k2, the desired rate constant of the reaction is obtained (8). 
 𝑘𝑜𝑏𝑠 = 𝑘2 ∗ 𝑐(𝑐𝑦𝑠𝑡𝑒𝑎𝑚𝑖𝑛𝑒)0 → 𝑘2 =
𝑘𝑜𝑏𝑠
𝑐(𝑐𝑦𝑠𝑡𝑒𝑎𝑚𝑖𝑛𝑒)0
 ( 8 ) 
A mixture of 100 mM Tris-HCl buffer with 2 mM EDTA pH 7.4 (20 %) and ethylene glycol 
(80 %) was optimized as the reaction medium. The neutral pH in the buffer mimics physio-
logical conditions while ethylene glycol increases the solubility of test substances and slows 
the reaction rate of very fast-reacting compounds to a level observable by the user. Me-
dium to fast, slow and very slow reacting chalcones were easily measured in 96-well micro-
titer plates via microplate photometer. Stopped-flow measurements were performed for 
very fast-reacting chalcones. This assay can be used to examine a large number of test sub-
stances to compare their reaction rates under the same conditions. The requirement is an 
absorption at a wavelength > 300 nm, more precisely a sufficient chromophore, which de-
creases during the reaction with cysteamine, but also complete solubility at test concen-
trations of 40-80 µM. Wavelengths < 300 nm are not suitable for measurement due to the 
self-absorption of the assay material (buffer, 96-well plate, cover foil). In α-H-chalcones, k2 
values of 0.103 to 5.08 M-1s-1 were obtained under these conditions. In addition, relation-
ships between the substituents on both aromatic rings and the reactivity of the correspond-
ing compounds could be detected.[35] 
A structure-reactivity relationship was also found for the α-X-TMCs since a high influence 
of the substituent X on the reaction rate was demonstrated.[36] It has been shown that the 
more electron-withdrawing the substituent X is, the faster the reaction with cysteamine 
takes place. The lowest reactivity is found in α-COOH-TMC, which is present as an anion 
under assay conditions and thus increases the electron density to the detriment of a 
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nucleophilic attack. The k2 range for α-X-chalcones comprises a total of more than six or-
ders of magnitude. Furthermore, the determined reactivity of α-X-TMCs was compared to 
their anti-inflammatory activity concerning HO-1 activation and NO inhibition. Structure-
activity relationships were established. Kinetic and biological results are summarized in Ta-
ble 1.  
Reactivity of α-X-TMCs correlates with their HO-1 induction properties. The stronger the 
reactivity determined by the thiol assay, the stronger the HO-1 induction and thus inflam-
mation inhibition, but the cell toxicity tends to increase simultaneously. The same goes for 
the NO-inhibition properties that follow the same order with α-CF3-TMC as most potent 
inhibitor, as it inhibits 84.6% of NO production at a very small concentration of 0.5 µM. Two 
obvious exceptions are the most reactive derivatives, α-CN- and α-NO2-TMC, in which no 
or only small anti-inflammatory activity and relatively low cell toxicity was detected. The 
electrophilic properties of these two substances are strong enough that they are most likely 
rapidly inactivated by the cellular detoxification agent glutathione (GSH, 7, Scheme 3). 
Table 1: Results of the reactivity of α-X-TMCs determined by the kinetic thiol assay and biological data.  
α-X-TMC  
X = 
k2 [M-1s-1] 
Toxicity limit 
[µM][a] 
HO-1  
induction 
Inhibition of NO production 
cα-X-TMC [µM] inhibition [%] 
CN 5750 ± 130 25 - 1 16.4 ± 8.7 
NO2 749 ± 9.0 25 - 1 1.7 ± 8.5 
CF3 17.1 ± 1.8 0.5 +++ 0.5 84.6 ± 8.9 
Br 2.89 ± 0.08 1 +++ 1 67.4 ± 11.7 
Cl 1.65 ± 0.021 5 +++ 1 47.2 ± 14.6 
p-NO2-Ar 0.293 ± 0.025 25 ++ 1 1.1 ± 9.8 
I 0.282 ± 0.015 5 ++ 1 22.0 ± 12.4 
COOEt 0.281 ± 0.029 10 - 5 46.0 ± 9.4 
H 0.193 ± 0.019 10 + 5 60.9 ± 18.8 
F 0.0168 ± 0.00035 25 - 5 29.6 ± 20.2 
p-OMe-Ar 0.00856 ± 0.0013 25 - 5 -2.2 ± 4.3 
Me 0.00750 ± 0.00039 25 - 5 -34.7 ± 15.2 
Ph 0.00669 ± 0.00029 25 - 5 9.7 ± 12.9 
COOH 0.00371 ± 0.00006 25 - 5 -0.7 ± 12.2 
The induction of HO-1 expression in RAW 264.7 macrophages was determined by Western Blot. +++ = strong 
induction; ++ = medium; + = weak induction in comparison to control; - = no induction. Kinetic and biological 
data were measured and/or analyzed by Nafisah Al-Rifai, Hannelore Rücker, Dita Fritsch and Sabine Am-
slinger.[35] [36] [37] 
The excellent correlation of these data shows how well a reactivity study can predict the 
biological activity of a substance class. Figure 7 visualizes this relationship by using the log-
arithmic k2 and IC50 values which give a linear correlation. With α-CF3-TMC, an optimal re-
activity/activity window was found for the α-X chalcones. However, as toxicity also in-
creases, the question arises whether optimization within the substance class could still be 
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achieved. It can also be promising to test potent active substances such as chalcones for 
further positive cell effects. In continued research, some selected compounds have been 
investigated in further assays concerning cytoprotectivity with very promising results for E-
α-p-OMe-Ar-TMC.[38] A clear antiapoptotic effect was found at nontoxic concentrations. 
 
Figure 7: Correlation of the inhibition of NO production with the second-order rate constants (lg(k2)) of the 
Michael addition of α-X-TMCs with an anti-inflammatory activity and cysteamine. Line indicates the linear fit. 
A 1.6 α-X-Hydroxychalcones (α-X-HCs) 
The investigation of chalcones was further developed towards an improvement of their 
reactivity and biological activity. Nafisah Al-Rifai synthesized 8 substituted, methoxylated 
chalcones with a 2’-OH group during her PhD thesis, called α-X-hydroxychalcones, α-X-HCs 
(University of Regensburg, 2014, Figure 8).[39]  
 
Figure 8: α-X-HCs and their cysteamine addition products. Syntheses and investigations by Nafisah Al-Rifai 
(Dissertation, 2015, University of Regensburg).[39] 
Due to the free 2’-OH group, an enhancement of electrophilicity in comparison to α-X-
TMCs is expected, which might be beneficial also for the biological activity. Table 2 shows 
the summary of the kinetic and biological investigations so far. Indeed, a two- or threefold 
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increased reactivity of α-F-HC and α-H-HC respectively in comparison to their TMC ana-
logues was proven.[35] However, for all α-X-HCs a significant decrease or complete loss of 
toxicity and biological activity was found when compared to α-X-TMCs. 
Table 2: Kinetic results and biological activities of α-X-HCs (unpublished results) compared to their corre-
sponding α-X-TMCs.[36] 
α-X 
com-
pound 
X = 
k2 [M-1s-1] 
Cell viability 
IC50[µM] 
Inhibition of NO production 
IC50 [µM] 
TMC HC TMC HC TMC HC 
CN 5750
[a] n. d. > 100 > 100 n.d. 30.8 ± 1.2 
CF3 17.1
[a] n. d. 7.91 ± 0.98 > 100 0.120[c] n. a. 
Br 2.89
[a] n. d. 9.65 ± 1.04 43.1 ± 6.8 0.640[c] n. a. 
Cl 1.65
[a] n. d. 13.1 ± 2.4 57.0 ± 1.8 0.992[c] 31.8 ± 7.4 
p-NO2-Ar 0.293
[a] n. d. > 100 > 100 n. d. 99.4 ± 11.4 
H 0.193
[b] 0.717 ± 0.019 23.7 ± 5.7 37.5 ± 2.9 4.44[c] 9.84 ± 3.32 
F 0.0168
[a] 0.0347 ± 0.0029 > 100 52.2 ± 7.2 12.9[c] 15.8 ± 3.0 
Me 0.00750
[a] n.d. > 100 > 100 n. d. 55.0 ± 21.3 
[a]: Value taken from Al-Rifai et al.[36]; [b]: value taken from Amslinger et al.[35]; [c]: value taken from Rücker 
et al.[37]; n. a.: not active at non-toxic concentrations; n. d.: not determined. 
This effect is explained by the loss of the enone system due to the well-known cyclization 
to the corresponding flavanones (structure: α-X-flavanones, Table 3).[40] [41]The extent of 
this reaction depends on various factors, including the α-X-substituent. Table 3 shows UV-
Vis ad LC-MS investigations of α-X-HCs under kinetic assay conditions. Indeed, flavanone 
formation was detected for all α-X-HCs containing an electron-withdrawing substituent X. 
Due to this loss of the electrophilic position, the biomolecular mechanism of action is hin-
dered or even prevented. This applies to the substances only in aqueous medium. All com-
pounds were isolated as chalcones after synthesis and purification. 
Table 3: Results of LC-MS studies of -X-HCs without and with 60-fold cysteamine. 
 Compounds detected by LC-MS 
α-X-HC 
X = 
-/+ 
cyste-
amine 
α-X-HC 
 
α-X-HC-cysteamine adduct 
CN[a, b] 
- ++ +++ - 
+ - ++ ++ 
CF3[a, b] 
- + ++ - 
+ + ++ - 
Br[a] 
- + +++ - 
+ tr. + - 
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 Compounds detected by LC-MS 
Cl[a] 
- ++ +++ - 
+ tr. + - 
p-NO2-Ar 
- + +++ - 
+ + +++ + 
H[a] 
- > 95% tr. - 
+ + - +++ 
F[a] 
- > 95% tr. - 
+ +++ tr. ++ 
Me 
- > 95% tr. - 
+ > 95% tr. tr. 
Reactions were carried out in 100 mM Tris-HCl buffer pH 7.4 with 2 mM EDTA/ethylene glycol 20:80 with 
40 µM of α-X-HCs and 1-2 h incubation time prior to measurement. HPLC column temperature: 40 °C. Molec-
ular ratios were estimated by UV-Vis measurement and are assigned as follows: +++: 95-60%; ++: 60-30%; +: 
30-5%; tr.: traces. [a]: Additional compounds (fragmentation and elimination products) were detected[39]; [b]: 
measured directly after mixing and at 25 °C column temperature. 
These results show that more aspects have to be considered when optimizing reactivity 
and activity, as this strategy only leads to limited success. 
A 1.7 Synthesis of oxadiazoline enones (OXEs): a library of new 
electrophilic substances with an enone unit 
The presented concept of a substance library containing a core unit, whose reactivity is 
influenced by variable substituents in order to optimize the biological activity, was applied 
in this work group to another, newly designed class of substances. The first results are taken 
from the doctoral thesis of Anas Rasras[42] and the Master theses of Rainer Herzog[43] and 
Lukas Wirth.[44] 
Molecule design 
In the endeavor to create novel fine-tuned electrophiles, which are suitable model com-
pounds for drug development, a new class of compounds was designed and synthesized in 
the work group of PD Dr. Sabine Amslinger.[42] 
It was chosen to decorate a heterocyclic system with an additional enone unit, which is 
able to bind covalently to pharmacological targets. Thereby it was important to use a scaf-
fold which allows for a conjugation with the enone unit to modify its reactivity. Thus, nine 
classes of 3-enone-substituted 2,3-dihydro-1,3,4-oxadiazoles (oxadiazoline enones, OXEs) 
were envisioned. These molecules were composed, according to Figure 9, from three vari-
ations in the 2-position, R2 - a CH3, H or CF3 group - together with three different enone 
moieties in the 3-position and variations of the aromatic group attached to the 5-position 
(R1) of the oxadiazoline skeleton. 
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Figure 9: Design and structural features of the compound library of oxadiazoline enones (OXEs). 
A combination of the two main structural features enone + R3 and substituent in 2-position 
(R2) leads to the nine different OXE classes named OXE1 to OXE9, which are summarized in 
Table 4.[43] [44] 
Table 4: Overview and naming of nine OXE classes. 
Enone + R3 Substituent in 2-position / R2 OXE class 
acryl CH3 OXE1 
acryl H OXE2 
acryl CF3 OXE3 
crotyl CH3 OXE4 
crotyl H OXE5 
crotyl CF3 OXE6 
cinnamoyl CH3 OXE7 
cinnamoyl H OXE8 
cinnamoyl CF3 OXE9 
The different substituents decorating the heterocyclic unit should influence the enone re-
activity by different effects. The 2-position was chosen to potentially influence the reactiv-
ity of the enone unit by a more indirect sp3-coupled variation in the electron density. Sub-
stituted phenyls and pyridine are the selected aromatic units in the 5-position. A stronger 
modulation of electrophilicity was expected when the electron-poor 4-pyridyl-substituent 
is introduced to the 5-position. Furthermore, pyridine provides a free electron pair to in-
teract with potential pharmacological targets via hydrogen bond. The largest effect was 
anticipated when the 3-enone functionality itself was modified directly in the -position to 
form acrylic, crotonic and cinnamic amides as the electrophilic units. A mesomeric connec-
tion between the enone carbonyl and the heterocycle is achieved via the free electron pair 
of the nitrogen in the heterocyclic 3-position (Scheme 7).  
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Scheme 7: Mesomeric interaction of the oxadiazoline and enone units in OXEs. 
There are few literature-known examples for these kinds of compounds. Prior to the work 
presented here, a set of six compounds having these structural features were already pub-
lished,[45] however without the involvement of the pyridine unit (Figure 10). Since they 
carry a cinnamoyl unit in the 3-position and are 2-H-substituted, these molecules would be 
classified as OXE8s. They were tested for antibacterial activity on different bacterial cell 
lines with promising results.  
 
Figure 10: Oxadiazoline derivatives synthesized and tested for antibacterial activity.[45] 
Synthesis of OXEs 
The synthesis was done via a classical heterocyclic synthesis forming the 3,4-dihydro-1,3,4-
oxadiazole ring in the last step of the sequence containing up to 4 steps (Scheme 8).[42]  
 
Scheme 8: Synthesis of 2,5-diaryl-3,4-dihydro-1,3,4-oxadiazoles with additional 3-enone unit (OXEs). 
Depending on the commercial availability of starting materials, the sequence was either 
started from carboxylic acids 19 or esters 20 producing with hydrazine mono hydrate 
known hydrazides 21,[46] which were transformed into the mostly known hydrazones 23[47] 
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using acetophenones or benzaldehydes 22. In the last step, the heterocyclic ring was 
formed from hydrazones 23 in the presence of the corresponding acid chlorides 24. 
A mechanism for the oxadiazoline ring formation is proposed in Scheme 9.[48] Basic condi-
tions lead to the formation of anion 26 which cyclizes to 27 and is subsequently trapped by 
the electrophile 24. 
 
Scheme 9: Proposed mechanism for the formation of OXEs[48]. 
For the nomenclature, first the OXE class is named according to Table 4. Further substitu-
ents are reflecting the type of aromatic unit in 5-position as well as p-substituents on the 
different aromatic rings R1 and R3. Among the aromatic units, only the pyridine residue is 
termed; phenyl and aryl are not included in the name. The substituents are named in the 
following order: 
1. Substituents on the aromatic ring in 2-position  
2. Substituents on the aromatic ring in β-position of the enone unit (only in the case 
of cinnamoyl in OXE7s and OXE8s) 
3. Substituents in 5-position (only pyridinyl or a 4-Ar substituent) 
and may placed in labelled brackets according to: 
1. - 
2. ()’ 
3. ()’’ 
Two examples given in Scheme 10 illustrate these explanations. 
 
OXE class 2-H + cinnamoyl = OXE8 
substituent on 2-Ar Cinnamoyl-Ar 5 
 OCH3 NO2 4-pyridinyl 
NAME: OXE8-OMe,(NO2)’,(4py)’’ 
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OXE class 2-CH3 + acryl = OXE1 
substituent on 2-Ar Cinnamoyl-Ar 5 
 - - Ar-NO2 
NAME: OXE1-(NO2)’’ 
Scheme 10: Examples for the nomenclature developed for the OXE substance library. 
Since it is known that N-oxides of pyridines can show special binding properties, three pyr-
idinyl-substituted OXE compounds were turned into their corresponding N-oxide deriva-
tives[44] using the oxidation reagent mCPBA (m-chloroperbenzoic acid).[49] All synthesized 
OXE compounds are summarized in Table 5 and Figure 11, which reflects seven different 
classes of OXEs from the nine classes that were envisioned in principle. Attempts to syn-
thesize representatives of OXE6 and OXE9 were not successful. Additionally, one control 
compound was synthesized, OXE1-(4py)’’-H2, which represents the dihydro derivatives 
lacking the enone motif. One α-substituted compound α-Me-OXE1-(4py)’’ was synthe-
sized. More representatives with different structural features were included in the library: 
the spiro-compound OXCE-(4py)’’ and two compounds with quinolinyl and naphthyl sub-
stituents in position 5 (Figure 11). 
Table 5: Overview of OXEs of the classes 1-5 and 7-8 synthesized in the Amslinger group. 
Classes NAME R1 R2 R3 X R4 Syn 
 
OXE1 H CH3 - C H LW 
OXE1-(NO2)’’ H CH3 - C NO2 RH 
OXE1-(CN)’’ H CH3 - C CN RH 
OXE1-(4py)’’ H CH3 - N - AR 
OXE1-NO2,(4py)’’ NO2 CH3 - N - AR 
OXE1-(4py-N-oxide)’’ H CH3 - N+ O- LW 
OXE1-CF3,(4py)’’ CF3 CH3 - N - AR 
OXE1-OCF3,(4py)’’ OCF3 CH3 - N - AR 
OXE1-4py,(4py)’’ 4-py CH3 - N - Ar 
OXE1-2py,(4py)’’ 2-py CH3 - N - Ar 
OXE2-(4py)’’ H H - N - RH 
OXE2-NO2,(4py)’’ H H - N - RH 
OXE2-OMe,(4py)’’ H H - N - RH 
OXE3-(4py)’’ H CF3 - N - RH 
        
 
OXE4-(4py)’’ - CH3 - N - AR 
OXE4-(4py-N-oxide)’’ - CH3 - N - LW 
OXE5-(4py)’’ - H - N+ O- LW 
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Classes NAME R1 R2 R3 X R4 Syn 
 
OXE7 H CH3 - C  AR 
OXE7-(4py)’’ H CH3 - N  AR 
OXE7-OMe,(4py)’’ OCH3 CH3 - N  AR 
OXE7-(CF3)’,(4py)’’ H CH3 CF3 N  AR 
OXE7-(OMe)’,(4py)’’ H CH3 OCH3 N  AR 
OXE8-(4py)’’ H H - N  AR 
OXE8-(4py-N-oxide)’’ H H - N+ O- LW 
OXE8-NO2,(4py)’’ NO2 H - N  AR 
OXE8-OMe,(4py)’’ OCH3 H - N  AR 
OXE8-(OMe)2,(4py)’’[a] 2xOCH3 H - N  RH 
OXE8-OMe,(NO2)’,(4py)’’ OCH3 H NO2 N  RH 
OXE8-(OMe)’,(4py)’’ H H OCH3 N  RH 
OXE8-OMe,(OMe)’,(4py)’’ OCH3 H OCH3 N  RH 
Syn = Synthesized by: AR = Anas Rasras, RH = Rainer Herzog, LW = Lukas Wirth; [a]: the 3,4-dimethoxy com-
pound was produced.  
 
Figure 11: OXEs with further structural features synthesized in the Amslinger work group. Synthesized by: AR 
= Anas Rasras, RH = Rainer Herzog, LW = Lukas Wirth. 
Synthesis of OXE analogues: epoxides and acyl-substituted oxadiazolines 
Additionally, the epoxide functionality as alternative electrophilic unit was of interest. This 
functional group also occurs in natural products that are able to bind covalently to nucleo-
philic amino acid side chains in active sites of certain enzymes by undergoing epoxide open-
ing.[12, 50] Some epoxide-containing compounds have been proven to bind to thiol groups 
of cysteines, e.g. in cysteine proteases, in particular.[51] Antimicrobial, anti-angiogenetic 
and anti-inflammatory effects are described,[12, 52] making these compounds important in 
drug discovery and development for decades. To investigate the effect of a different elec-
trophilic moiety on the OXE compounds, two oxadiazoline representatives with an addi-
tional epoxide were synthesized from their OXE1 and OXE4 analogues using n-
BuLi/tBuOOH,[53] whereby two compounds were produced[44] (Table 6). As further control 
compounds, three representatives of OXAc-(4py)’’s known from the literature where 
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synthesized.[54] OXAcs stem from OXE2-(4py)’’ and carry an acyl group in 3-position instead 
of acryl (Table 6). 
Table 6: Synthesized OXE analogues: OXEp and OXAc compounds. Syn = synthesized by: AR = Anas Rasras, 
LW = Lukas Wirth. 
Classes NAME R1 R3 Syn 
 
OXEp1-(4py)’’ - H LW 
OXEp2-(4py)’’ - CH3 LW 
 
 
OXAc-(4py)’’ H - AR 
OXAc-NO2,(4py)’’ NO2 - AR 
OXAc-OMe,(4py)’’ OCH3 - AR 
Synthesis of oxadiazol-thioesters 
For a variation of the heterocyclic scaffold, a further structure concept differing from the 
OXE skeleton was designed. It was constructed from a saturated oxadiazole core unit with 
the enone moiety linked to the heterocycle in 2-position via a thioether and also pyridinyl 
in 5-position. Two compounds of this type where synthesized and named oxadiazol-thio-
esters OXTE and OXTE-OMe (Table 7).[42] 
Table 7: Oxadiazol compounds synthesized by Anas Rasras. Syn = synthesized by AR = Anas Rasras. 
Structure NAME R1 Syn 
 
OXTE H AR 
OXTE-OMe CH3 AR 
A 1.8 Synthesis of further electrophiles in the Amslinger work group 
Phenylacrylamide derivatives as reactive units in drug development 
Reactive units that differ from the enone functionality are able to react as Michael accep-
tors with nucleophilic pharmacological targets as well. Before combining those varied re-
active units to drug-like fragments, the assessment of a structure-reactivity relationship is 
useful to find out if the electrophilicity of the unit is tunable by different substituents as 
described before for α-X-TMCs. For that purpose, a library of simplified molecules of the 
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aromatic acrylamide type and of the phenylethene sulfonamide type were synthesized by 
Lukas Wirth.[44] Figure 12 gives an overview of all synthesized compounds.  
 
Figure 12: N-Phenylacrylamide and phenylethenesulfonamide derivatives synthesized by Lukas Wirth.[44] 
For compounds 29 and 30 only the unsubstituted and the pyridine derivatives were syn-
thesized. With 31a and 31b an unsubstituted and a OMe-decorated representative of N-
phenylethenesulfonamides was obtained. But in the case of N-phenylacrylamides 32, a li-
brary of 16 compounds with a great variety of electron-withdrawing and electron-pushing 
substituents in various positions was produced. Although OXEs can be considered as en-
amide derivatives as well, the difference between acrylamides and OXEs is that the amide 
nitrogen is not included in a heterocycle but N-aryl substituted. 
Reactivity assessment methods for electrophiles binding to thiols in a covalent fashion 
were previously reported also for this so-called fragment-based approach.[55] [30] The aim is 
to establish a structure-reactivity relationship so that the reactivity can easily be tuned by 
simply exchanging substituents. These reactivity fragments can subsequently be combined 
to one or more small, drug-like fragments to find the optimal toxicity/activity window for a 
certain biological effect. Since it has often been shown that reactivity and biological activity 
correlate, electrophilicity can be used as a modification tool in the first place. 
Juglone and Juglone derivatives 
Another project dealing with the synthesis, kinetic and biological evaluation of small elec-
trophilic molecules was the investigation of the natural product juglone (5-
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hydroxynaphthalene-1,4-dione, 33a), a naphthoquinone found in Juglans (walnut) spe-
cies[56] in the course of the Master thesis of Sebastian Schlegel.[57] Table 8 summarizes the 
substance library of 33a and 14 of its synthesized derivatives, which are O-methylated (R3) 
and/or substituted in position 2 or 3 (R1 and R2). Compound 33e could only be obtained as 
a mixture of two chloro-substituted regioisomers due to separation issues. 
Table 8: Structures and names of Juglone 33a and its derivatives synthesized by Sebastian Schlegel.[57] 
 
Nr R1 R2 R3 name 
a H H H Juglone 
b H H CH3 O-Methyljuglone 
c H Br H 3-Bromojuglone 
d H Br CH3 3-Bromo-O-methyljuglone 
e Cl/H Cl/H H 2- and 3-Chlorojuglone (mixture) 
f H Cl CH3 3-Chloro-O-methyljuglone 
g H F CH3 3-Fluoro-O-methyljuglone 
h H N3 H 3-Azidojuglone 
i H N3 CH3 3-Azido-O-methyljuglone 
j H NH2 H 3-Aminojuglone 
k H NH2 CH3 3-Amino-O-methyljuglone 
l H piperidino H 3-Piperidinojuglone 
m piperidino H H 2-Piperidinojuglone 
n H morpholino H 3-Morpholinojuglone 
o morpholino H H 2-Morpholinojuglone 
Biological activity such as anticancer[58], anti-inflammatory[59] and antimicrobial[60] [61] activ-
ity of 33a has been described, which is explained by the redox properties of the quinone 
system, including the formation of radical species, as well as Michael addition with nucle-
ophiles of various pharmacological targets.[62] Therefore, not only studies of the biological 
activity but also the reactivity of juglone and some derivatives are published. For example, 
the thia-Michael addition of hydrogen sulfide[63] and GSH[64] to juglone (33a) were kinet-
ically investigated. Furthermore, a study was published on the relationship between the 
reactivity of the addition-elimination reaction of 3-OR-substituted juglone derivatives and 
their anticancer activity.[65] 
In the work group of PD Dr. Sabine Amslinger the compounds were tested towards their 
anti-inflammatory properties in the NO inhibition assay. All compounds with an amine sub-
stituent in 2- or 3-position (33j-o) and bromo-substituted 33d provided anti-inflammatory 
activity in the µM range. 3-Amino-O-methyljuglone 33k was the most active substance with 
an IC50 of 1.10 µM. All other derivatives were inactive at nontoxic concentrations. All IC50 
values in the MTT toxicity assay were determined in the range of 4.05 – 63.3 µM with a 
medium of 30.0 µM; no relation between toxicity and anti-inflammatory activity was 
found.[57] Biological results determined by Sebastian Schlegel and Sina Malenke are sum-
marized only for compounds with an anti-inflammatory activity in Table 9. 
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Table 9: Biological data of Juglone derivatives with anti-inflammatory properties. Evaluation of toxicity and 
NO-inhibition properties in murine macrophages RAW264.7. Cell viability (MTT) assay was performed and 
evaluated by Sebastian Schlegel. Anti-inflammatory (iNOS) assay was performed by Sina Malenke and evalu-
ated by Sina Malenke and Monika Enzinger. 
Compound 
Cell viability MTT 
(IC50 / µM) ± SD 
Inhibition of NO production 
(IC50 / µM) ± SD 
3-Aminojuglone 33j 36.7 ± 8.1 5.95 ± 2.20 
3-Amino-O-methyljuglone 33k 18.8 ± 6.9 1.10 ± 0.49 
3-Piperidinojuglone 33l 63.3 ± 19.8 9.48 ± 0.66 
2-Piperidinojuglone 33m 41.8 ± 7.8 4.18 ± 0.48 
3-Morpholinojuglone 33n 36.4 ± 3.3 12.3 ± 8.8 
2-Morpholinojuglone 33o 30.9 ± 5.0 17.0 ± 7.8 
Bromo-O-methyljuglone 33d 22.5 ± 12.4 5.82 ± 1.09 
A 1.9 Further development of the kinetic thiol assay towards the 
investigation of colorless electrophiles 
Purpose and concept of the new assay 
The previous chapters have dealt with enones that have an absorbance in the range of 300-
350 nm or higher. But there are some interesting electrophiles which are not suitable for 
the presented assay due to unsuitable absorbance properties. Figure 13 shows examples 
for compounds which absorbance bands do not extend as far as < 300 nm and can there-
fore not be kinetically evaluated by the thiol assay. 
 
Figure 13: Compounds that cannot be examined by the kinetic thiol assay due to insufficient absorbance 
properties. 
Compounds 34 (cyclohexenone) and 35 (phenylvinylketone or acrylophenone) are struc-
tural motifs that occur in biologically active molecules. For example, antimicrobial[66] and 
EGF-receptor (epidermal growth factor receptor) inhibition[67] properties have been found 
for 35, which are probably at least partly based on their Michael acceptor activity. Based 
on the kinetic properties of these two simple test substances, it would also be possible to 
estimate the reaction rates of substances containing these structural elements. 15d-PGJ2 
(4, 15-deoxy-Δ12,14-prostaglandine J2) is the most active representative of cyclopente-
none-type prostaglandins which show strong anti-inflammatory activity in vitro and in vivo. 
This is based, among other mechanisms, on their Michael acceptor activity provided by the 
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electrophilic cyclopentenone moiety which alkylates, among other targets, the IKK subunit 
of the IκB kinase, leading to an inhibition of NF-κB as transcription factor for inflammation-
triggering proteins.[68] Therefore, a quantification of the Michael acceptor properties of 4 
would be of great interest. 
As a result, this work examines strategies and approaches to further develop the present 
assay in favor of an investigation of completely colorless enones. The concept is to reverse 
the roles of the two reactants enone and thiol. Since the enone test substances lack the 
required chromophore, thiol dyes should be produced that change their absorption prop-
erties by Michael addition. These thiol dyes function as the probe or probes in the new 
assay. The concept of new assay in comparison to the existing kinetic thiol assay is shown 
in Figure 14. To obtain the desired change in the UV spectrum from free thiol to alkylated 
thiol, it is advantageous of the thiol group to be directly attached to the chromophore to 
increase the effect of electronic variations. Therefore, the concept initially includes only 
aromatic thiol dyes but attempts are also made towards alkyl thiols. 
 
Figure 14: Concepts of the existing kinetic thiol assay for electrophiles and the envisioned new kinetic thiol 
assay for colorless enones. 
Studies in the context of a Master's thesis and a Bachelor's thesis have shown that the 
principle for an UV-Vis assay works and the desired effect was found in anthraquinone de-
rivatives[69] (36) and p-nitrothiophenols[70] (37, both structures see Figure 15). In contrast 
to the free thiolates of 36, the absorption band of the alkylated thiols occurred at shorter 
wavelengths whereas alkyl derivatives of 37 had an absorbance maximum < 300 nm. 
 
Figure 15: Aromatic thiols investigated as probes in a further development of the kinetic thiol assay. 
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However, the following problems occurred: 
1. Free aromatic thiols were prone to oxidation to disulfides. 
2. Aromatic thiols reacted very slowly with electrophiles. 
3. Relatively high concentrations must be used for sufficient absorption. 
In the course of both works, some improvements have been made to problem 1. Careful 
degassing, covering with foils and antioxidant additives are promising measures. Oxidation 
must be prevented because disulfide formation led to absorbance decrease as well, pre-
tending a higher reaction rate. The low reactivity of aromatic thiols compared to cysteam-
ine could also be accepted, although this already represents a large limit for test sub-
stances. The biggest hurdle was posed by the high concentrations of both thiol dyes and 
test compounds. In order to maintain pseudo-first-order reaction conditions, the test com-
pounds must be present in excess in the new assay. Under these conditions, it was impos-
sible to use test substances of all kinds in the high µM and mM range, and optimization 
attempts with regard to co-solvents were also unsuccessful. It was therefore decided to 
use fluorescent dyes instead of UV-Vis active thiol dyes. Fluorescence-active substances 
can be used even at very low concentrations < 1 µM. This can also reduce the concentration 
of electrophiles, but also increase the overall excess, which speeds up reaction times and 
reduces possible thiol oxidation. 
Target compounds as thiol probes 
Figure 16 gives an overview of thiol-containing substances with fluorescence properties 
which can be investigated towards their applicability as thiol probes in the new assay. All 
three structures DCY, Acetyl-MSTI and NBD are literature-known[71] [72] [73] and were origi-
nally used for non-kinetic fluorescence-based investigations, which are explained in more 
detail below. 
 
Figure 16: Target structures of fluorescent thiol dyes envisioned in this work.[71] [72] [73] 
Avonto's research group focused on the synthesis and characterization of DCY (dansyl cys-
teamine) which was used in a new HTS (high throughput screening) assay (DCYA, dansyl 
cysteamine assay) to identify potential allergenic chemicals.[71] The purpose of the new as-
say is to replace animal experiments, for example in the cosmetics industry, with animal-
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free chemoassays. Electrophiles of all kinds are held responsible for skin sensitizing effects 
and allergies through their non-specific reaction with nucleophilic residues in proteins.[74] 
DCY was therefore designed as a "fluorescent cysteamine" to quickly detect particularly 
reactive substances in a 96-well format. As the measurement principle, unreacted DCY is 
isolated by reaction to silica-bound maleimide and subsequent fluorescence spectroscopy 
of the adduct. The reactivity of the electrophilic test compound is therefore indirect pro-
portional to the measured fluorescence intensity. The assay principle is depicted in Figure 
17. DCY was chosen to be tested for the applicability as fluorescent thiol probe for the 
planned further development of the kinetic thiol assay in the course of the work for this 
thesis. 
 
Figure 17: Principle of the DCY HTS assay to identify highly reactive electrophiles as potential skin sensitizers 
developed by Avonto et al.[71] 
McCallum and coworkers followed a similar approach with the synthesis of Acetyl-MSTI 
(MSTI = mercaptostyryl-trimethylindolium iodide, Figure 16), and its use in a HTS for the 
identification of highly reactive electrophilic compounds in the early state of drug develop-
ment.[72] With this new assay, these electrophiles are to be detected and excluded from 
further drug development, since their potential for side effects due to non-specific alkyla-
tion of biological targets is very high. Since the free thiol MSTI (38, Scheme 11) was found 
to be highly susceptible to oxidation, the alkylated form was used for the assay and 38 was 
produced in situ in a first step. In the second step, the test substances are added and the 
fluorescence measurement is performed after a short time. The occurrence of MSTI-elec-
trophile adducts (39) is indicated by a decrease of fluorescence due to alkylation of MSTI 
to a certain level and electrophiles with too high reactivity are sorted out by a hit-or-no-hit 
principle. It is reported that Acetyl-MSTI and MSTI (38) have different fluorescence emis-
sion properties, therefore they would be perfectly suited for the planned further develop-
ment of the kinetic thiol assay. The principle of the HTS assay is depicted in Scheme 11. 
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Scheme 11: Principle of the HTS assay to identify highly reactive electrophiles in the early state of drug de-
velopment by McCallum et al.[72] 
The non-fluorescent NBD (7-nitrobenzo[c][1,2,5]-oxadiazol-4-thiolate) was also a candi-
date of interest for the thiol probe in the planned assay. The basis for this is the work of 
Montoya et al., which describes differences in the fluorescence properties of free NBD and 
alkylated NBD compound 41; these properties are used for example in fluorescence mi-
croscopy.[73, 75] The ability of non-fluorescent NBD to gain fluorescence activity when alkyl-
ated is a very promising property for the planned assay (Scheme 12). 
 
Scheme 12: NBD and derivatives show different fluorescence properties. 
A 1.10 Aim of the present work 
The work presented in this chapter focuses on the reactivity study of the synthesized com-
pounds and compound libraries presented using the kinetic chemoassay for enone-type 
electrophiles towards thiols. Therefore, all substances were first examined for their general 
applicability for the assay by UV-Vis spectroscopy and LC-MS. Measurement parameters 
and second order rate constants k2 were determined and detailed investigations of product 
formation and stability under assay conditions were performed.  
Figure 18 provides an overview of the investigated compounds. In addition to the already 
existing substances, the library of oxadiazoline enones (OXEs) was extended by further rep-
resentatives that are relevant for a structure-reactivity analysis. In cooperation with Sina 
Malenke and Dita Fritsch, all substances were investigated towards their toxicity and anti-
inflammatory activity using the two in-vitro cell assays. The murine macrophages cell line 
RAW264.7 was used due to the ability to express the inflammatory-inducing enzyme iNOS. 
Structure-activity/reactivity relationships (SAR) were analyzed and derived from the assay 
results. 
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In a fragment-based approach, the presented set of N-phenylacrylamides was investigated 
towards its reactivity and the influence of substituents. The natural product juglone (33a) 
and its derivatives (33b-o) were also tested towards their suitability for the use in the ki-
netic thiol assay. 
Furthermore, another required member of the group of α-X-HC derivatives, namely α-NO2-
HC, was synthesized and investigated within this work. 
 
Figure 18: Compounds and compound libraries synthesized and evaluated towards their reactivity and bio-
logical activity in this study. Note: Since each project is a cooperation of Amslinger group members, the con-
tribution of each person is listed in the respective chapter. 
Investigations towards the further development of the kinetic thiol assay for the use of 
colorless enones with absorptions < 300 nm as test compounds as described in A 1.9 were 
performed. In addition to the literature-known thiol compounds DCY, Acetyl-MSTI and 
NBD, further fully synthetic fluorescent dyes with thiol function were investigated towards 
their synthesis. 
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A 2 Results and Discussion I: Synthesis, kinetic and biological 
evaluation of oxadiazoline enones (OXEs): a library of new 
anti-inflammatory electrophilic compounds 
These results are not published yet (05/2019). 
The following persons and work groups participated in this project as follows:  
Group members of the work group of PD Dr. Sabine Amslinger participated in this project 
according to the participation list. 
Josef Kiermaier, MS department of the University of Regensburg: MS measurements. 
Georgine Stühler, Anette Schramm and Fritz Kastner, NMR department of the University of 
Regensburg: kinetic NMR measurements. 
Dr. Sandra Schlee and Thomas Klein, Department of Biochemistry II, University of Regens-
burg, work group of Prof. Dr. Sterner: Introduction to and help with Stopped-Flow measure-
ments. 
I gratefully acknowledge the help, support and expertise of everyone involved in this project. 
Participation list of Amslinger work group members 
Group member Work for the project presented in this chapter 
Dr. Anas Rasras 
(PhD thesis) 
Syntheses: OXE1-(4py)''; OXE1-NO2,(4py)''; OXE1-CF3,(4py)''; OXE1-
OCF3,(4py)''; OXE1-4py,(4py)''; OXE1-2py,(4py)''; α-Me-OXE1-(4py)’’; 
OXE1-(4py)''-H2; OXE4-(4py)''; OXE7; OXE7-(4py)''; OXE7-
OMe,(4py)''; OXE7-(CF3)',(4py)''; OXE7-(OMe)',(4py)''; OXE8-(4py)''; 
OXE8-NO2,(4py)''; OXE8-OMe,(4py)''; OXCE-(4py)''; OXAc-(4py)''; 
OXAc-OMe,(4py)''; OXAc-NO2,(4py)''; OXTE; OXTE-OMe and precur-
sors 
Lukas Wirth 
(Master thesis) 
Syntheses: OXE1; OXE1-(6qui)''; OXE1-(4py-N-oxide)''; OXE2-(2na)''; 
OXE4-(4py-N-oxide)''; OXE5-(4py)''; OXE8-(4py-N-oxide)''; OXEp1-
(4py)''; OXEp2-(4py)'' and precursors 
Rainer Herzog 
(Master thesis) 
Syntheses: OXE1-(CN)''; OXE1-(NO2)''; OXE2-(4py)''; OXE2-NO2,(4py)''; 
OXE2-OMe,(4py)''; OXE3-(4py)''; OXE8-(OMe)2,(4py)''; OXE8-
OMe,(NO2)',(4py)''; OXE8-(OMe)',(4py)''; OXE8-OMe,(OMe)',(4py)'' 
and precursors 
Monika Enzinger 
(this work) 
Syntheses: OXE1; OXE1-(OMe)''; OXE1-OMe,(4py)''; OXE1-(6qui)'', 
OXE3-(4py)''; OXE4-(4py-N-oxide)''; OXE8-(OMe)'; OXE8-OMe,(4py)''; 
OXE8-(4py)''-H2; OXE8-(4py-N-oxide)''; OXEp1-(4py)'' and precursors 
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Group member Work for the project presented in this chapter 
Biological testing and evaluation: OXE1; OXE1-(6qui)'', OXE3-(4py)''; 
OXE8-(OMe)'; OXE8-(OMe)’,(4py)''; OXE8-(4py)''-H2; OXE8-(4py-N-ox-
ide)''; OXEp1-(4py)''; OXEp2-(4py)’’; OXAc-(4py)’’; OXAc-OMe,(4py)’’; 
OXAc-NO2,(4py)’’ and precursors 
UV-Vis characterization, kinetic measurements, stopped-flow kinetic 
(with the help of Sandra Schlee and Thomas Klein), LC-MS analysis and 
LC-MS kinetic measurements (together with Josef Kiermaier): all OXEs 
and OXE analogues 
NMR kinetics (together with Anette Schramm): OXE1-(4py)’’ 
Sina Malenke 
(PhD thesis) 
Biological testing and evaluation: OXE1-(OMe)’; OXE1-(4py-N-oxide)’’; 
OXE2-(2na)’; OXE3-(4py)’’; OXE4-(4py-N-oxide)’’ 
Dita Fritsch 
(Technical staff) 
Biological testing: all other OXEs and OXE analogues 
Sabine Amslinger Evaluation of biological testing:  all other OXEs and OXE analogues 
A 2.1 Synthesis 
Synthesis of OXEs 
In this work new hydrazones and OXEs were synthesized, which contain further required 
structural elements. In addition, several known substances were synthesized to complete 
the analytical data. The synthesis was generally carried out according to the established 
method[42] (Scheme 8), some procedures were adapted to counteract product instabilities 
and increase yields. Hydrazone 23c was synthesized starting from the corresponding acid 
in three steps (Scheme 13 and Table 10) and four further hydrazones 23 were synthesized 
from pre-existing hydrazides 21a and 21c, summarized in Table 10. With the exception of 
23c, hydrazones 23 were received in moderate to good yields. Due to their low solubility, 
compounds 23 were usually already crystalline after quenching of the reaction with water 
and could easily be isolated by filtration, making a further purification step unnecessary. 
Reasons for lower yields are the formation of side products and/or the appearance of the 
product in very small and fine crystals, partly dissolved as colloids (turbid aqueous phase), 
which led to filtration issues. 
 
Scheme 13: Synthesis of hydrazide 21b as a precursor in the synthesis of hydrazone 22c. 
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Table 10: Synthesis of hydrazones 23 performed during this work. 
 
  Ar   R1 R2   Ar R1 R2  t, yield  
 21a Ph  22a Ph CH3  23a 4-OMe-C6H4 Ph CH3  18 h, 71%  
 21b 4-OMe-C6H4  22b 4-NO2-C6H4 CH3  23b 4-pyridyl 4-NO2-C6H4 CH3  24 h, 68%  
 21c 4-pyridyl  22c 4-OMe-C6H4 CH3  23c 4-pyridyl 4-OMe-C6H4 CH3  24 h, 22%  
    22d Ph H  23d Ph Ph H  26 h, 94%  
    22e Ph CF3  23e 4-pyridyl Ph CF3  24 h, 41%  
               
Carboxylic acid chloride 24b needed in the last synthesis step, the OXE heterocycle for-
mation, was easily obtained in quantitative yield by heating of the corresponding carboxylic 
acid 42 in excess thionyl chloride, which was removed on high vacuum after completion of 
the reaction. Another method was used to obtain the saturated cinnamic acid chloride 24d, 
which was required for the further saturated control substance OXE8-(4py)’’-H2. The start-
ing material 43 reacted with oxalyl chloride at room temperature[76] and 24d was received 
in quantitative yield (Scheme 14). 
 
Scheme 14: Synthesis of carboxylic acid chlorides 24. 
With the synthesized and pre-existing precursors in hand, OXEs were synthesized by the 
reaction of hydrazones 23 and aldehydes/ketones 22 under basic conditions. All com-
pounds produced in this work including the literature-known OXE8-(OME)’[45] are summa-
rized in Table 12. In general, the syntheses gave moderate to good yields, but due to the 
difference in the steric and electronic properties of the involved educts, a great variety in 
the type and number of side products was observed during reaction control by thin layer 
chromatography (TLC). This resulted in low yields of 1-11% for some representatives. Espe-
cially OXEs lacking the pyridinyl unit, namely OXE1, OXE1-(OMe)’’ and OXE1-(6qui)’’, were 
prone for low yields due to a high amount of side products. A recurring problem in these 
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cases was the ongoing product decomposition during the workup steps. For OXE1, decom-
position in solution (CDCl3) within 24 h was monitored by NMR. Improvement of yields 
were achieved for OXE1 (9% to 48%) and OXE1-(6qui)’’ (2% to 11%) by shortening of the 
reaction times with accepting incomplete consumption of the starting material, quick 
workup and low temperatures on the rotary evaporator water bath. A typical side product 
for these OXEs was the open-chained N-acryl-substituted hydrazone 44 (Figure 19). Here, 
the reaction of anion 26 with acrylic acid chloride 24a occurred faster than cyclisation to 
27 (Scheme 9).  
 
Figure 19: Open-chained side product received in the OXE cyclization reaction. 
Side products of the type 44 have the same molecular weight as their corresponding OXEs 
but the two compounds can be distinguished by the characteristic 13C NMR peaks. The het-
erocyclic C-2 in OXE compounds appear at 90-100 ppm. This peak is not found in 44, while 
their spectra show an additional carbonyl peak instead. In the attempted synthesis of 
OXE1-(OMe)'' with NaH as base, 44 appeared as the main product and no desired product 
was formed at all. Using triethylamine (TEA) instead gave no reaction within seven days at 
room temperature. As a result, the synthesis of OXE1-(OMe)’’ was only successful without 
the use of a base after stirring both educts 23d and 24a in THF at room temperature for 7 
days. A yield of 10% was received from a complex mixture after normal phase column chro-
matography and additional reversed phase HPLC purification. 
Particularly OXE3-(4py)’’ gave only a very poor yield since multiple purification steps were 
necessary to isolate the desired product from a complex mixture. Interestingly, the product 
was formed within 1 h during the reaction, visible by a very prominent TLC spot, but de-
composed rapidly during workup and purification. Due to this finding, an optimization of 
reaction conditions was inefficient, but also workup variations did not lead to higher yields. 
Attempted optimizations of the reaction conditions were shorter reaction times (1 h) and 
lower temperatures (0-5 °C). The workup was also varied. The reaction was quenched with 
water and the crude product was extracted in EtOAc. Furthermore, the solvent was re-
moved from the reaction mixture without quenching and at the same time a dry-load in 
silica gel was produced. Finally, filtration experiments of the reaction mixture were per-
formed through layers of kieselgur (Celite®), Al2O3, normal and reversed phase silica gel, 
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as it was suspected that by-products or salts in the reaction mixture or the crude product 
cause the rapid decay of OXE3-(4py)’’. No measure resulted in a yield of more than 1%. 
Table 11: Additional hydrazones 23f-j produced in this work group used for the synthesis of OXEs.  
     
 
 Ar R1 R2  
23f Ph CH3 Ph  
23g 6-quinolinyl CH3 Ph  
23h 4-pyridyl H 4-NO2C4H6  
23i 4-pyridyl H Ph  
23j 4-pyridyl H 4-H3CO-C4H6  
     
Table 12: Syntheses of OXEs performed during this work. 
 
  R3 R4   Ar R1 R2 R3 R4  t, yield  
 24a H H  OXE1 Ph Ph CH3 H H  4 h, 48%  
 24b H 4-OMe-C6H4  OXE1-(OMe)’’[a] 4-OMe-C6H4 Ph CH3 H H  7 d, 10%  
 24c H Ph  OXE1-OMe,(4py)’’ 4-pyridyl 4-OMe-C6H4 CH3 H H  23 h, 29%  
 24d H2 HPh  OXE1-(6qui)’’ 6-quinolyl Ph CH3 H H  1 h, 11%  
     OXE2-NO2,(4py)’’ 4-pyridyl 4-NO2-C6H4 H H H  1.5 h, 45%  
     OXE3-(4py)’’ 4-pyridyl Ph CF3 H H  1 h, 1%  
     OXE8-(OMe)’ Ph Ph H H 4-OCH3-C6H4  20 h, 41%  
     OXE8-OMe,(4py)’’ 4-pyridyl 4-OMe-C6H4 H H Ph  5 h, 66%  
     OXE8-(4py)’’-H2[b] 4-pyridyl Ph CH3 H2 H, Ph  10 min, 75%  
              
[a] The compound was synthesized by stirring hydrazone 23d and acyl chloride 24a in THF without a base; [b] 
The saturated compound was produced. 
Synthesis of OXE-N-oxides and OXEp1-(4py)’’ 
The synthesis of OXE4-(4py-N-oxide)’’ and OXE8-(4py-N-oxide)’’ from pre-existing precur-
sors was also carried out according to the already established procedure,[44] giving a slightly 
improved yield (Scheme 15). 
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Scheme 15: Synthesis of OXE-(4py-N-oxide)’’ compounds. 
Less successful was the synthesis of OXEp1-(4py)’’, which yielded only 9% product despite 
many trials (Scheme 16). The problem was also here, as with OXE3-(4py)’’, a continuous 
degradation during the workup which required several cleaning steps. In addition, the 
product decomposed during the reaction. There was no improvement in keeping reaction 
times short and temperatures low. 
 
Scheme 16: Synthesis of OXEp1-(4py)’’. 
With all these substances in hand, the preliminary studies on reactivity were approached. 
Figure 20 shows a complete overview of all synthesized and subsequently investigated sub-
stances from this project. 
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Figure 20: Overview of all OXE, OXCE, OXEp and OXAc compounds synthesized in the work group of PD Dr. 
Sabine Amslinger. Synthesized by: Anas Rasras, Rainer Herzog, Lukas Wirth and Monika Enzinger. 
A 2.2 UV-Vis spectral properties of OXEs and OXE analogues 
Selected OXEs and OXE analogues were investigated using UV-Vis spectroscopy regarding 
their chromophores. All measurements were performed with 40 µM substance concentra-
tion in 100 mM Tris-HCl buffer pH 7.4 with 2 mM EDTA/ethylene glycol 20:80, which is fur-
ther referred to as kinetic thiol assay solvent system. The substance spectra regarding the 
influence of the substituent in the 5-position of the oxadiazole ring on the molecule chro-
mophore (Figure 21A) show the expected effects. 
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Figure 21: UV-Vis spectra of OXEs. A: OXE1s with different substituents in the 5-position of the oxadiazoline 
ring; B: OXE1-(4py)’’s with different substituents in the 2-position of the oxadiazoline ring; C: OXE-(4py)’’s; 
D: Comparison of OXE analogues. 
In comparison to the unsubstituted phenyl ring in OXE1 (Figure 21A, red spectrum), OXE1s 
with a -M substituent show a chromophore enhancement due to an increased conjugated 
electron system. In Figure 21A, a hyperchromic and bathochromic shift for OXE1-(CN)’’ and 
a bathochromic shift for OXE1-(NO2)’’ is visible (blue and cyan, resp.). The electronic rear-
rangement is shown in Figure 22A for OXE1-(NO2)’’. Also, OXE1-(OMe)’’ (pink spectrum) 
with a +M substituent shows a small chromophore shift towards longer wavelength when 
compared to unsubstituted OXE1, which can also be explained by chromophore enhance-
ment as visualized in Figure 22B.  
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Figure 22: Chromophore enhancement A: by -M substituent (OXE1-(NO2)’’), B: by +M substituent (OXE1-
(OMe)’’). 
The influence of the inductive effect of Ar-X-substituents in position 2 of the oxadiazoline 
ring is visible in the UV-Vis spectra of OXE1s (Figure 21B). Increased UV-Vis intensity in the 
spectra of OXE1-(4py)’’s with -I substituents were found, most prominent for OXE1-
CF3,(4py)’’ (Figure 21B, blue spectrum). Only OXE1-OMe,(4py)’’ has a reduced absorbance 
due to its +I methoxy substituent (yellow). 
An overview of the UV-Vis spectra of all synthesized unsubstituted OXE-(4py)’’s is shown 
in Figure 21C. In general, phenyl substitution of the enone causes a chromophore enhance-
ment due to an enlargement of the chromophore by the phenyl π-system. Therefore, 
OXE8-(4py)’’ (black spectrum) and OXE7-(4py)’’ (blue spectrum) have the most prominent 
chromophores. The influence of the inductive effect on the OXE chromophore is visible by 
the 2-substituent: A methyl group in position 2 of the oxadiazoline unit (OXE1, OXE4, OXE7) 
gives a chromophore enhancement in comparison to H in OXE2, OXE5 and OXE8. A remark-
able decrease in the absorbance intensity is visible in the spectrum of OXE3-(4py)’’ ( Figure 
21C, cyan spectrum), giving the lowest absorbance intensity of all OXE compounds. These 
differences are explained by the stabilization of the mesomeric structure (especially the 
positive charge on nitrogen, see chapter A 1.7, Scheme 7 or Figure 22) by the +I effect of 
the methyl group. This stabilization is not provided by 2-H and CF3 in 2-position even de-
stabilizes the system by its -I effect. 
When regarding certain OXE1 analogues, the expected effects are found: N-oxidation lead-
ing to a bathochromic shift due to chromophore enhancement (Figure 21D, blue) while the 
chromophore decreases by epoxidation (Figure 21D, cyan). 
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A 2.3 Kinetic evaluation of OXE and OXE analogues 
Pre-investigation of the compounds under assay conditions 
All substances were kept in 10 mM DMSO stock solutions at -20 °C and were stable under 
these conditions for at least one year. Initial UV-Vis screenings of all OXE compounds were 
used to determine the appropriate parameters for the kinetic measurements. For these 
investigations, the UV-Vis spectra of the substances were measured in the later used assay 
concentrations of 40 µM in kinetic thiol assay solvent system, both as controls and during 
the reaction with cysteamine. By following the reactions with excess cysteamine concen-
trations of 20, 100 and 500-fold, it was possible to estimate the appropriate thiol concen-
tration range for each compound and the measurement interval to cover the whole reac-
tion time. Figure 23 shows two examples for these pre-kinetic investigations via UV-Vis. For 
the reaction of OXE1 with cysteamine (Figure 23A) an excess of 100-fold thiol is shown and 
the reaction is finished after 2 h, which is visible because the spectra do not change any 
more. On the other hand, the reaction of OXE7-(4py)’’ and 500-fold cysteamine is com-
pleted within 135 h (more than five days, Figure 23B). These spectra show that OXE7-
(4py)’’ is too slow for a full kinetic measurement which should be complete within three 
days.  
 
Figure 23: Pre-kinetic UV-Vis investigations: Reaction equations and absorption spectra of 40 µM OXEs in 
100 mM Tris-HCl buffer pH 7.4 with 2 mM EDTA/ethylene glycol 20:80. A: OXE1 + 100-fold cysteamine, B: 
OXE7-(4py)’’ + 500-fold cysteamine, * = OXE7-(4py)’’ is abbreviated OXE7. 
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Additionally, the product formation and potential byproducts were confirmed before the 
kinetic measurement by LC-MS analysis. With both analysis methods it was furthermore 
possible to compare both the UV spectra of starting materials and products. Thus, for each 
substance the best wavelength was determined for the kinetics measurements, i.e. a wave-
length at which the absorption bands of educts and products do not overlap. In all OXE and 
OXE-(4py-N-oxide)’’ compounds a time-dependent decrease of the absorbance in the 
range of 300 – 400 nm was observed, which fulfills the requirement for the kinetic UV-Vis 
measurement. An expected exception was the control compound OXE1-(4py)’’-H2, which 
contains no electrophilic enone site for the addition of cysteamine. Furthermore, cysteam-
ine does also not get attached at the heterocycle of OXE1-(4py)’’-H2. Byproduct formation 
of this kind was detected in OXE2s and OXE8s and is discussed later in the stability chapter. 
For OXEps the product formation was proven by LC-MS but both epoxide-containing com-
pounds were unsuitable for a UV-Vis kinetic measurement, which is discussed in more de-
tail later. However, pre-kinetic UV-Vis and MS studies performed with OXTEs show quanti-
tative cleavage of both thioesters and also their cysteamine adducts by the buffer ingredi-
ent ethylene glycol (Figure 24). Detectable reaction products are ethylene glycol esters of 
the cinnamic acids 46 and their cysteamine adducts 47. Pyridinyloxadiazol-thiol 45 could 
not be detected under standard LC-MS conditions, therefore further cleavage products of 
45 are assumed. Due to this instability, the two compounds OXTE and OXTE-OMe where 
excluded from further investigations. 
 
Figure 24: OXTE and OXTE-OMe and their cleavage products in kinetic thiol assay solvent system. 
Chemical reactivities towards thiols were determined by using the electrophilicity assay, 
which was developed in this work group[35] and presented in chapter A 1.5, termed as ki-
netic thiol assay. It is based on the Michael addition of the model thiol cysteamine to the 
enone moiety of OXEs (Figure 25A) and provides the second-order rate constant k2. By UV-
Vis monitoring of the reaction of OXEs with five excess cysteamine concentrations in kinetic 
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assay buffer, kobs values can be obtained by a decrease of the electrophile chromophore 
(Figure 25B and C). Plotting of these kobs against their corresponding thiol excess concen-
trations yields k2 of the reaction (Figure 25C, insert). When the reaction equilibrium is 
reached after 30 – 60 min, the chromophore of the OXE1-(4py)’’-cysteamine adduct has a 
similar absorbance as the saturated control compound OXE1-(4py)-H2, which is depicted 
for comparison in Figure 25B.  
 
Figure 25: Kinetic studies on the thia-Michael addition of cysteamine (thiol) to OXE1-(4py)‘‘. A: Reaction 
equation. B: Absorption spectra of 40 µM OXE1-(4py)‘‘ (OXE1*) in 100 mM Tris-HCl buffer pH 7.4 with 2 mM 
EDTA/ethylene glycol 20:80 with and without 50-fold cysteamine. OXE1-H2* refers to OXE1-(4py)‘‘-H2. C: 
Time-dependent absorption of OXE1-(4py)‘‘ at 330 nm after addition of cysteamine. One representative 
curve with 36-fold cysteamine is shown to determine kobs by the 1st order decay fit: y = A1*exp(-x/kobs) + y0. C 
insert: Linear regression to determine k2, based on five different thiol concentrations in duplicates. 
NMR studies with OXE1-(4py)’’ towards product formation and reversibility 
NMR studies were performed as well in order to verify the thiol addition to the enone sys-
tem of the OXEs. For these experiments, OXE1-(4py)’’ was picked together with a 12-fold 
excess of cysteamine (Figure 26a) in a solution of 1 mL DMSO-d6. For optimal results in 
terms of spectra resolution and signal visibility while avoiding precipitation, OXE1-(4py)’’ 
was used in an amount of 5 mg (17 µmol, 17 mM). 
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Figure 26: 1H NMR studies of OXE1-(4py)’’ with 12-fold cysteamine in DMSO-d6 under different conditions.  
Electrophiles of the enone-type and the investigation of their reactivity and biological activity 
44 
NMR spectra were measured every 30 min over a period of 4 h. The thiol addition is demon-
strated by the disappearance of the significant double doublets at 7.13, 6.25, and 5.88 ppm 
within 4 h, while new signals appear at 3.05 and 2.80 ppm (Figure 26b-c). No shift was de-
tected in all aromatic signals of educt OXE1-(4py)’’ and product (9 – 7.3 ppm), but a small 
shift of the methyl group signal from 2.23 to 2.27 ppm is detectable during addition, visible 
in Figure 26b. Additionally, it was of interest whether reversibility of the Michael addition 
occurs in this system. Therefore, the NMR sample was heated to 50 °C for 1 h, where re-
versibility had been found for the compound -CN-TMC under similar conditions.[36] For 
OXE1-(4py)’’, no reversibility was detected (Figure 26d), not even when using a dilution 
method with CDCl3[26] (Figure 26e). All attempts to perform the same experiments with 
cinnamoyl substituted OXEs led to non-evaluable results due to precipitation and overlap-
ping of the significant signals. 
Determination of Michael acceptor activity of OXEs and OXE-N-oxides by kinetic studies 
After the pre-kinetic investigations and the determination of all assay parameters, the 
measurements to determine the second order rate constant k2 were performed. All param-
eters are summarized in Table 13 including the overall measuring time for each compound, 
within which the reaction with excess cysteamine was complete. The results of the kinetic 
measurements, second-order rate constants k2, are also given in Table 13. 
Table 13: Parameters and results for the kinetic measurements: Wavelengths, fold cysteamine and time in-
tervals (Δt) used in the kinetic assay for OXEs and resulting k2 values.  
compound λ [nm] 
Fold  
cysteamine 
Δt 
t measured 
(Δt x 380) 
k2 / M-1s-1 ± SD 
OXE1 330 60-108 18 s 1 h 54 min 0.330 ± 0.017 
OXE1-(CN)’’ 340 12-24 20 s 2 h 7 min 1.20 ± 0.07 
OXE1-(NO2)’’ 355 12-24 20 s 2 h 7 min 1.19 ± 0.13 
OXE1-(OMe)‘‘ 330 60-100 25 s 2 h 38 min 0.260  0.019 
OXE1-(4py)’’ 330 12-48 25 and 30 s 
2 h 38 min and 
3 h 10 min 
1.40 ± 0.03 
OXE1-NO2,(4py)’’ 330 12-48 20 s 2 h 7 min 2.26 ± 0.11 
OXE1-CF3,(4py)’’ 330 12-48 20 s 2 h 7 min 1.86 ± 0.09 
OXE1-OCF3,(4py)’’ 330 12-24 15 s 1 h 35 min 2.10 ± 0.06 
OXE1-OMe,(4py)’’ 330 12-48 25 s 2 h 38 min 1.18 ± 0.03 
OXE1-4py,(4py)’’ 330 12-24 15 s 1 h 35 min 2.87 ± 0.05 
OXE1-2py,(4py)’’ 330 12-24 and 12-48 15 s 1 h 35 min 1.83 ± 0.19 
OXE1-(4py-N-oxide)'' 350 12-48 and 20-60 18 s 1 h 54 min 1.51 ± 0.05 
OXE1-(6qui)’’ 365 50-90 25 s 2 h 38 min 0.534 ± 0.037 
α-Me-OXE1-(4py)’’[a] 320-350 500 11 min 3 d (incomplete) < 0.0001 
OXE1-(4py)’’-H2 320-350 500 11 min 3 d n. r. 
OXE2-(4py)’’ 330 12-24 and 12-48 15 s 1 h 35 min 3.04 ± 0.51 
OXE2-NO2,(4py)’’ 330 12-24 15 s 1 h 35 min 4.27 ± 0.28 
OXE2-OMe,(4py)’’ 330 12-24 19 s 2 h 2.24 ± 0.14 
OXE2-(2na)’’ 330 12-60 and 30-70 25 and 30 s 
2 h 38 min and 
3 h 10 min 
1.21 ± 0.11 
OXE3-(4py)’’ 330 100-300 Stopped-Flow 3-5 min 14.3 ± 3.1 
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compound λ [nm] 
Fold  
cysteamine 
Δt 
t measured 
(Δt x 380) 
k2 / M-1s-1 ± SD 
OXE4-(4py)’’ 330 300-500 2 min 12 h 40 min 0.00861 ± 0.00214 
OXE4-(4py-N-oxide)'' 370 300-500 4 min 25 h 20 min 0.00764 ± 0.00088 
OXE5-(4py)’’ 350 300-500 1 and 5 min 
6 h 20 min 
and 31 h 29 min 
0.00937 ± 0.00135 
OXE7[a] 320-350 500 11 min 3 d (incomplete) < 0.0001 
OXE7-(4py)’’ [a] 320-350 500 11 min 3 d (incomplete) < 0.0001 
OXE7-OMe,(4py)’’ [a] 320- 350 500 11 min 3 d (incomplete) < 0.0001 
OXE7-(CF3)’,(4py)’’ 340 1000-3000 5 min 31 h 29 min 0.000501 ± 0.000019 
OXE7-(OMe)’,(4py)’’ [a] 320-350 500 11 min 3 d (incomplete) < 0.0001 
OXE8-(OMe)’‘[a] 320-350 500 11 min 3 d (incomplete) < 0.0001 
OXE8-(4py)’’ 340 
300-500 
1000-3000 
10 min 
5 min 
63 h 20 min 
31 h 29 min 
0.000478 ± 0.000070 
OXE8-NO2,(4py)’’ 340 
300-500 
1000-3000 
10 min 
5 min 
63 h 20 min 
31 h 29 min 
0.000685 ± 0.000119 
OXE8-OMe,(4py)’’ [b] 340 300-500 133 s 14 h 2 min < 0.005[b] 
OXE8-(OMe)2,(4py)’’ [b] 350 300-500 135 s 14 h 15 min < 0.007[b] 
OXE8-OMe,(NO2)’,(4py)’’ 
[b] 
350 300-500 135 s 14 h 15 min < 0.01[b] 
OXE8-(OMe)’,(4py)’’ [b] 350 300-500 10 min 63 h 20 min < 0.0009[b] 
OXE8-
OMe,(OMe)’,(4py)’’ [b] 
350 300-500 135 s 14 h 15 min < 0.005[b] 
OXE8-(4py-N-oxide)'' [c] 390 
300-500 
100-300 
10 min 
9 min 
63 h 20 min 
57 h 
n. e. 
OXCE-(4py)’’ [a] 320-350 500 11 min 3 d (incomplete) < 0.0001 
Reactions were carried out in 100 mM Tris-HCl buffer pH 7.4 with 2 mM EDTA/ethylene glycol 20:80 under 
pseudo-first order conditions at concentrations of 40 µM of OXEs together with 12-3000-fold cysteamine. 
Fold cysteamine: 12-24: 12, 15, 18, 21, 24; 12-48: 12, 18, 24, 36, 48, 12-60: 12, 24, 36, 48, 60; 20-60: 20, 30, 
40, 50, 60; 30-70: 30, 40, 50, 60, 70; 60-100: 60, 70, 80, 90, 100; 60-108: 60, 72, 84, 96, 108; 100-300: 100, 
150, 200, 250, 300; 300-500: 300, 350, 400, 450, 500; 1000-3000: 1000, 1500, 2000, 2500, 3000; λ [nm]: 320-
350 nm: 320, 330, 340, 350 nm was measured over the weekend; [a]: k2 < 0.0001 M-1s-1, reaction is not com-
plete within 3 days and 500-fold cysteamine excess; [b]: cysteamine addition to heterocycle, the represented 
maximum k2 values with second addition reaction are given; [c]: k2 could not be determined, conditions for 
the two evaluable experiments that gave k2 values of 0.000933 and 0.00264 M-1s-1; n. r. = not reactive, n. e. 
= not evaluable due to side product formation. 
A wavelength of 330 nm was utilized for all OXE1-X,(4py)‘‘ derivatives, except for the OXE1-
(phenylene-R’’)’’ derivatives, namely OXE1-(NO2)‘‘, OXE1-(CN)‘‘ and OXE1-(6qui)‘‘, where 
wavelengths of 340 – 365 nm were used for the k2 determination. All OXE2, OXE3 and OXE4 
compounds were also measured at 330 nm, while OXE7s and OXE8s were assayed at 340 
or 350 nm, according to their chromophore shifted to longer wavelengths. For all 4-pyridyl-
N-oxides (OXE1-(4py-N-oxide)'', OXE4-(4py-N-oxide)'', OXE8-(4py-N-oxide)''), the same 
wavelengths used for their OXE classes were chosen. From the initial screenings the reac-
tivity order of the OXE classes could already be estimated in advance. Additionally, com-
pounds with very low reactivity (k2 < 0.0001 M-1s-1) were detected. Their reaction with cys-
teamine was not complete within three days and 500-fold excess thiol. For the data analysis 
it is important to note that the measurements were programmed to collect 380 data points. 
Table 13 shows that the parameters were varied in some cases, which was done to find the 
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best combination of excess thiol and Δt. For some slow compounds in particular (OXE7-
(CF3)’,(4py)’’, OXE8s) lower thiol concentrations with longer reaction time gave non-evalu-
able kobs data due to side processes, only partly characterizable via LC-MS (later discussed 
in “Stability of OXEs in reactivity assay buffer”). Therefore, thiol concentrations of 1000 to 
3000-fold excess were also included in the parameters.  
In the kinetic measurements k2 values of 14.3 M-1s-1 for OXE3-(4py)’’ as the most active 
electrophile, ranging to the very weak OXE7 electrophiles with k2 values below 0.0001 M-
1s-1 were found. In general, for all acrylates (OXE1s, OXE2s, OXE3) a medium strong elec-
trophilicity with values of 14.3 – 1.02 M-1s-1 was observed. The only exceptions were the 
more electron-rich compounds OXE1 and OXE1-(OMe)’’ where the 4-pyridyl substituent in 
position 5 was replaced by a phenyl or a 4-OMe-phenylene residue, causing k2 values of 
0.338 and 0.260 M-1s-1. This clearly proves the direct influence of the substitution pattern 
of the aromatic 5-substituent, since OXE1-(CN)’’ and OXE1-(NO2)’’ gave k2 values of 1.20 
and 1.19 M-1s-1, which is in the same range as OXE1-(4py)’’ with 1.40 M-1s-1. The 6-quinoline 
residue in OXE1-(6qui)’’ gave a k2 value of 1.02 M-1s-1 being significantly lower than for 
OXE1-(4py)’’. This proves the effectiveness of 4-pyridyl substituent as an electron-with-
drawing substituent when in conjugation. Moreover, after proving that a directly conju-
gated 5-substituent is very efficient, the question was now whether the substitution pat-
tern at the sp3-hybridized 2-position is also influential on the electrophilicity of the enone 
moiety. Within the OXE1-R,(4py)’’ derivatives, electron-withdrawing residues such as 4-
pyridyl with a k2 value of 2.87 M-1s-1, 4-NO2-phenylene (2.26 M-1s-1), and 4-OCF3-phenylene 
(2.10 M-1s-1) gave up to a 2-fold increase of electrophilicity compared to 4-OMe-phenylene 
(1.18 M-1s-1), where a reduction compared to OXE1-(4py)’’ was observed. Thus, the initial 
concept to have both an sp2 and sp3-coupled handle was achieved. An additional -substit-
uent on the ,-unsaturated carbonyl, the enone system, in -Me-OXE1-(4py)’’ strongly 
diminished the electrophile activity (k2 < 0.0001 M-1s-1). This is in agreement with results of 
chalcones (1,3-dipenylprop-2-ene-1-ones), where the -Me-TMC (-Me-tetramethoxy-
chalcone) had a 26-fold lower electrophilicity compared to -H-TMC.[36] Changing the OXE 
class from OXE1 to OXE2 and OXE3, which differ in the non-aromatic substituent at position 
3 of the oxadiazoline ring – from Me to H to CF3 – gave an increase for the k2 values as 
exemplified for OXE2-(4py)’’ with 3.04 M-1s-1 and OXE3-(4py)’’ with 14.3 M-1s-1. The nature 
of the neighboring phenylene residue gave further enhancement or reduction of the Mi-
chael acceptor activity as seen in the OXE1 analogues. Switching to OXE4-(4py)’’ and OXE5-
(4py)’’ by formally introducing now a crotyl enone unit gave a strong reduction (160-fold) 
of the electrophilicity, namely k2 values of 0.00861 and 0.00937 M-1s-1. This is caused by 
the electron-donating methyl group on the -position of the enone unit. Adding a 
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conjugated aryl ring to the -position of the enone, which overall represents a cinnamyl 
residue, gave generally very low electrophilicities for OXE7s and OXE8s. While k2 values for 
OXE7s were mostly below 0.0001 M-1s-1, for OXE8s higher reactivities were found. A careful 
consideration of the LC-MS data of the reactions proved the typical thia-Michael addition 
for OXE8-(4py)’’ and OXE8-NO2,(4py)’’ with k2 values of 0.000478 and 0.000685 M-1s-1 
while all other more electron-rich OXE8s showed a double addition reaction causing false 
higher k2 values by further destroying the chromophore. In these cases, the k2 values given 
in Table 15 represent only an estimation for the upper limit of k2.  
For OXE-(4py-N-oxides)’’, similar k2 values as for their non-N-oxide analogues could be de-
tected with 1.51 M-1s-1 (OXE1-(4py-N-oxide)’’) and 0.00676 M-1s-1 (OXE4-(4py-N-oxide)’’). 
A k2 determination of OXE8-(4py-N-oxide)’’ was not possible since the time-dependent ab-
sorption curves usually gave no evaluable data due to stability issues and an exothermic 
side reaction (H2O condensed on the cover foil, which falsified the absorption). Only two 
successful experiments yielded k2 values of 0.000933 and 0.00266 M-1s-1, which allows to 
estimate a faster addition of cysteamine to OXE8-(4py-N-oxide)’’ than to its non-N-oxide 
analogue. 
Kinetic evaluation of OXEp compounds 
During the investigation of the kinetic properties of the epoxide analogues, it turned out 
that due to the lack of an enone moiety the chromophores of OXEp1-(4py)’’ and OXEp2-
(4py)’’ are unsuitable for the investigation by the kinetic thiol assay. Unlike the reaction of 
cysteamine with OXEs, which is a thia-Michael addition, the reaction mechanism with both 
OXEps is a nucleophilic substitution reaction, which leads to a ring opening. As the nucleo-
philic substitution reaction of OXEp1-(4py)’’ and cysteamine is a non-regioselective pro-
cess, both epoxide carbons are attacked by the sulfur nucleophile, leading to two regioiso-
mers which occurred as two diastereomeric pairs each (Figure 28A). Together with the re-
ferring enantiomers, the reaction results in a mixture of eight product molecules. 
Due to the lack of involved π electrons, no absorption difference between both OXEps and 
their corresponding cysteamine adducts can be detected via UV-Vis spectroscopy. At-
tempts towards a kinetic measurement of OXEp1-(4py)’’ using NMR spectroscopy (Figure 
27) was also unsuccessful due to overlapping of relevant analyzable signals 2, 3 even with 
12-fold excess of cysteamine (Figure 27b). However, the excess cysteamine cannot be in-
creased very much either since the overlap issue increases dramatically with increasing 
amount of cysteamine. Therefore, the possibilities of kinetic NMR investigations are lim-
ited. The reaction mixture was monitored over 48 h, but after 24 h nearly quantitative cys-
teamine oxidation in DMSO-d6 had taken place (Figure 27c). Based on these data, it is not 
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possible to determine whether OXEp1-(4py)’’ reacts with cysteamine at all. Therefore, an-
other method of evaluation had to be found.  
 
Figure 27: 1H NMR studies of OXEp1-(4py)’’ with 12-fold cysteamine in DMSO-d6 as attempts for a kinetic 
measurement. 
As a consequence, the reaction was proven by LC-MS and additionally monitored by the 
time-dependent decrease/increase of the educt/product LC-MS signals (Figure 28B). En-
couraged by the first results, it was decided to determine the k2 for OXEp1-(4py)’’ as rep-
resentative for the two epoxide analogues and for the reaction of epoxide containing com-
pounds with thiols in general. To the best of knowledge, no k2 for such a reaction has been 
published so far. OXE4-(4py)’’ with a k2 (determined by the kinetic assay) of 0.00861 M-1s-
1 was selected as comparative compound after approximately estimating the duration of 
the reaction until equilibrium is reached. Three cysteamine excess concentrations (500-, 
600-, 700-fold) were chosen and kobs values were determined in triplicates. Plotting the 
mean kobs values against their corresponding thiol concentrations yielded the k2 values. This 
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method gave k2 values of 0.00315 M-1s-1 for OXEp1-(4py)’’ and 0.00381 M-1s-1 for OXE4-
(4py)’’ (Figure 28C). Although the two different detection methods produce different k2 
values for OXE4-(4py)’’, these kinetic constants are of the same order of magnitude and 
therefore confirm each other. With these data it can be shown that the replacement of the 
enone functionality by an unsubstituted epoxide leads to the same dramatic decrease of 
reactivity of OXE1-(4py)’’ as enone methylation in the β-position. Thus, under these condi-
tions, the epoxide unit is a much weaker electrophile than an enone. 
 
Figure 28: Kinetic studies of the reaction of OXEp1-(4py)’’ with cysteamine. A: Reaction equation and struc-
tures of the cysteamine adducts. B: Decrease of educt during the reactions with excess cysteamine monitored 
by LC-MS measurement of the total mass signal counts of OXEp1-(4py)’’, one representative experiment for 
each thiol concentration. C: Plotting of kobs values against cysteamine concentrations to determine k2 based 
on three different thiol concentrations in triplicates for OXE4-(4py)’’ (red) and OXEp1-(4py)’’ (black). The k2 
values determined from the slope of the linear functions are 0.00381 and 0.00315 M-1s-1 for OXE4-(4py)’’ and 
OXEp1-(4py)’’ resp. 
Figure 29 shows one representative experiment of OXEp1-(4py)’’ reacting with 500-fold 
cysteamine in kinetic thiol assay solvent system after 100 min. 
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Figure 29: HPLC run and MS/UV-Vis spectra of the compounds detected in a representative kinetic experi-
ment with MS measurement (ESI-MS, M-H+): OXEp1-(4py)’’ 40 µM + 500-fold excess cysteamine (20 mM) 
after 100 min; [a]: UV-Vis-active artifact with no detectable compound in MS. 
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The product formation showing the two diastereomeric pairs 48a and b (Figure 28A) is 
proven by the HPLC run. The ring opening products occur in four peaks which represent the 
two regioisomers and their two diastereomers each, as explained above. Additionally, a 
small amount of two isomers 49 of the epoxide opening reaction by Cl- (from the Tris-HCl 
buffer) as a nucleophile was found whose amounts did not change during the time of the 
reaction. Since the epoxy-CH2 as the more reactive electrophilic position (for steric reasons) 
is preferably attacked by nucleophiles, the two isomers detected during the HPLC run can 
be assigned to structure 49 (Figure 29, again two diastereomers). The other regioisomer of 
49 is not formed because Cl- is a much weaker nucleophile than the thiol group. 
Stability of OXEs in kinetic thiol assay solvent system 
HPLC MS was furthermore used to investigate the stability of OXEs and their cysteamine 
adducts under assay conditions. OXE species with CH3 and CF3 in 2-position of the oxadia-
zoline ring (OXE1, OXE3, OXE4, OXE7) as well as OXE5-(4py)’’ show no side products in our 
buffer system. OXE2 compounds are stable during their short reaction time of < 2 h and 
show side reactions only after longer incubation time; therefore, their k2 value is not influ-
enced. Table 14 summarizes the structures and amounts of side reaction products found 
for OXE2 and OXE8 species, which cause a false higher k2 value in the latter. Especially, the 
addition of a second cysteamine molecule increases the k2 by a faster and stronger de-
crease of the chromophore. This reaction is only found in OXE8s with an aromatic methoxy 
substituent. A mono-adduct with ethylene glycol as alternative nucleophile was found in 
three compounds after more than 20 h of incubation. Furthermore, hydrolysis can occur 
on the 5-position of the oxadiazoline ring followed by decomposition to aldehyde and hy-
drazide fragments (54, Table 14 and later, Scheme 17) and was detected in OXE2-(2na)’’, 
OXE8-OMe,(4py)’’ and OXE8-(4py)-N-oxide)’’. The LC-MS analysis results of OXE8-
(OMe)’,(4py)’’ are shown as an example for the detected compounds in Figure 30 for the 
control and in Figure 31 for the reaction with 500-fold cysteamine.  
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Table 14: Results of LC-MS studies of OXE2s, OXE8s and control compounds OXAcs, OXE1-(4py)’’-H2 and 
OXE8-(4py)’’-H2. The reaction products with cysteamine and the buffer stability was investigated. 
 
Compound k2 [M-1s-1] ± SD 
Single 
cysteamine 
addition 
Double 
cysteamine 
addition (52) 
Ethylene 
glycol addi-
tion (53) 
Hydrolysis 
(54) 
OXE2-(4py)’’ 3.04 ± 0.51 +++ (50) + + - 
OXE2-NO2,(4py)’’ 4.27 ± 0.28 > 95% (50) - - - 
OXE2-OMe,(4py)’’ 2.24 ± 0.14 ++ (50) ++ - - 
OXE2-(2na)’’ 1.21 ± 0.11 ++ (50) - - ++ 
OXE8-(OMe)’ < 0.0001 > 95% (50) - - - 
OXE8-(4py)’’ 0.000478 ± 0.000070 > 95% (50) - tr. - 
OXE8-NO2,(4py)’’ 0.000685 ± 0.000119 > 95% (50) - - - 
OXE8-OMe,(4py)’’ < 0.005 ++ (50) ++ - + 
OXE8-(OMe)2,(4py)’’ < 0.007 +++ (50) ++ - - 
OXE8-OMe,(NO2)’,(4py)’’  < 0.01 +++ (50) + - - 
OXE8-(OMe)’,(4py)’’ < 0.0009 ++ (50) ++ ++ + 
OXE8-OMe,(OMe)’,(4py)’’ < 0.005 +++ (50) + - - 
OXE8-(4py-N-oxide)'' not evaluable[a] ++ (50) - - ++ 
OXAc-(4py)’’ - ++ (51) - - - 
OXAc-NO2,(4py)’’ - tr. (51) - - - 
OXAc-OMe,(4py)’’ - > 95% (51) - - - 
OXE1-(4py)’’-H2 - - - - - 
OXE8-(4py)’’-H2 - + (51) - - - 
Reactions were carried out in 100 mM Tris-HCl pH 7.4 with 2 mM EDTA/ethylene glycol 20:80 with 40 µM of 
OXE and OXE analogues and 500-fold excess of cysteamine. The incubation time prior injection was 5-24 h 
and the HPLC analysis was performed at 40 °C column temperature. Molecular ratios were estimated by UV 
detection and the relative amounts are assigned as follows: +++ = 95-60%; ++ = 60-30%; + = 30-5%; tr. = traces, 
< 5%; [a]: due to exothermic side reactions and product mixture, for the results of two successful experiments 
see Table 13. 
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Figure 30: OXE8-(OMe,)’,(4py)’’ in kinetic thiol assay solution after 24 h. 
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Figure 31: OXE8-(OMe)’,(4py)’’ with 500-fold cysteamine after 24 h in kinetic thiol assay solution. a: unknown 
compounds; b: solvent system fragment, no compound in MS detectable; c: no UV-Vis absorbance > 200 nm.  
OXAcs and OXE8-(4py)’’-H2 were used to verify the second cysteamine addition observed 
in the LC-MS measurements of OXE2s and OXE8s. They were incubated with 500-fold cys-
teamine and investigated by LC-MS and UV-Vis spectroscopy as well. In all cases, a decay 
in the UV-Vis spectra was found, which indicates an addition to the conjugated system. An 
anticipated addition to the 5-position of the 1,3,4-oxadiazoline ring as the only available 
electrophilic site was confirmed by MS data, showing the surprisingly stable adducts (Figure 
32). Figure 33 shows the detailed results of the UV-Vis measurements. This reaction was 
fast for OXAc-OMe,(4py)’’ (Figure 33C), moderate fast in OXAc-(4py)’’ (Figure 33A) and 
OXE8-(4py)’’-H2 (Figure 33D) and very slow in the NO2 analogue (Figure 33B). This finding 
is consistent with the additional products found in OXE2s and OXE8s. No cysteamine ad-
duct was found in this experiment when performed with another enone-free control com-
pound OXE1-(4py)’’-H2. These data show that a less electron-rich heterocycle with a 2-H 
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substituent in OXE8s and OXE2s allows the second cysteamine addition while the more 
electron-rich CH3 group (e.g. in OXE1s) prevents this.  
 
Figure 32: Structures of the products proven by LC-MS of the control compounds OXAc-(4py)’’ (51a), OXAc-
NO2,(4py)’’ (51b), OXAc-OMe,(4py)’’ (51c) and OXE8-(4py)’’-H2 (51d) with 500-fold cysteamine. 
 
Figure 33: UV-Vis spectra of the time-dependent reactions of the control compounds. A: OXAc-(4py)’’, B: 
OXAc-NO2,(4py)’’, C: OXAc-OMe,(4py)’’ and D: OXE8-(4py)’’-H2 with cysteamine. Reactions were carried out 
in kinetic thiol assay solvent system with an electrophile concentration of 40 µM and 20 mM (500-fold excess) 
cysteamine. 
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The observed hydrolysis (Table 14) is a cleavage of the heterocycle of the concerned OXE8s 
to the N-cinnamoylisonicotinohydrazides 54 and the corresponding aldehydes 55. This de-
cay occurs for example in OXE8-(OMe)’,(4py)’’ in the form of compound 54a (Figure 30). 
 
Scheme 17: Reaction to form hydrolysis products 54 for OXE2-(2na)’’, OXE8-OMe,(4py)’’ and OXE8-(4py-N-
oxide)’’. Ar = Ph, C4H6OCH3, Ar’’ = pyridyl, py-N-oxide, naphthyl, R3 = H, Ph.  
For OXE8-(4py-N-oxide)’’, this effect was very pronounced and lead to assay conditions, 
under which a precise k2 determination fails as described before. N-Cinnamoylisonicotino-
hydrazide 54a was additionally synthesized[43] and investigated towards toxicity and anti-
inflammatory activity to exclude any effect caused by this substance. 
A 2.4 Biological evaluation of the OXE and OXE analogues substance library 
MTT test for the determination of cell viability 
In order to find a concentration range in which the tested compounds show no toxicity, the 
MTT test described in chapter A 1.3 was performed. As explained there, the IC50 value is a 
measure for that concentration when the cell viability of the murine macrophages 
RAW264.7 is reduced by 50%. This number can be used to compare the toxicities of com-
pounds. For testing other cellular phenomena, the IC20 value (toxicity limit) is the important 
factor that indicates the concentration range below which the influence of a reduction of 
cell viability is neglected in general. The results of both the MTT assay and the later dis-
cussed NO-inhibition assay are summarized in Table 15. The toxicity limit is here given as 
the highest concentration used for the subsequent NO-inhibition assay. 
Table 15: Biological data of OXEs and OXE analogues: evaluation of toxicity and NO-inhibition properties in 
murine macrophages RAW264.7. 
Compound 
Cell viability MTT 
(IC50 / µM) ± SD 
Toxicity limit MTT 
Inhibition of NO 
production 
(IC50 / µM) ± SD 
OXE1 35.8 ± 3.8 10 6.94 ± 0.34 
OXE1-(CN)’’ 32.9 ± 2.8 5 30.6 ± 10.8 
OXE1-(NO2)’’ 41.8 ± 13.4 10 24.9 ± 20.7 
OXE1-(OMe)’’ 43.1 ± 3.5 25 11.0 ± 0.2 
OXE1-(4py)’’ 38.3 ± 3.9 10 5.34 ± 1.66 
OXE1-NO2,(4py)’’ 29.5 ± 8.1 6.25 6.31 ± 2.32 
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Compound 
Cell viability MTT 
(IC50 / µM) ± SD 
Toxicity limit MTT 
Inhibition of NO 
production 
(IC50 / µM) ± SD 
OXE1-CF3,(4py)’’ 24.2 ± 8.6 6.25 5.15 ± 3.43 
OXE1-OCF3,(4py)’’ 29.1 ± 1.6 6.25 3.35 ± 0.98 
OXE1-OMe,(4py)’’ 46.6 ± 5.8 30 5.06 ± 2.57 
OXE1-4py,(4py)’’ 32.0 ± 1.8 10 5.09 ± 2.38 
OXE1-2py,(4py)’’ 39.6 ± 2.6 10 5.60 ± 3.06 
OXE1-(4py-N-oxide)'' 46.7 ± 9.9 15 22.2 ± 7.0 
OXE1-(6qui)’’ 37.4 ± 1.8 10 7.16 ± 1.30 
α-Me-OXE1-(4py)’’ 78.5 ± 10.6 3.13 n. a. 
OXE1-(4py)’’-H2 > 100[a] 50 n. a. 
OXE2-(4py)’’ 34.2 ± 0.1 12.5 6.01 ± 1.39 
OXE2-NO2,(4py)’’ 24.6 ± 1.6 5 4.22 ± 1.16 
OXE2-OMe,(4py)’’ 32.3 ± 5.3 10 6.72 ± 1.24 
OXE2-(2na)’’ 67.1 ± 4.6 40 42.6 ± 31.5 
OXE3-(4py)’’ 40.6 ± 3.5 20 13.6 ± 2.2 
OXE4-(4py)’’ 89.6 ± 31.4 50 61.8 ± 20.0 
OXE4-(4py-N-oxide)'' > 100[a] > 100 69.4 ± 26.8 
OXE5-(4py)’’ 29.1 ± 3.4 10 n. a. 
OXE7 84.4 ± 8.8 40 n. a. 
OXE7-(4py)’’ 47.5 ± 4.5 6.25 n. a. 
OXE7-OMe,(4py)’’ 17.0 ± 2.0 5 n. a. 
OXE7-(CF3)’,(4py)’’ 31.8 ± 5.4 15 n. a. 
OXE7-(OMe)’,(4py)’’ 43.6 ± 10.5 6.25 n. a. 
OXE8-(OMe)’ 107 ± 44 50 > 50[b] 
OXE8-(4py)’’ 18.9 ± 4.8 0.4 n. a. 
OXE8-NO2,(4py)’’ 14.7 ± 7.3 1 n. a. 
OXE8-OMe,(4py)’’ 54.1 ± 4.3 6.25 n. a. 
OXE8-(OMe)2,(4py)’’ 83.7 ± 31.3 40 n. a. 
OXE8-OMe,(NO2)’,(4py)’’ 8.40 ± 2.80 1 n. a. 
OXE8-(OMe)’,(4py)’’ 52.8 ± 7.5 25 n. a. 
OXE8-OMe,(OMe)’,(4py)’’ 65.4 ± 12.4 20 n. a. 
OXE8-(4py-N-oxide)'' 73.3 ± 6.2 75 63.1 ± 17.0 
OXE8-(4py)’’-H2 80.1 ± 12.1 50 [c] 
OXCE-(4py)’’ 50.5 ± 10.6 6.25 n. a. 
OXEp1-(4py)’’ > 100[a] 50 27.7 ± 1.0 
OXEp2-(4py)’’ > 100[a] 50 36.8 ± 3.0 
OXAc-(4py)’’ > 100[a] > 100 > 100[b] 
OXAc-OMe,(4py)’’ > 100[a] > 100 101 ± 22 
OXAc-NO2,(4py)’’ > 100[a] > 100 > 100[b] 
N-cinnamoylisonicotino-
hydrazide (54a) 
97.8 ± 23.7 50 n. a. 
Biological data were measured and/or evaluated by Dita Fritsch, Sina Malenke, Monika Enzinger and Sabine 
Amslinger. [a]: no relevant toxicity was observed up to a concentration of 100 µM; [b]: small anti-inflamma-
tory activity was found up to a concentration of 50 or 100 µM respectively due to toxicity limits; [c]: small 
pro-inflammatory effect was detected; n. a. not active at concentrations up to toxicity limit. 
OXEs overall show a concentration range for the IC50 values of 8.4 – 89.6 µM with a mean 
value of 46.1 µM. More specifically, for the kinetically most active 13 OXE1s most values 
are 24.2 – 46.7 µM, where OXE1-CF3,(4py)’’ is most toxic. A similar IC50 range was found 
for OXE2s, OXE3-(4py)’’ and OXE5-(4py)’’ (24.6 – 40.6 µM) with the exception of OXE2-
(2na)’’ which is less toxic (IC50 of 67.1 µM). The toxicity of OXE1-(4py)’’ decreases to 
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78.5 µM by the influence of α-methyl substitution in α-Me-OXE1-(4py)’’ and even further 
to an IC50 of > 100 µM by the reduction of the enone double bond in OXE1-(4py)’’-H2. In 
contrast, no general toxicity trend was discovered in both phenyl-substituted classes OXE7s 
and OXE8s. Very different IC50 values were obtained for these compounds, varying from 
8.40 µM for OXE8-OMe,(NO2)’,(4py)’’ as most toxic substance from our library to > 100 µM 
in OXE8-(OMe)’. 
Regarding the OXE analogues, only a small toxicity (IC50 > 100 µM) was found for both OXEp 
compounds, however the toxicity limit (IC20) was 50 µM. In each case of the N-oxidized 
compounds, a lower toxicity was found than in their non-N-oxide analogues. This effect is 
only minor in OXE1-(4py-N-oxide)’’ and OXE4-(4py-N-oxide)’’ while OXE8-(4py-N-oxide)’’ 
has a four times lower IC50 of 73.3 µM than OXE8-(4py)’’ (18.9 µM) and is therefore less 
toxic. OXAc compounds, decorated with an acyl unit, were found to be not toxic at all up 
to a concentration of 100 µM (IC20 > 100 µM). 
Inhibition of NO production 
As explained in chapter A 1, the pro-inflammatory protein iNOS (inducible NO synthase) is 
an enzyme, whose gene expression is regulated by the transcription factor NF-κB. Thus, its 
activity in a cellular setting is a model system for the induction of anti-inflammatory activity 
in immune cells like macrophages. The cell line RAW264.7 has been extensively used for 
this purpose and was also applied in prior studies involving the electrophilicity-tuned α-X-
TMCs. In the case of α-X-TMCs the observed inhibition of NO-production was directly linked 
to the inhibition of NF-κB activation.[36] In this work, the in-vitro activity of iNOS in LPS-
stimulated murine macrophages RAW264.7 (inhibition of NO production) was used as a 
measure for anti-inflammatory activity. It is important to note that only concentrations of 
neglectable toxicity, determined by MTT test, were used for all compounds. All results in 
the form of IC50 values are summarized in Table 15. 
In OXE1s and OXE2s, single-digit IC50 values (µM) for NO inhibition of 3.35 – 7.16 µM with 
a mean of 5.58 µM were found; exceptions are non-pyridinyl-substituted OXE1-(OME)’’, 
OXE1-(CN)’’, OXE1-(NO2)’’ and OXE2-(2na)’’. The non-pyridinyl compounds OXE1-(CN)’’ 
and OXE1-(NO2)’’ stand out clearly as they show a five to six times lower IC50 value of NO 
inhibition with 30.6 and 24.9 µM, respectively, while the completely unsubstituted OXE1 is 
still in the single-digit range (6.94 µM). OXE2-(2na)’’ in comparison with the other OXE2s 
also shows only a small activity with an IC50 of 42.6 µM. Steric hindrance and/or electron-
withdrawing effect of the additional substituents may result in a weakened binding to phar-
macological targets. In other OXE1s and OXE2s a further influence of functional groups of 
any kind is not apparent: electron-withdrawing units like in OXE1-NO2,(4py)’’ as well as the 
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methoxy-containing compound OXE1-OMe,(4py)’’ have similar IC50 of 6.31 and 5.06 µM, 
respectively. N-Oxidation in OXE1-(4py-N-oxide)’’ decreases the IC50 to 22.2 µM. But the 
strongest influence on the anti-inflammatory activity is caused by an alteration of the 
enone functionality itself: α-CH3-substituted α-Me-OXE1-(4py)’’ and the reduced com-
pound OXE1-(4py)’’-H2 are inactive in concentrations up to 100 µM. Substitution of the β-
position of the enone unit with CH3 or phenyl also has a dramatic effect on the NO inhibition 
properties of OXEs. Both OXE4 compounds have an IC50 value ten times lower than the 
average OXE1s, while OXE5-(4py)’’ and OXE7s are inactive. This is also true for most OXE8s 
with the exceptions OXE8-(OMe)’ and OXE8-(4py-N-oxide)’’, where low activity with IC50 
values > 50 µM was found. For these considerations, however, it must be taken into ac-
count that most inactive compounds could not be tested at higher concentrations due to 
toxicity. Possibly, biological activity could be detected in OXE8s and OXE7s at concentra-
tions higher than their corresponding toxicity limit. However, this would not be useful, 
since the anti-inflammatory effect is to be shown in living cells triggered by LPS in their NO 
synthesis, but otherwise functioning normally. The metabolism of cells damaged or dying 
by toxins deviates from the normal one and could falsify the assay results. 
OXE3-(4py)’’, the most active substance in the kinetic assay, has an IC50 value of 13.6 µM 
and therefore a surprisingly lower activity than OXE1s and OXE2s. Since it is the only 2-CF3 
compound in this library, it cannot be assumed that this is a general effect with OXEs con-
taining CF3 in the 2-position such as the hypothetical OXE6s and OXE9s, CF3 analogues of 
OXE4/5s and OXE7/8s. Trapping of strong electrophiles by the intracellular detoxification 
agent GSH (7) is a possible explanation for lower biological activity, as shown before in α-
X-TMCs. However, this effect was only found for the very strong electrophiles α-NO2-TMC 
and α-CN-TMC with k2 values of 749 and 5750 M-1s-1 resp,[36] so it is unlikely that this is also 
true for OXE3-(4py)’’ (k2 = 14.3 M-1s-1). Probably, pharmacokinetic and pharmacodynamic 
properties such as cellular uptake and cytoplasmic stability of OXE3-(4py)’’ are impaired by 
the CF3 group. Weakened target binding properties due to altered steric and electronical 
properties in the molecule could be further reasons for such a finding. 
A relatively moderate NO inhibition activity was found in the iNOS assay for both epoxide-
containing compounds. Steric and electronic effects explain the expected lower anti-in-
flammatory activity of OXEp2-(4py)’’ (36.8 µM) in comparison to OXEp1-(4py)’’ (27.7 µM): 
the additional methyl group in OXEp2-(4py)’’ lowers the electrophilicity of the enone and 
increases steric hindrance. Compared to OXE1-(4py)’’ and OXE4-(4py)’’, these epoxide an-
alogues are less active but also less toxic, as discussed above. This may be due to inactiva-
tion by other nucleophiles and/or cellular detoxification mechanisms. Small amounts of a 
chloride adduct were at least proven for OXEp1-(4py)’’ by LC-MS (chapter A 2.3, Figure 29). 
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Nevertheless, these two substances are the second-best class of substances (after OXE1s, 
OXE2s and OXE3-(4py)’’ in this library in terms of biological activity. 
In summary, for the compound library presented in this study, a free enone or epoxide unit 
is indispensable for anti-inflammatory activity. This was proven by the completely inactive 
control compounds OXE1-(4py)’’-H2 and the three OXAcs lacking the electrophilic unit. Fur-
thermore, covalent binding as the key part in the mechanism of action is confirmed. How-
ever, the electrophilic unit is also responsible for the cell toxicity that was detected in con-
centrations of up to 100 µM. Biological activity generally corresponds to the reactivity of 
the compounds. With the exception of OXE3/5, both reactivity and biological activity of 
OXE classes follows the order OXE1/2 >> OXE4 > OXE8 > OXE7. The various substituents 
within the individual OXE classes were not observed to have an influence on the anti-in-
flammatory activity. But a reactivity fine-tuning is achieved in OXE1/2/8 which is explained 
by ±I/M effects. Another exception of the activity/reactivity correlation is OXEp1-(4py)’’. 
Interestingly, its biological activity is remarkably high compared to its low reactivity. In com-
parison to OXE1-(4py)’’, the k2 value of OXEp1-(4py)’’ is around 400 times lower, but the 
IC50 value, which represents biological activity, is only five-fold reduced. However, OXE4-
(4py)’’, which is in the same range of electrophilicity as OXEp1-(4py)’’, shows a 12-fold de-
crease of the IC50 value of biological activity. Together with the promising low toxicity of 
OXEps, one can assume a more specific mode of action due to the different electrophilic 
moiety. 
Based on the data collected, the best window for reactivity/activity in non-toxic concentra-
tions is achieved by an α,β-unsubstituted enone unit in combination with pyridine in 5’-
position. These properties were found in OXE1s and OXE2s with k2 values in the general 
range of 1.18 – 4.27 µM. For compounds with these structural features and k2, single-digit 
IC50 values for an anti-inflammatory activity in the iNOS test were found. It can be assumed 
that further new compounds with these structural characteristics will also show reactivities 
and biological activities in this range. There are indications that 2-CF3 substitution on the 
heterocycle (in further, new compounds of the OXE3 class) leads to lower anti-inflamma-
tory activity despite higher reactivity. All the discussed influences on structural features of 
OXE1-(4py)’’ as model compound are summarized in Figure 34 for OXEs with an enone 
functionality and Figure 35 for OXE derivatives with variations on the electrophilic position. 
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Figure 34: Summary of influences of substituents on OXE1-(4py)’’. IC50 = anti-inflammatory activity, NO-inhi-
bition, Tox = toxicity. 
 
Figure 35: Summary of influences by OXE analogue structural features. IC50 = anti-inflammatory activity, NO-
inhibition, Tox = toxicity. 
Figure 36 shows the relationship between reactivity in terms of the k2 value and biological 
activity in terms of the IC50 value of some substances that are active in both categories 
using logarithmic representation. The approximately linear relationship is represented by 
a straight line. Beside OXE4s as lower limit a few outliers can be seen. The "agglomeration 
area" of the OXE1s and OXE2s in the graph indicates the current upper limit of the structure 
activity optimization, which is achieved with the previous substances of the library. It re-
mains the exciting question, in which directions the further development of this field of 
research must go, in order to exceed these limits.  
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Figure 36: Correlation of the inhibition of the NO production with the second-order rate constants (as lg (k2)) 
of the Michael addition of biologically active OXE compounds with cysteamine. Blue circles: OXE1-X,(4py)’’s, 
remaining substances in the cluster are OXE1-(4py)’’, OXE1-NO2,(4py)’’, OXE1-OMe,(4py)’’ and OXE1-
2py,(4py)’’; orange squares: OXE1-(X)’’s, green triangles: OXE2s, pink triangles: OXE4s. Line indicates the lin-
ear fit. 
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A 3 Results and Discussion II: Reactivity assessment of further 
electrophiles by the kinetic thiol assay 
A 3.1 Reactivity modification of phenylacrylamide derivatives as reactive 
units in drug development 
These results are not published yet (05/2019). 
Participants in this work are: Lukas Wirth: Synthesis of all substances (Master thesis, Uni-
versity of Regensburg, 2016), Monika Enzinger: UV-Vis, kinetics and LC-MS investigations, 
Sina Malenke and Dita Fritsch: Biological testing. 
All compounds of the type 29, 30, 31 and 32 (chapter A 1.8) were screened in the UV-Vis 
thiol assay in a concentration of 80 µM, due to the small chromophore, and with 20, 100 
and 500-fold excess cysteamine. In the spectra of the four sulfonamide compounds 30 and 
31, no cysteamine-induced chromophore decreases or any other differences due to a reac-
tion with cysteamine were observed, however a cysteamine adduct was proven for 30a by 
LC-MS. Therefore compounds 30 and 31 were excluded from further kinetic investigations 
because the minimum requirements concerning their chromophores were not fulfilled. 
More precisely, the lack of a sufficient chromophore > 300 nm leads to no detectable dif-
ference between the spectra of products and cysteamine adducts. For compounds 29 and 
31, a time-dependent decrease of the chromophore due to a Michael addition could be 
detected in their UV-Vis spectra. The cysteamine adduct formation was proven by LC-MS 
and both educts and products were stable under assay conditions for > 72 h. Compounds 
29 only gave a very slow and incomplete reaction within three days (k2 < 0.0001 M-1s-1) with 
barely visible difference in the educt/product spectra. Figure 37 shows the chromophores 
of all substances 32 which were recorded during the usual screening prior to the kinetic 
assay. 
Due to their absorbance maxima < 300 nm, most substances were measured at wavelength 
between 305 and 315 nm except nitrophenylacrylamides 32a and 32f, were the NO2 groups 
in ortho and para-position lead to a chromophore enhancement as shown for OXEs in chap-
ter A 2.2. Outstanding is the absorbance band with λmax = 330 nm for the para-NO2 substi-
tuted compound 32f (Figure 37A, blue spectrum). All substances were subsequently inves-
tigated in the kinetic thiol assay and their reactivity towards cysteamine in the form of k2 
values was determined.  
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Figure 37: Chromophores of acrylamide derivatives 32 in a concentration of 80 µM in Tris-HCl buffer pH 7.4 
with 2 mM EDTA/ethylene glycol 20:80, bearing substituents with A: electron-withdrawing properties; B: 
electron-pushing properties and halogen substituents. 
The assay conditions and results are summarized in Table 16. K2 values in the range of 5.20 
– 0.00250 M-1s-1 were obtained for the 16 evaluated compounds 32. The substances are 
listed in descending order according to their reaction rates. 
Table 16: Parameters for the kinetic measurements and kinetic results of N-phenylacrylamide derivatives, 
listed in descending order according to k2 values. 
Compound 
Fold 
cysteamine 
Δt λ / nm k2 / M-1s-1 ± SD 
(2-Acrylamido)pyridine-1-oxide 32o 12-24 18 s 315 5.20 ± 0.80 
2-(Nitrophenyl)acrylamide 32a 20-100 18 s 350 0.548 ± 0.027 
4-(Nitrophenyl)acrylamide 32f 20-100 25 s 330 0.365 ± 0.021 
3,5-(Dinitrophenyl)acrylamide 32k 60-140 18 s 305 0.310 ± 0.030 
2-(Cyanophenyl)acrylamide 32c 100-300 32 s 310 0.111 ± 0.012 
4-(Cyanophenyl)acrylamide 32i 100-300 32 s 310 0.102 ± 0.010 
(2-Pyridinyl)acrylamide 32n 100-300 43 s 305 0.0925 ± 0.0072 
3-(Nitrophenyl)acrylamide 32d 100-500 43 s 305 0.0493 ± 0.0094 
2-(Bromophenyl)acrylamide 32b 100-500 32 s 310 0.0263 ± 0.0027 
4-(Iodophenyl)acrylamide 32h 100-300 2 min 310 0.0190 ± 0.0021 
(1-Naphthyl)acrylamide 32p 100-300 2 min 310 0.0137 ± 0.0024 
3,5-(Dimethoxyphenyl)acrylamide 32l 100-300 4 min 310 0.0134 ± 0.0002 
4-(Fluorophenyl)acrylamide 32g 100-300 2 min 310 0.00787 ± 0.00131 
N-Phenylacrylamide 32e 300-500 2 min 305 0.00523 ± 0.00018 
4-(Methoxyphenyl)acrylamide 32j 300-500 8 min 310 0.00458 ± 0.00052 
3,4-(Dimethylphenyl)acrylamide 32m 300-500 4 min 310 0.00250 ± 0.00003 
N-(Pyridin-4-yl)-cinammamide 29a 500 11 min 305-330 < 0.0001 
N-Phenylcinnamamide 29b 500 11 min 305-330 < 0.0001 
Fold cysteamine: 12-24: 12, 15, 18, 21, 24; 20-100: 20, 40, 60, 80, 100; 60-140: 60, 80, 100, 120, 140; 100-
300: 100, 150, 200, 250, 300; 100-500: 100, 200, 300, 400, 500; λ [nm] for slow compounds 29: 305, 310, 320, 
330.  
The reactivities generally follow a trend caused by the influence of the inductive and me-
someric effects of the aromatic substituents on the enamide unit and are observed in the 
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following order: pyridine-N-oxide > 2/4-NO2 >CN > halogen > OCH3 > CH3. By far the highest 
k2 of 5.20 M-1s-1 was found for the only 2-pyridine-N-oxide compound 32o. After OXE3-
(4py)’’, this is the second fastest k2 of all investigated compounds presented in this work. 
Compared with (2-pyridinyl)acrylamide 32n, its N-oxidation leads to a reactivity enhance-
ment of about 50-fold. This effect can be explained by the strong electron-withdrawing 
properties of the N-oxide which is moreover in close proximity to the reactive unit. NO2 
and CN-substituted compounds have moderate reactivity due to the -I and -M effects of 
those groups. In both cases the ortho-substituted compounds 32a and 32c are slightly more 
reactive than para-substituted 32f and 32i. This is explained by the shorter distance of the 
ortho substituent to the reactive unit, increasing the influence of the -I effect.  An exception 
is meta-NO2 substituted phenylacrylamide 32d with a reactivity ten-fold lower than its or-
tho or para regioisomers, which is due to the lacking -M effect. However, this is compen-
sated by the presence of two nitro groups in 32k, whose reactivity is again in the moderate 
range due to a strong -I effect. The halogen-substituted compounds are next in the order 
of reactivity with low k2 values of 0.0263 – 0.00787 M-1s-1, which is due to their -I effect, in 
comparison to unsubstituted N-phenylacrylamide (32e). It follows the order Br > I > F which 
is the same as found in α-X-TMCs.[36] Methoxy- and methyl-substituted phenylacrylamides 
32j and 32m have the expected lowest reactivity of investigated compounds, which is at-
tributable to +I and +M effects. 
A small selection of substances was tested in the two cell assays, toxicity (MTT assay) and 
anti-inflammatory activity (iNOS assay). Results are summarized in Table 17. For these few 
examples it was found that reactivity and anti-inflammatory activity correlate in the order 
of substituents on the acryl group: 
Py-N-oxide > 4-NO2-Ar > Py >> Ph, 4-CH3O-Ar 
Table 17: Biological data of a selection of N-phenylacrylamides and N-phenylethenesulfonamide (30a). Eval-
uation of toxicity and NO-inhibition properties in murine macrophages RAW264.7.  
Compound 
Cell viability MTT 
(IC50 / µM) ± SD 
Inhibition of NO production 
(IC50 / µM) ± SD 
2-Acrylamido)pyridine-1-oxide 32o 36.7 ± 8.1 5.95 ± 2.2 
4-(Nitrophenyl)acrylamide[a] 32f 56.7 2.74 
(2-Pyridinyl)acrylamide 32n > 100 33.6 ± 10.2 
N-Phenylacrylamide[a] 32e > 100 > 100 
4-(Methoxyphenyl)acrylamide[a] 32j > 100 > 100 
N-Phenylethensulfonamide[a] 30a 47.1 2.49 
Biological data were measured and analyzed by Sina Malenke. [a]: These data are taken from the master 
thesis of Lukas Wirth[44] and are listed here again for comparison purposes. 
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Activities in the single-digit µM range were found for the three most reactive substances. 
A clear correlation between toxicity and activity can be detected. 
In summary, it can be said that for the presented simplified molecules with different reac-
tive units only representatives bearing the acrylamide unit could be kinetically measured. 
The spectra show the minimum requirements for the chromophore of test substances to 
be used in the kinetic thiol assay. The reactivity of the enamide unit can be adjusted by 
substituents with different electronic properties on the aromatic ring in a range of four 
orders of magnitude. The order of reactivity follows very exactly the electronic influences 
of the substituents. Even the expected reactivity differences for o/m/p substitution in the 
case of NO2 are visible. 
A 3.2 Juglone and juglone derivatives and their reactivity towards 
cysteamine 
These results are not published yet (05/2019). 
Participants in this work are: Sebastian Schlegel: Synthesis and cell viability (toxicity) assay 
of all substances (Master thesis, University of Regensburg, 2016), Sina Malenke: Anti-in-
flammatory (iNOS) assay of all substances, Monika Enzinger: UV-Vis and MS investigations, 
evaluation of the iNOS assay (together with Sina Malenke). 
UV-Vis and LC-MS investigations of juglone derivatives 33 (chapter A 1.8, structures see 
Table 18, below) were performed in the kinetic thiol assay solvent system to show whether 
a kinetic evaluation with cysteamine is possible for this substance class. Therefore, the elec-
trophiles were investigated under assay conditions in a concentration of 40 or 80 µM and 
500-fold excess cysteamine. In contrast to OXEs or N-phenylacrylamides, alkylation of ju-
glone-type electrophiles is expected to lead to an increase in absorption and/or a shift of 
λmax towards higher wavelengths. This is due to the immediate tautomerization of the prod-
ucts 56 to the more stable aromatic naphthyl system 57 (Scheme 18).  
 
Scheme 18: Michael addition of cysteamine to juglone (33a) and its 3-substituted derivatives and the tau-
tomerization to the naphthyl core structure; R2 = H, OCH3, Br, Cl, F, N3, NH2, piperidino, morpholino; R3 = OH, 
OCH3. 
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In general, the recorded UV-Vis spectra for the different juglone compounds at a concen-
tration of 40 µM were only partially analyzable due to low absorbance intensities. There-
fore, assay concentrations of 80 µM of juglones 33 and 40 mM cysteamine was used for 
higher intensity of the compounds absorbances. All UV-Vis spectroscopic data are summa-
rized in Table 18; Figure 38 and Figure 39 show the time-dependent UV-Vis spectra of all 
15 compounds of the juglone derivative library without and with 500-fold cysteamine.  
In the case of 3-azido-O-methyljuglone (33i) no distinct educt band in the control sample 
could be observed, but a broad absorbance band in the range of 330 - 550 nm. Several 
overlapping absorbance bands in the spectra of the halide-substituted O-methyljuglones 
33d, 33f and 33g were found. An amine-substituent in 2-position (2-piperidinojuglone 33m, 
2-morpholinojuglone 33o) led to a broad absorbance band in the region of 420-520 nm 
each. All other compound control spectra show more or less distinct absorbance bands at 
420 and 430 nm and of A < 0.4 in general. Exceptions are 3-piperidino- and 3-morpholinoju-
glone (33l and 33n) with maxima at 480 and 500 nm. 
UV-Vis spectra of 3-amino-substituted juglones 33j and 33k did not show a change in the 
presence of cysteamine within 24 h, which indicates no reaction. In all other cases, the ab-
sorbance bands in the reaction mixtures increase in intensity compared to those of the 
controls, as expected for a reaction. A distinct new band, which appeared after the start of 
the reaction (10 min) could be found in the spectra of non-methylated juglones 33a, 3-
bromojuglone (33c), 3-chlorojuglone (33e) and 3-azidojuglone (33h), all at wavelengths of 
360 – 365 nm. For all other compounds a time-dependent decrease of the educt absorb-
ance was observed. However, methylated Juglones, namely O-methyljuglone (33b), 3-
bromo-O-methyljuglone (33d), 3-chloro-O-methyljuglone (33f) and 3-azido-O-methylju-
glone (33i) gave several absorbance maxima with cysteamine, which indicates product mix-
tures. For the basic substituted piperidino- and morpholinojuglones a new product band 
could be observed at 360 – 370 nm together with an increased absorbance in the range of 
450 – 700 nm. An exception is 3-morpholinojuglone (33n) where the 370 nm band is miss-
ing. The latter results indicate rather a product mixture due to a reaction with the buffer 
system and/or cysteamine than a clear, single mono-addition reaction, which can be kinet-
ically evaluated by the kinetic thiol assay. 
Electrophiles of the enone-type and the investigation of their reactivity and biological activity 
68 
Table 18: Summary of the UV-Vis experiment of 40 µM of juglone derivatives with/without 500-fold 
cysteamine in the kinetic thiol assay solvent system. 
 
33a juglone 
33b O-Methyljuglone 
33c 3-Bromojuglone 
33d 3-Bromo-O-methyljuglone 
33e 2- and 3-Chlorojuglone 
33f 3-Chloro-O-methyljuglone 
33g 3-Fluoro-O-methyljuglone 
 
33h 3-Azidojuglone 
33i 3-Azido-O-methyljuglone 
33j 3-Aminojuglone 
33k 3-Amino-O-methyljuglone 
33l 3-Piperidinojuglone 
33m 2-Piperidinojuglone 
33n 3-Morpholinojuglone 
33o 2-Morpholinojuglone 
 
Compound Analyzable absorbance bands 
33 R1 R2 R3 
control reaction 
λmax [nm] Amax λmax [nm] Amax t[a] 
a H H H 425 0.28 365 0.66 1 h 
b H H CH3 405 0.27 
355 
490 
0.48 
0.17 
12 h 
c H Br H 430 0.29 360 0.60 3 h 
d H Br CH3 
350 
410 
0.28 
0.24 
350 
490 
0.50 
0.14 
2 h 
e Cl/H Cl/H H 425 0.26 365 0.65 2 h 
f H Cl CH3 
350 
410 
0.26 
0.24 
350 
490 
0.48 
0.15 
8 h 
g H F CH3 
350 
400 
0.28 
0.24 
350 
490 
0.45 
0.12 
3 h 
h H N3 H 405 0.26 365 0.52 1 h 
i H N3 CH3 none - 
350 
490 
0.34 
0.12 
5 h 
j H NH2 H 425 0.36 425 0.35 5 h 
k H NH2 CH3 400 0.30 400 0.29 8 h 
l H piperidino H 500 0.29 370 0.46 3 h 
m piperidino H H 
430 
470-500[b] 
0.31 
0.28 
360 0.46 3 h 
n H morpholino H 480 0.34 none - 18 h 
o morpholino H H 425 0.37 360 0.47 18 h 
[a]: spectra were evaluated when the reaction was finished and/or distinct bands were visible and/or no 
bands evaluated and no more change in the spectra could be detected; [b]: broad absorbance band. 
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Figure 38: Juglone derivatives (80 µM) in the kinetic thiol assay solvent system without and with 500-fold 
cysteamine. A: juglone (33a); B: O-methyljuglone (33b); C: 3-bromojuglone (33c); D: 3-bromo-O-methylju-
glone (33d); E: 3- and 2-chlorojuglone (33e); F: 3-chloro-O-methyljuglone (33f); G: 3-fluoro-O-methyljuglone 
(33g); H: 3-azidojuglone (33h). Note: The reaction was followed over 36 h, here the spectra are shown up to 
a time, from which no more substantial changes took place. 
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Figure 39: Juglone derivatives in kinetic thiol assay solvent system without and with 500-fold cysteamine. A: 
3-azido-O-methyljuglone (33i); B: 3-aminojuglone (33j); C: 3-azido-O-methyljuglone (33k); D: 3-piperidinoju-
glone (33l); E: 2-piperidinojuglone (33m); F: 3-morpholinojuglone (33n); G: 2-morpholinojuglone (33o). Note: 
The reaction was followed over 36 h, here the spectra are shown up to a time, from which no more substantial 
changes took place. 
LC-MS investigations were subsequently performed to provide information about what 
processes take place. A general experiment was performed with 40 µM compound 
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concentration and 500-fold excess cysteamine after an incubation time of 3-5 h. The results 
of the LC-MS experiment are summarized in Table 19 for the control samples and in Table 
20 for the reaction mixtures of juglones with 500-fold cysteamine. 
Juglone (33a), its 14 investigated analogues and the products of the reactions with cys-
teamine were difficult to detect by MS and UV-Vis upon HPLC separation. In general, the 
substance signals in the control and reaction samples were very low and partly could only 
be found in traces. Exceptions were the six amine-substituted compounds 33j-o where 
prominent peaks could be found. Probably the buffer/ethylene mixture or the HPLC sepa-
ration process create conditions for the further conversion of juglones to substance mix-
tures. Also, low ionization during the usual LC-MS procedures could be a reason. The prob-
lem of only very low compound amounts detected by LC-MS occurred also during the ana-
lysis of the neat substances in the course of characterization by Sebastian Schlegel. In his 
work the problem could partly be overcome by changing the method from LC-MS with ESI 
ionization to GC-MS and EI ionization.[57] 
Table 19: Summary of LC-MS results for control samples of juglone derivatives. 
 
Compound Mass signals found in control samples 
33 R1 R2 R3 educt 
ethylene glycol 
substitution 
other 
a H H H - - no compound detected 
b H H CH3 ✓ (low) - - 
c H Br H - 59a - 
d H Br CH3 ✓ (traces) 59b - 
e H Cl H - 59a - 
f H Cl CH3 - - unknown compound 
g H F CH3 - - unknown compound 
h H N3 H - 59a - 
i H N3 CH3 - - no compound detected 
j H NH2 H ✓ - - 
k H NH2 CH3 ✓ - - 
l H piperidino H ✓ - - 
m piperidino H H ✓ - unknown compound 
n H morpholino H ✓ - - 
o morpholino H H ✓ - - 
✓ = found 
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For juglone (33a) no substance at all could be found in the control samples despite the 
experiment was repeated with higher substance concentration and after 10 min – 1 h. Only 
for the control samples of the amino-substituted juglones 33j-o, O-methyljuglone 33b and 
O-methyl-bromojuglone 33d the educts were found (Table 19). All other control samples 
contained unknown compounds and/or ethylene glycol-substituted juglones 59a or 59b 
(Table 19). These compounds are formed by an addition-elimination mechanism of the nu-
cleophile ethylene glycol to the double bonds of 33 with halogens or N3 as leaving groups 
to give structure 59.  
A surprising outcome was also found in the reactions, which resulted partly in mixtures of 
different grades of complexity (Table 20). O-Methyljuglone (33b) was the only substance 
were the anticipated cysteine monoadduct was detected among a mixture of four products 
in total. All reaction mixtures, except 4, contained products 60a or 60b with double added 
cysteamine due to the high cysteamine excess (Table 20). These products were additionally 
present in their re-oxidized form. In these cases, as before with the educts, the substituent 
was eliminated in the 2- or 3-position as leaving group. For some of those double cysteam-
ine-substituted and re-oxidized products, imine formation to a six-membered ring occurred 
(two isomers 62a and b, Table 20). This reaction is probably favoured by an O-methylation, 
because it only occurs in O-methyljuglones 33b, 33d, 33f and 33g. For all amine-substituted 
compounds 33j-o, except 33m (2-piperidinojuglone), cysteamine monoadducts were ini-
tially formed, but were oxidized back to their quinone form each (product mass minus 2H, 
61a-e, Table 20). 
Enzymatic re-oxidation by oxygen of electrophiles after Michael addition is a characteristic 
process in cells.[61] The oxidized species found in the LC-MS investigations prove that this 
process takes place for the investigated juglone derivatives without enzymes under these 
assay conditions over time. This was reported before for other assay systems.[64] 
Some of the reaction samples contained detected mass signals for which no corresponding 
structures could be proposed, they are listed as unknown compounds in Table 20. The LC-
MS data can be viewed in the appendix. Note: Only compounds with distinct and conclusive 
MS AND UV-Vis data were evaluated. Assay fragments or artifacts and other unknown com-
pounds which appeared only in the LC-run and/or in the UV-Vis detection with no evaluable 
MS data and/or no UV-Vis absorbance > 200 nm were not considered in the evaluation. 
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Table 20: Summary of the LC-MS results for reactions of juglone and juglone derivatives with 500-fold cys-
teamine detected by LC-MS analysis and found oxidized structures in the reaction mixtures.  
 
Educt Mass signals detected in reaction samples 
33 R1 R2 R3 Educt 
single cysteamine 
addition 
double cysteam-
ine addition 
other 
a H H H - - 60a - 
b H H CH3 - 57a 60b, 62a and 62b - 
c H Br H - - 60a unknown 
d H Br CH3 - - 60b, 62a or 62b - 
e H Cl H - - 60a unknown 
f H Cl CH3 - - 60b, 62a or 62b - 
g H F CH3 - - 60b, 62a or 62b unknown 
h H N3 H - - 60a - 
i H N3 CH3 - - 60b - 
j H NH2 H ✓ 61a - - 
k H NH2 CH3 ✓ 61b - - 
l H pip. H ✓ 61c 60a - 
m pip. H H ✓ - 60a - 
n H morph. H ✓ 61d - unknown 
o morph. H H ✓ 61e - - 
pip = piperidino, morph = morpholino; ✓ = found; unknown = unknown compound(s) detected, see appendix.  
One can summarize that juglone and its derivatives are not easily evaluated in the kinetic 
thiol assay due to stability issues in the buffer/ethylene glycol system and no distinct single 
product reaction outcome but rather a complex product mixture. Since for each compound 
33 at least two processes always take place, one has to consider that the determined k2 will 
be inaccurate, more precisely the value would be an average of the rate constants of all 
reactions taking place. 
With the help of LC-MS analyses, the UV-Vis bands could now be assigned to products and 
the processes that can be seen in the time-dependent spectra becomes understandable. 
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Juglon 33a, 3-azidojuglon 33h and both halogen-substituted, non-methylated compounds 
33c and 33e form the group of substances that together with cysteamine form the double-
substituted re-oxidized product 60a, to which the absorption band at 365 nm belongs. A 
kinetic measurement is very well feasible for this group if it is tolerated that the obtained 
k2 value will be a mixture of several processes taking place. It could still be investigated 
whether only a single addition takes place with less excess cysteamine. However, due to 
the instability of the substances, which manifests itself within 24 h until un-detectability, it 
is more recommended to use higher excess concentrations for fast reactions. In order to 
optimize stability, changing the reaction medium to solvent-free buffers would be a possi-
bility, since ethylene glycol was revealed as the causative component. 
In the reaction solutions of all O-methylated compounds, as well as in the UV-Vis spectra, 
substance mixtures were identified as products which also contain the oxidized substances 
60. Since the k2 value becomes even less accurate due to several products, a kinetic meas-
urement without optimization of the assay conditions (solvent system, excess thiol) is not 
recommended.  
If the further, amine-substituted compounds 33j and 33k of the juglon substance library 
are regarded, one finds a special feature in the two amino compounds, since they have 
been shown to react to products 61a and 61b, but the process is not visible in the UV-Vis. 
It is most likely that the chromophores of educts and products are very similar so that there 
is no overall time-dependent change in the course of the reaction. Therefore, kinetic meas-
urement with the kinetic thiol assay is not possible for these two substances either.  
Finally, for the last group, the piperidino and morpholino substituted substances 33l – 33o, 
kinetic measurement is possible by UV-Vis measurement but the k2 value obtained does 
not reflect a single process but several successive reactions.  
In the literature it was shown that the processes of Michael addition and subsequent oxi-
dation can be separated by lowering the reaction temperature to 10 °C. The oxidation takes 
place sufficiently slowly at this temperature so that a k2 value of 0.022 M-1s-1 for the Mi-
chael addition of GSH to juglon (33a) in HEPES buffer could be determined.[64] This shows, 
that optimization of the conditions for a kinetic measurement is possible and also temper-
ature changes can thus be taken into consideration. A detailed kinetic investigation and 
assay optimization of the juglone substance library could not be performed within this 
work. In general, a moderate to high reactivity is assumed due to the double electron-with-
drawing effect of two carbonyl groups. 
Concerning biological activity, the finding that most of all amine-substituted compounds, 
i.e. more electron-rich electrophiles, have an anti-inflammatory effect, is surprising. This 
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supports the findings that the biological activity for this compound class in general is not 
entirely due to its electrophilicity. For the anti-inflammatory activity it seems reasonable, 
that these properties could be a result of other molecular effects such as radical-scavenging 
and/or redox properties. 
A 3.3 α-Nitro-hydroxychalcone (α-NO2-HC) as part of the α-X-hydroxy-
chalcone (α-X-HC) substance library 
These results are not published yet (05/2019). 
Participants in this work are: Nafisah Al-Rifai, Lukas Wirth, Maria Landa and Grigor Gurza-
dyan: Attempts towards the synthesis of  α-NO2-HC; Monika Enzinger: Synthesis, UV-Vis and 
MS investigation of NO2-Flavanone/α-NO2-HC; Sina Malenke: Biological testing of NO2-Fla-
vanone/α-NO2-HC. 
As NO2 as further interesting α-substituent was required for this compound library, the 
synthesis, kinetic and biological investigation of α-NO2-HC was included in the work of this 
thesis. 
Synthesis 
Standard procedures to get the desired structure α-NO2-HC by demethylation of the 2’-
OCH3 group of the literature-known substance α-NO2-TMC[36] had failed before (performed 
by Lukas Wirth, Maria Landa and Grigor Gurzadyan, unpublished). Several conditions such 
as BCl3, BBr3 and basic cleavage with KOH were screened, but only a mixture of species with 
free OH groups on ring B was obtained (Structures 63 and 64, Scheme 19). This was de-
tected by careful evaluation of the MS fragments via LC-MS during the regular pre-kinetic 
screening under assay conditions. 
 
Scheme 19: Attempt to synthesize α-NO2-HC by demethylation of α-NO2-TMC. 
Therefore, α-NO2-HC was provided by the synthesis of the isopropyl-protected precursor 
70 and subsequent selective deprotection in 2-position (Scheme 20).  
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Scheme 20: Synthesis route to obtain α-NO2-HC/NO2-flavanone. 
The first three synthesis steps to obtain the isopropyl-protected α-NO2-hydroxychalcone 
70 were performed according to known procedures[36] [77] and moderate to good yields 
were achieved. For the deprotection two conditions were applied with AlCl3 in acetonitrile 
at room temperature[78] being superior to BCl3 in DCM at -78 °C (45 vs 40% yield). Purifica-
tion of the crude material was only possible with reversed phase chromatography as the 
product gave no distinct band on normal silica gel but a yellow area blurred from the base-
line to the middle of the TLC plate with various screened solvent mixtures including the 
addition of TFA. 1H NMR analysis in CDCl3 shows the cyclized NO2-flavanone as main prod-
uct, recognizable by two prominent doublets at 5.80 and 5.74 ppm with a typical coupling 
constant (J = 11.9 Hz) and approximately 10% of α-NO2-HC. In DMSO-d6 the equilibrium is 
completely shifted to the flavanone. It was possible to separate both species by preparative 
HPLC, but isolation of α-NO2-HC failed due to the quick re-adjustment of the initial 10:1 
equilibrium of α-NO2-HC/NO2-flavanone in the solvent system water/acetonitrile/HCOOH 
(40:60:0.1). It has already been reported that in the case of similar NO2-substituted com-
pounds only the cyclized product was obtained.[79] For steric reasons, the diastereomer 
with the nitro and phenyl group trans-positioned to each other at positions 2 and 3 is 
formed as a racemate (2S,3S or 2R,3R-configured). 
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UV-Vis and LC-MS analysis 
A 10 mM stock solution in DMSO followed by dilution in kinetic thiol assay solvent system 
was prepared from the solid NO2-flavanone. The reaction in a concentration of 40 µM with 
12, 100 and 500-fold of cysteamine was investigated by UV-Vis spectroscopy over a period 
of three days. The prominent absorption band with a maximum at 380 nm decreases slowly 
in the presence of cysteamine. This decay is slow for the 12-fold, faster for 100-fold and 
complete within 48 h for the 500-fold cysteamine excess.  
 
Figure 40: A: Comparison of the chromophore of NO2-flavanone in different solvent systems; blue: 100 mM 
Tris-HCl buffer pH 7.4 with 2 mM EDTA/ethylene glycol 20:80; red: HPLC solvent mixture Water/Acetoni-
trile/HCOOH 20:80/0.1%. B: Time-dependent UV-Vis spectra of 40 µM NO2-flavanone and 500-fold (20 mM) 
cysteamine in thiol assay buffer.  
Due to this finding, a reaction of the open-chained α-NO2-HC with cysteamine to adduct 
71, subsequent back equilibration and thus consumption of NO2-flavanone can be assumed 
(Scheme 21). This would be the expected and well-known thia-Michael addition of thiols to 
enones such as chalcones. 
 
Scheme 21: Equilibrium of NO2-flavanone and α-NO2-HC with subsequent Michael addition of cysteamine to 
71. 
To further investigate the process witnessed by UV-Vis spectroscopy, the reaction of NO2-
flavanone/α-NO2-HC with cysteamine was monitored by LC-MS over a period of 24 h. 
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Interestingly, the addition product 71 was immediately produced, but only in a very small 
amount. It is consumed completely during the time between 8 and 24 h. Moreover, the 
reaction leads to a substance mixture containing educt and product fragments without 
complete consumption of the starting material. More precisely, NO2-flavanone was still the 
main compound in the LC run after 24 h. Figure 41 exemplarily shows the results of this 
experiment after 8 h of reaction time and suggests structures for the substance mixture. 
 
Figure 41: HPCL run of the reaction mixture of NO2-flavanone with cysteamine 500-fold after 8 h, MS and 
UV-Vis spectra of the fractions and structure suggestions. HPLC-[a]: no UV-Vis detection at 300 nm; [b]: no 
compounds detected, neither in MS nor in UV-Vis; [c]: UV-Vis-active artifacts with no detectable compounds 
in MS. 
Fragmentation of the cysteamine adduct to 72 was similarly observed in α-X-TMCs and α-
X-HCs.[39] For unknown compound 73, three structure suggestions are possible. One is pro-
duced by a Schiff base formation of the NH2 moiety of adduct 71 with the carbonyl group 
and subsequent reduction to 73a by excess cysteamine which itself is oxidized to its disul-
fide. This might occur due to the strong electron-withdrawing effect of the nitro group. But 
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more likely, its -M/-I effect leads to immediate imine formation of NO2-flavanone with cys-
teamine-NH2 and subsequent reduction to 73b as described before. The same process 
could also occur for the small amounts of α-NO2-HC to 73c. However, 73b is the most likely 
structure, derived from NO2-flavanone. This is also visible in the post-LC UV-Vis spectrum 
of NO2-flavanone in water/acetonitrile, 0.1% HCOOH (Figure 40A and Figure 41, com-
pounds 73 and NO2-flavanone). Both spectra show a very similar chromophore which ex-
cludes 73c. For 73c, an absorbance band > 300 nm would be expected.  
This poor reactivity is also reflected in the biological activity: neither cell toxicity nor anti-
inflammatory properties were found in the in-vitro assays (Table 21). 
Table 21: Result of the in-vitro testing of NO2-flavanone with murine RAW264.7 macrophages done by Sina 
Malenke. 
Compound 
Cell viability MTT 
(IC50 / µM) ± SD 
Toxicity limit MTT  
(IC20 / µM) 
Inhibition of  
NO production 
(IC50 / µM) ± SD 
NO2-flavanone > 100 µM > 100 µM > 100 µM 
In summary, it was found that by introducing the NO2 group, the strong electron withdraw-
ing properties lead to an almost complete conversion of α-NO2-HC into its flavanone form, 
resulting in the loss of Michael acceptor reactivity and biological activity. The effect is so 
strong that, in contrast to all other α-X-HCs,[39] the NO2 compound was not isolated as chal-
cone but as flavanone. 
A 4 Results and Discussion III: Investigations for a further devel-
opment of the kinetic thiol assay towards the use of colorless 
enones as test substances 
A 4.1 Syntheses 
For a further development of the kinetic thiol assay towards the kinetic investigation of 
completely colorless electrophiles (chapter A 1.9), the synthesis of several possible fluores-
cent thiol probes was approached. All three known compounds DCY, acetyl-MSTI and NBD 
where synthesized as reported in the literature. Scheme 22 shows the synthesis path and 
the yields achieved for DCY.[71] The starting material dansyl chloride (74) contains already 
of the fluorescent molecule part and is equipped with the cysteamine part first by dimeri-
zation to DCY disulfide 75 which was obtained in a very good yield. The second step was a 
reduction of the disulfide by NaBH4 to the desired free thiol compound which was received 
in 47% yield after column chromatography. One advantage of the substance is its high sta-
bility against oxidation. 
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Scheme 22: Synthesis of DCY.[71] 
Acetyl-MSTI was synthesized[72] according to Scheme 23 by first converting p-methylthio-
benzaldehyde (76) into the non-commercially available acetyl-protected compound 78 
which was received in moderate yield. This reaction is a combination of deprotection of the 
methylated thiol to the free thiolate which is acetylated subsequently. An aldol condensa-
tion of 78 and tetramethylindolium iodide (79) with NaOAc as base was performed to ob-
tain the target compound Acetyl-MSTI. In comparison to the literature[72] the yield was 
improved from 55% to quantitative yield by dropwise addition of 78 to the indolium solu-
tion over 1 h and a longer reaction time. The obtained orange solid product is stable due 
to the thiol protection. 
 
Scheme 23: Synthesis of Acetyl-MSTI.[72] 
NBD was obtained by a SNAr of the chlorobenzofurazan 80 and NaSH in MeOH[73] in nearly 
quantitative yield as association with 1 eq. NaCl. This was accepted due to the simplicity of 
the synthesis, since NaCl does not interfere with all spectroscopic investigations or the 
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buffer. 80 is converted quantitatively to NBD when treated with 2 eq. NaSH. All experi-
ments with less eq. NaSH led to a complex mixture of substances. Likewise, no purification 
method for the separation of NaCl was successful, it repeatedly led to thiol oxidation and 
other impurities, which were possibly caused by further nucleophilic substitutions to phe-
nyl-S-phenyl species. 
 
Scheme 24: Synthesis of NBD.[73] 
In addition to those known from literature, new fluorescent thiol dyes designed during this 
work were also originally to be synthesized (Figure 42). 
 
Figure 42: Target structures of new fluorescent thiol dyes approached in this work. 
One of these target structures is the azetidine-substituted phenoxazine-thiol 81, which was 
inspired by the work of Grimm et al., published in 2015,[80] in which a large number of new 
substances for fluorescence microscopy were synthesized and characterized. The group in-
vestigated various phenoxazines and found that representatives containing of the double 
amine-substituted salt structure as in 81 have an improved quantum yield and extinction 
coefficient, of which azetidine-substituted representatives have the best results. These two 
properties would help to significantly reduce the concentration of the thiol probe in the 
assay. Therefore 81 was designed, which carries the required thiol group. Scheme 25 shows 
the retrosynthesis of 81. The thiol group can be introduced by nucleophilic substitution of 
the halogen in 83, the azetidine groups by a Pd-catalyzed Buchwald-Hartwig coupling. Since 
substance 86 or similar halogenated phenoxazines are not commercially available, this het-
erocycle must be synthesized from the two building blocks 4-chloro-6-nitrosoresorcinol 
(84) and resorcinol (85). 
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Scheme 25: Retrosynthesis of the desired structure of the thiol-containing phenoxazine dye 81. 
The synthesis of substance 81 could unfortunately not be completed within this work, but 
most of the precursors were successfully synthesized according to Scheme 26. The known 
substance 4-chloro-6-nitrosoresorcinol (84) could be obtained with a very good yield by 
electrophilic aromatic substitution with chlororesorcinol (87) and isopentyl nitrite (88) in 
methanolic KOH.[81] Heterocycle 86 was synthesized by heating the two starting materials 
in concentrated sulfuric acid.[81] Substance 86 turned out to be a very poorly soluble, dark 
violet, almost black material, which could not be characterized by NMR but only by MS. In 
addition, the successful synthesis of triacylated reduced phenoxacine 89 shows the exist-
ence of 86. Since 86 is most soluble in H2O, NMR experiments were performed to charac-
terize the substance in D2O, D2O/NaOD and D2O/DCl, which was unsuccessful. Substance 
89 was obtained by reduction by SnCl2 followed by acetylation in Ac2O in moderate yield.[82] 
The reason for this was a difficult workup, as the crude product had to be isolated from 
voluminous insoluble tin salts, which prevented phase separation. One improvement was 
the workup in a non-polar organic solvent and separating the insoluble residues by filtra-
tion. The reduction of the heterocycle is necessary to introduce both azetidine groups by 
means of Pd-catalyzed coupling, for which both substitution sites must first carry triflates 
as leaving groups. For this purpose both hydroxy groups at the phenoxazine phenyl rings 
were first deprotected,[82] whereby 90 was obtained in a very good yield. By using a selec-
tive method for the deprotection of esters only, the heterocyclic nitrogen remains pro-
tected. Also the triflation to ditriflated phenoxazine 92 could be accomplished by the use 
of trifluoro-N-phenyl-N-((trifluoromethyl)sulfonyl)methanesulfonamide (91) with good 
yields.[83] The reaction with triflic acid anhydride as a reagent only produced yields of 1-
10% after isolation of product 92 from a complex mixture.  
Finally, the palladium-catalyzed Buchwald-Hartwig coupling turned out to be very problem-
atic. Although the reference reports a promising yield of 92% in this reaction if the molecule 
is not chlorine-substituted,[80] this could not be observed for substance 93. A complex mix-
ture of substances was always obtained in the experiments, even if the reaction was carried 
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out at room temperature or even on ice. After some time, the baseline spot became dom-
inant in TLC control, suggesting oligomerization or polymerization. MS studies showed that 
the desired product 93 was not present in the mixture. In the context of this doctoral thesis 
a successful optimization of the reaction was not achieved. 
 
Scheme 26: Attempted synthesis of an azetidine-containing phenoxazine dye.  
Another approach for a new substance to be used as a thiol probe in the kinetic thiol assay 
was the fluorescein derivative 82. Fluorescein (95) was selected as fluorophore because of 
its excellent and well-known fluorescence properties. Analogous to the assay already pre-
sented by McCallum et al for Acetyl-MSTI, 72 should also initially be protected with an 
acetyl residue, which is cleaved in situ to the free thiolate in the first step of the assay. 
Scheme 27 shows the retrosynthesis: 82 can be produced from fluorescein and a protected 
p-halogen-thiophenol 94 by a palladium-catalyzed coupling.  
 
Scheme 27: Retrosynthesis of the thiophenol-substituted fluorescein derivative 72. 
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Suzuki coupling was chosen as the method, for which the two literature-known precursors 
97 and 98 were synthesized in moderate to good yields (Scheme 28). 4-Bromothiophenol 
(96) was first protected with a tert-butyl-group[84] to 94 and subsequently converted into 
the phenyl-substituted boronic acid 97 using n-BuLi, then B(OMe)3 and HCl for demethyla-
tion.[85] The monotriflation of fluorescein to form 98 gave only a moderate yield of 40% 
when stirred in a round-bottom flask for two days,[86] but was much faster performed using 
a microwave reactor by accepting a slightly lower yield of 36%.[87] NMR spectroscopy 
showed that the lactone structure is present in 98. Yields could not be improved, since a 
ditriflated by-product was formed. 
 
Scheme 28: Synthesis of the precursors for a Suzuki coupling reaction. 
The Suzuki coupling could be successfully carried out in the microwave reactor and 99 was 
obtained in good yield.[88] The final step, the replacement of the tert-butyl group by an 
acetyl protecting group on the thiol to target structure 82, Figure 16), could not be investi-
gated within the scope of this work. 
 
Scheme 29: Synthesis of tert-butyl-protected thiophenol-fluorescein 99. 
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A 4.2 Fluorescence investigations of Michael addition reactions 
The obtained potential thiol probes DCY, NBD and Acetyl-MSTI were examined towards 
their spectroscopic properties and their reaction with enone-type electrophiles.  
DCY was measured in a concentration of 10 µM under the usual assay conditions in kinetic 
thiol assay solvent system. As the excitation wavelength that produces the highest fluores-
cence at 525 nm, 350 nm was determined and used for all further investigations. Cyclohex-
enone (34), OXE1-(4py)’’ and the chalcone α-Br-TMC were used as test electrophiles in 20-
fold excess in the Michael addition with DCY. 
Initially, a quick decrease of the fluorescence intensity of DCY was found 1 min after the 
start of the reaction for OXE1-(4py)’’ and α-Br-TMC (Figure 43 A). No such decrease was 
found for 34, although a DCY-cyclohexenone Michael adduct was proven by LC-MS. To in-
vestigate the possible influence of quenching effects, the non-reactive DCY synthesis pre-
cursors were additionally investigated as controls. It was shown that mixtures of DCY disul-
fide (75) and all three electrophiles show the same decrease in fluorescence intensity as 
the free thiol DCY (Figure 43B). An LC-MS control experiment showed no reaction products 
of any kind for DCY disulfide and 34, as expected. Figure 43C shows for cyclohexenone 34 
that even after 20 min there are no significant changes in the spectra for both DCY and its 
disulfide.  
It appears that the relatively high excess of electrophiles has quenching effects on the flu-
orescence of DCY, which is also true for non-reactive fluorescent DCY derivative DCY disul-
fide. No indication was found that a detectable reaction occurs. The use of DCY for the 
planned new assay is therefore excluded as the substance is not suitable. 
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Figure 43: Fluorescence measurements with DCY as thiol probe in the reaction with test electrophiles in Tris-
HCl buffer pH 7.4 with 2 mM EDTA/ethylene glycol 20:80, λex = 350 nm. A: Fluorescence spectra of the reac-
tions of 10 µM DCY and 20-fold excess of three different enone electrophiles: cyclohexenone (34), α-Br-TMC 
and OXE1-(4py)’’ after 1-4 min); B: Fluorescence spectra of control compound DCY disulfide (75) and 20-fold 
excess of three different enone electrophiles: cyclohexenone (34), α-Br-TMC and OXE1-(4py)’’ after 1-4 min; 
C: Time-dependent fluorescence spectra of DCY (dark spectra) and DCY disulfide (75, bright spectra) without 
and with 20-fold cyclohexanone (34). 
Furthermore, Acetyl-MSTI was tested according to the assay developed by McCallum et 
al.[72] Acetyl-MSTI was first converted to MSTI in PBS pH 12 - MeOH 1:1 and then added to 
the test electrophile cyclohexenone (34) in PBS pH 7.4 (dilution factor PBS pH 12 to PBS pH 
7.4: 1:30). The assay concentration of MSTI was 30 µM with 12-fold excess of 34. Non-
deprotected Acetyl-MSTI was measured as control compound. Additionally, the very 
strong electrophile benzoquinone was investigated as it is reported to be a “hit” com-
pound.[72] Figure 44A shows the probe spectra over time as control while Figure 44B and C 
shows emission spectra of both investigated reactions. For the in-situ deprotected free 
thiol MSTI only a very low fluorescence intensity < 5 x 10-4 CPS (counts per second) was 
found even with intensity-increasing instrument settings (broadening of the excitation slot, 
longer detection). 
Free thiol MSTI and Acetyl-MSTI differ significantly in their emission properties. Immedi-
ately after starting the reaction of MSTI with both electrophilic compounds 34 and benzo-
quinone, a decrease in fluorescence is observed, leading to a complete decay of the MSTI 
emission band in the reaction with benzoquinone, whereas this only occurred partially for 
34. Subsequent time-dependent measurements of both reaction mixtures showed no 
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changes (Figure 44B and C). Furthermore, both electrophiles were measured as controls 
without MSTI, whose emission spectra are at the intensity level of the blank and Acetyl-
MSTI. Unfortunately, the anticipated instability of MSTI also becomes apparent (Figure 
44A). After 30 min, the emission band of MSTI had clearly decreased due to most likely 
oxidation. Neither optimizations of the conditions with regard to oxidation stability of MSTI 
nor kinetic investigations could be carried out within this work. In order to get meaningful 
kinetic data, the oxidation sensitivity of MSTI must be addressed first. Although, despite 
the poor emission properties of MSTI, the substance would certainly be suitable as a probe 
in the new assay. Based on these and the previous studies[72] one can propose that MSTI 
probably reacts very quickly with strong to medium-strong electrophiles. Similar results 
have also been obtained in studies on the UV-Vis absorbance of MSTI with and without test 
electrophiles under the same conditions (data not shown). 
 
Figure 44: Fluorescence measurements with MSTI as thiol probe in the reaction with test electrophiles in PBS 
buffer pH 7.4, λex = 350 nm. A: 30 µM MSTI as control; B: 30 µM MSTI and 1.5-fold benzoquinone; C: 30 µM 
MSTI and cyclohexanone (34). Measurements were performed in PBS pH 7.4. 
Finally, assessments of NBD by fluorescence spectroscopy with various test electrophiles 
revealed no evidence that a Michael addition was taking place (data not shown). With op-
timized instrument settings, a small emission could be measured for both NBD and test 
electrophiles alone. In most of the investigated reactions, only a fluorescence addition of 
both components was detected moreover. A Michael reaction adduct could not be con-
firmed by LC-MS studies. It was also found that the NBD control solution was not stable 
since emission intensity increased over time. This is probably due to auto-SNAr reactions to 
diphenyl sulfide species. 
In summary, a suitable thiol probe could not be found in the performed investigations. A 
Michael addition that could clearly be detected by fluorescence spectroscopy was only 
measured with MSTI, as literature reported before.[72] Furthermore, the susceptibility of 
aromatic free thiols to oxidation is a major problem, since false reaction rates would be 
obtained in kinetic measurements. Two proposals for further thiol probes are shown in 
Figure 45.[75] Both are reported in the literature to have different fluorescence properties 
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depending on whether a free or an alkylated thiol group is present. Since this fact is only 
mentioned in the literature but not explained in detail, further investigations are needed 
in the future. Not only the emission properties make these compounds interesting, also a 
reduced susceptibility to oxidation can be expected, since they are not aromatic but alkyl 
thiols. During this work syntheses of 100 and 101 were attempted, but due to various issues 
this work could not be completed. While 100 was detected by LC-MS, but could not be 
isolated, synthesis attempts of 101 were not successful. 
 
Figure 45: Suggested compounds for further investigations of their suitability as probes in the kinetic assay 
for colorless electrophiles.[75] 
A 5 Summary of Chapter A 
The demanded further representatives of the new compound library of the enone-substi-
tuted 1,3,4-oxadiazolines (OXEs) were synthesized. A thia-Michael addition of cysteamine 
to all compounds bearing the enone unit was proven via LC-MS and UV-Vis spectroscopy, 
exemplarily also via NMR for OXE1-(4py)’’. Appropriate reactivity assay conditions and the 
second-order rate constants for all suitable compounds were determined under pseudo-
first order conditions. Values between 14.3 and 0.000478 M-1s-1 for k2 values were meas-
ured. Thus, the range of values for this compound library covers five orders of magnitude. 
A detailed analysis under assay conditions shows by-products for some substances and thus 
limits for the determination of reactivity. OXEp1-(4py)'' was unsuitable for UV-Vis kinetic 
measurement, therefore the reactivity was measured by LC-MS using OXE4-(4py)’’ for com-
parison and a k2 value of 0.0032 M-1s-1 was determined for OXEp1-(4py)''. 
Anti-inflammatory properties in the form of an inhibition of NO production by NF-κB were 
found in-vitro in acryl- or crotyl-substituted OXE classes and both OXEp compounds. More-
over, the anti-inflammatory activity of the whole compound library correlates with its elec-
trophilic properties and can be controlled and predicted by their structure. An electrophilic-
ity in the form of 0.330 – 4.27 M-1s-1 together with the crucial structure elements free 
enone group and pyridinyl unit in the 5‘-position lead reliably to single-digit IC50 values of 
NO-inhibition. More compounds need to be synthesized and investigated to see if this 
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effect can be pushed further, especially the interesting role of CF3 representatives in the 
electrophilicity/biological activity ratio needs to be evaluated. This basic work provides a 
huge variety of structural adjustment features for a further fine-tuning of the desired ef-
fects. 
A library of small Michael acceptor reactive units was investigated for their reactivity. Re-
activity of sulfonic acid derivatives could not be determined due to insufficient absorbance 
properties of the compound chromophores. For all N-phenylacrylamides, the k2 values 
were determined and a structure-reactivity relationship was derived. 
Spectroscopic properties and reactivity towards cysteamine have been investigated for fur-
ther electrophiles, juglone derivatives and NO2-flavanone, using LC-MS and UV-Vis spec-
troscopy. A small anti-inflammatory activity was established for a few compounds. A k2 
value determination by the kinetic thiol assay is possible for most substances. For reasons 
of stability and the occurrence of several reactions, however, the assay conditions for ki-
netic measurements should be optimized first. The demanded NO2-flavanone was synthe-
sized from simple precursors. Since it is present both isolated and in solution almost quan-
titatively as flavanone, neither reactivity towards cysteamine nor anti-inflammatory activ-
ity could be demonstrated.  
In order to further develop the kinetic thiol assay for the testing of colorless enones with 
fluorescent dyes as probes, first investigations with literature-known fluorescence-active 
thiols and thiol precursors were carried out, of which MSTI has the best potential. The syn-
thesis and spectroscopic investigation of new aromatic fluorescent thiol dyes could not be 
completed within this work. 
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A 6 Experimental 
A 6.1 General synthesis information 
All reagents were purchased from commercial sources and were used without further pu-
rification. Solvents were distilled before use. All reactions were carried out under nitrogen 
gas and the glassware was heated at 110 °C before use when dry conditions were neces-
sary. The reactions were monitored by TLC on silica gel plates 60 F254 by MERCK (Darm-
stadt, Germany). Spots were detected under UV light (λ = 254 and 366 nm). Column chro-
matography was performed on silica gel Geduran Si 60 (0.063-0.200 mm) by MERCK (Darm-
stadt, Germany), while preparative plates were prepared using silica gel 60 GF254 by 
MERCK (Darmstadt, Germany). Melting points were determined using BÜCHI melting point 
B-545 (Flawil, Switzerland) and were uncorrected. 1H NMR spectra were recorded on a 
Bruker Avance 300 (Billerica, Massachusetts, USA) (300 MHz) and Bruker Avance 400 (400 
MHz) spectrometer. Chemical shifts δ are referenced to CDCl3 (7.26 ppm), DMSO-d6 (2.50 
ppm) and acetone-d6 (2.05 ppm). The NMR data were reported in ppm and the abbrevia-
tions were mentioned as: s = singlet, brs = broad singlet, d = doublet, t = triplet, q = quartet, 
sept = septet, m = multiplet, dt = doublet of triplets, dd = doublet of doublets, coupling 
constants in Hz. 13C NMR spectra were recorded on a Bruker Avance 300 (75 MHz) and 
Avance 400 (101 MHz) spectrometer and are given in ppm. Chemical shifts δ are referenced 
to CDCl3 (77.0 ppm), DMSO-d6 (39.4 ppm) and acetone-d6 (29.8 ppm). 19F NMR spectra 
were recorded on a Bruker Avance 300 (282 MHz) spectrometer. IR spectroscopy was car-
ried out on an Agilent Cary 630 FITR (Agilent, Santa Clara, USA), samples were measured as 
neat compounds and the wave numbers are reported in cm-1. Mass data were obtained on 
Agilent Technologies 6540 UHD (Agilent, Santa Clara, USA), Finnigan MAT 95 or Thermo 
Quest Finnigan TSQ 7000 instruments (Bremen, Germany). 
A 6.2 Syntheses of OXEs, OXE analogues and their precursors 
Ethyl-4-methoxybenzoate (20a) (synthesized according to a standard 
procedure). 4-Methoxybenzoic acid (19a) (5.00 g, 32.9 mmol, 1.0 eq.) 
in 250 mL EtOH together with 2 mL H2SO4 conc. (1.1 eq.) were refluxed 
for 20 h and the solvent was removed. The residue was dissolved in 
EtOAc (300 mL) and the solution washed with sat. aqueous Na2CO3 (2 x 200 mL) solution 
and sat. aqueous NaCl solution (200 mL). After drying over Na2SO4 and removal of the sol-
vent, 5.71 g (31.7 mmol, 99%) ethyl-4-methoxybenzoate (20a) were received as pale-yel-
low liquid and used without further purification. 1H NMR (300 MHz, CDCl3): δ = 8.02–7.98 
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(m, 2H, CHAr), 6.94-6.89 (m, 2H, CHAr), 4.34 (d, J = 7.1 Hz, 2H, CH2CH3), 3.86 (s, 3H, OCH3), 
1.38 (t, J = 7.1 Hz, 3H, CH2CH3). 
4-Methoxybenzohydrazide (21b).[89] Ethyl-4-methoxybenzoate (20a) 
(5.00 g, 27.7 mmol, 1.0 eq.), hydrazine monohydrate (1.67 g, 
33.3 mmol, 1.68 mL, 1.2 eq.) and 400 mg (2.89 mmol, 0.1 eq.) K2CO3 
in 50 mL EtOH were refluxed for 28 h. After completion of the reaction, the hot EtOH solu-
tion was separated from solid K2CO3 by decantation and the round bottom flask was rinsed 
out once more with hot EtOH. The solution was cooled to -10 °C and the formed precipitate 
was filtered off, washed with water (3 x 30 mL) and petroleum ether (3 x 30 mL) to yield 4-
methoxybenzohydrazide (21b) (3.44 g, 20.7 mmol, 75%), which was used without further 
purification. 1H NMR (300 MHz, CDCl3): δ = 9.68 (s, 1H, NH-NH2), 7.83–7.77 (m, 2H, CHAr), 
7.00-6.95 (m, 2H, CHAr), 4.42 (brs, 2H, NH-NH2), 3.79 (s, 3H, OCH3). 
General method for the preparation of hydrazones 23[90] 
Hydrazides 21a-c (0.500-3.81 g, 3.68-27.8 mmol, 1.0 eq.) and the corresponding aldehydes 
or ketones 22a-e (4.01-33.3 mmol, 1.1 eq.) in 10-20 mL EtOH with 0.1-0.2 mL HOAc were 
refluxed until the reaction was complete. At rt the mixture was poured on 50 mL water and 
the formed precipitate filtered off, washed with cold water (2 x 50 mL) and petroleum ether 
(2 x 50 mL) to yield the hydrazones 23a-e, which were used without further purification. 
The synthesis of hydrazones 23 with a broad variety of functional groups is widely reported 
in the literature, for example by van Dijken et al[90], Thomas et al[47] and Nigade et al.[91] 
4-Methoxy-N'-(1-phenylethylidene)benzohydrazide (23a). 4-
Methoxybenzohydrazide (21b) (2.50 g, 15.0 mmol, 1.0 eq.) 
gave with acetophenone 22a (1.2 eq.) after 18 h hydrazone 
23a (2.86 g, 10,7 mmol, 71%) as yellow solid. Rf = 0.73 (SiO2, 
EtOAc); M.p. 174-176 °C (Literature: 171-173.4 °C[92]); 1H NMR (400 MHz, DMSO-d6): δ = 
10.70 (s, 1H, NH), 7.90 (d, J = 8.6 Hz, 3H, CHAr), 7.83 (brs, 2H, CHPh), 7.46–7.41 (m, 3H, CHPh), 
7.04 (d, J = 8.7 Hz, 2H, CHAr), 3.83 (s, 3H, OCH3), 2.37 (s, 3H, CH3) ppm; 13C NMR (75 MHz, 
DMSO-d6): δ = 161.7 (CAr-OCH3), 138.1, 130.3, 129.2, 128.3, 126.3, 126.0, 113.4, 55.3 
(OCH3), 14.4 (CH3) ppm; IR (neat): 3008, 2987, 2840, 1599, 1543, 1212 cm-1; MS (ESI+) m/z 
(%): 269 [M+H]+ (100); HRMS (ESI+) calcd for C16H17N2O2 [M+H]+ 269.1285, found 269.1288. 
In the 13C-NMR the signals of C=N and C=O do not appear due to low intensity. The NMR 
data is in accordance with the literature.[92-93] 
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N'-(1-(4-Nitrophenyl)ethylidene)isonicotinohydrazide (23b). 
Isonicotinohydrazide (21c) (0.522 g, 3.81 mmol, 1.0 eq.) gave 
with acetophenone 22a (1.1 eq.) after 24 h hydrazone 23b 
(0.734 g, 2.58 mmol, 68%) as a pale yellow solid. Rf = 0.23 
(SiO2, EtOAc); 1H NMR (300 MHz, DMSO-d6): δ = 11.28 (s, 1H, NH), 8.77-8.76 (m, 2H, CHPy), 
8.31-8.29 (m, 2H, CHPy), 8.14-8.11 (m, 2H, CHPy), 7.82-7.81 (m, 2H, CHAr), 2.44 (s, 3H, CH3) 
ppm. The 1H NMR data is in accordance with those measured before in this work group.[42] 
This compound was published and described in the literature with NMR data in DMSO-d6[94] 
and CDCl3.[95] 
N'-(1-(4-Methoxyphenyl)ethylidene)isonicotinohydrazide 
(23c). Isonicotinohydrazide (21c) (0.500 g, 3.68 mmol, 1.0 eq.) 
gave with acetophenone 22a (1.1 eq.) after 25 h hydrazone 
23c (0.241 g, 0.795 mmol, 22%) as white solid. Rf = 0.28 (SiO2, 
petroleum ether/EtOAc 1:4); 1H NMR (300 MHz, DMSO-d6): δ = 10.95 (s, 1H, NH), 8.76 (d, J 
= 5.4 Hz, 2H, CHPy), 7.83 (d, J = 8.7 Hz, 2 H, CHAr), 7.79 (d, J = 5.4 Hz, 2H, CHPy), 7.00 (d, J = 
8.7 Hz, 2H, CHAr), 3.81 (s, 3H, OCH3), 2.35 (s, 3H, CH3) ppm; 13C NMR (75 MHz, DMSO-d6): δ 
= 162.1 (C=O), 160.7 (C-OCH3), 157.2 (C=N), 150.1 (CHPy), 141.2 (CPy), 130.2 (CAr), 128.1 
(CHAr), 121.8 (CHPy), 113.8 (CHAr), 55.3 (OCH3), 14.7 (CH3) ppm. The 1H NMR data is in ac-
cordance with those measured before in this work group.[42] This compound was also pub-
lished by Shirote et al[94] (NMR in CDCl3) and Cordeiro et al[96] (analytical data not pub-
lished). 
N‘-Benzylidenebenzohydrazide (23d). Benzohydrazide (21a) 
(1.00 g, 7.43 mmol, 1.0 eq.) gave with benzaldehyde (22d) (1.1 eq.) 
after 26 d hydrazone 23d (1.54 g, 6.87 mmol, 94%) as white solid. 
Rf = 0.66 (SiO2, petroleum ether/EtOAc 1:1); 1H NMR (400 MHz, DMSO-d6): δ = 11.86 (s, 1H, 
NH), 8.48 (s, 1H, N-N=CH), 7.93 (d, J = 7.4 Hz, 2H, CHPh), 7.74 (d, J = 6.6 Hz, 2H, CHPh), 7.59 
(d, J = 7.1 Hz, 1H, CHPh), 7.53 (t, J = 7.4 Hz, 2H, CHPh), 7.47-7.42 (m, 3H, CHPh) ppm; 13C NMR 
(101 MHz, DMSO-d6): δ = 163.6 (C=O), 148.3 (C=N), 134.8 (CPh), 133.9 (CPh), 132.2 (CHPh), 
130.6 (CHPh), 129.3 (2C, CHPh/CHPh), 129.0 (CHPh), 128.1 (CHPh), 127.6 (CHPh) ppm. The NMR 
data is in accordance with the literature[97]. 
N'-(2,2,2-Trifluoro-1-phenylethylidene)isonicotinohydrazide 
(23e). Isonicotinohydrazide (21c) (3.81 g, 27.8 mmol, 1.0 eq.) gave 
with 2,2,2-trifluoro-1-phenylethan-1-one 22e (1.2 eq) after 24 h 
hydrazone 23e (3.34 g, 11.4 mmol, 41%) as white solid. Rf = 0.49 (SiO2, EtOAc); M.p. >200 °C 
(decomposition); 1H NMR (300 MHz, DMSO-d6): δ = 11.45 (s, 1H), 8.71 (dd, J = 4.5, 1.4 Hz, 
2H, CHPy), 7.60–7.58 (m, 5H, CHPy+CHPh), 7.55-7.48 (m, 2H, CHPh) ppm; 13C NMR (75 MHz, 
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DMSO-d6): δ = 164.3 (C=O), 149.9 (CHPy), 140.5 (CPy), 131.1 (CHPh), 129.4 (CHPh), 128.4 
(CHPh), 126.8 (CPh), 122.2 (CHPy), 120.7 (q, J = 275 Hz, CF3) ppm; 19F NMR (376 MHz, DMSO-
d6): δ = -65.9 ppm; MS (ESI+) m/z (%): 294 [M+H]+ (100); HRMS (ESI+) calcd for C14H11F3N3O 
[M+H]+ 294.0849, found 294.0860. In the 13C-NMR the quartet signal of N-N=C-CF3 does 
not appear due to low intensity. The synthesis of 23e is reported by Bottari et al[98] [99] with-
out analytical data. This compound is mentioned in further literature.[100] [101] 
(E)-3-(4-Methoxyphenyl)acryloyl chloride (24b). 4-Methoxy-
cinnamic acid (42) (1.00 g, 5.61 mmol, 1 eq) was dissolved in thionyl 
chloride (5.47 ml, 28.1 mmol, 5 eq). DMF (0.5 mL, 6.50 mmol, 
0.2 eq.) was added and the mixture was stirred at room temperature for 2 h until no more 
gas formation was observed. Excess thionyl chloride was removed on the high vacuum and 
(E)-3-(4-methoxyphenyl)acryloyl chloride (24b) was received as pale brown solid and used 
without further purification. 
3-phenylpropanoyl chloride (24d). A solution of 4-methoxycinnamic acid 
(43) (1.00 g, 6.66 mmol, 1 eq) in 6 mL DCM was added to a solution of 
oxalyl chloride (1.27 g, 0.640 ml, 10.0 mmol, 1.5 eq) at 0-5 °C. The mix-
ture was stirred at room temperature for 14 h and DCM was removed. 1.12 g (6.66 mmol) 
3-phenylpropanoyl chloride (24d) was obtained as pale-yellow liquid in quantitative yield 
and used without further purification. 1H NMR (300 MHz, CDCl3): δ = 7.35-7.19 (m, 5H, 
CHPh), 3.24-3.19 (m, 2H, Ph-CH2-CH2), 3.02 (t, J = 7.5 Hz, 2H, Ph-CH2-CH2). The NMR data is 
in accordance with the literature.[76] 
General method for the preparation of 2,3-dihydro-1,3,4-oxadiazoles with 3-enone unit 
(OXEs) 
To a suspension of NaH (1.2 eq.) or a solution triethylamine (1.2 eq.) in 1-20 mL absolute 
THF were added the hydrazones 23a-c and 23e (50.0 mg-0.490 g, 0.185 mmol-2.18 mmol, 
1.0 eq.) at 0 °C. In the case of hydrazone 23d the educt was stirred in 15 mL THF without 
base and cooled to 0 °C. Then a solution of acid chlorides 24a-d (0.204 mmol-2.40 mmol, 
1.1 eq.) in 1-5 mL THF was added dropwise, the mixture warmed to room temperature and 
stirred until the reaction was complete. After removal of the solvent, the crude products 
were purified by column chromatography or preparative TLC (SiO2, petroleum ether/EtOAc, 
various mixtures: from 10:1 to 1:1) to afford 2,3-dihydro-1,3,4-oxadiazoles with 3-enone 
unit (OXEs). 
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1-(2-Methyl-2,5-diphenyl-1,3,4-oxadiazol-3(2H)-yl)prop-2-en-1-o-
ne (OXE1). Hydrazone 23f (0.400 g, 1.68 mmol, 1.0 eq.) gave with 
NEt3 (1.2 eq.) and acrylic acid chloride (24a) (1.1 eq.) after 4 h OXE1 
(0.237 g, 0.811 mmol, 48%) as colorless oil. Rf = 0.30 (SiO2, petroleum 
ether/EtOAc 10:1); 1H NMR (300 MHz, CDCl3): δ = 7.94-7.91 (m, 2H, 
CHPh), 7.64-7.61 (m, 2H, CHPh), 7.54-7.35 (m, 6H, CHPh), 7.21 (dd, J = 17.2, 10.4 Hz, 1H, 
CH=CH2), 6.44 (dd, J = 17.2, 1.9 Hz, 1H, CH=CH2), 5.78 (dd, J = 10.4, 1.9 Hz, 1H, CH=CH2), 
2.38 (s, 3H, CH3) ppm; 13C NMR (75 MHz, CDCl3): δ = 161.2 (C=O), 154.1 (C=N), 138.9 (CPh), 
131.5 (CHPh), 129.1 (CH=CH2), 128.6 (CHPh), 128.4 (CHPh), 128.1 (CPh), 128.0 (CH=CH2), 126.8 
(CHPh), 125.7 (CHPh), 124.6 (CHPh), 100.7 (N,O-C-CH3), 22.8 (CH3) ppm; IR (neat): 3064, 2989, 
2937, 1655, 1424, 1323, 1260, 764 cm-1; MS (ESI+) m/z (%): 293 [M+H]+ (100); HRMS (ESI+) 
calcd for C18H17N2O2 [M+H]+ 293.1285, found 293.1296. 
1-(5-(4-Methoxyphenyl)-2methyl-2-phenyl-1,3,4-oxadiazol-3-
(2H)-yl)prop-2-en-1-one (OXE1-(OMe)’’). Hydrazone 23b (0.300 
g, 1.12 mmol, 1.0 eq.) gave with acrylic acid chloride 24a (1.1 eq.) 
after 7 d and purification via preparative HPLC 35 mg (0.110 
mmol, 10%) OXE1-(OMe)’’ as colorless oil. Preparative HPLC was 
performed on an Agilent 1260 Infinity (Agilent Technologies, USA). Column: Agilent Flow 
XDB RP-18, Eurosphere 100 (5 µm, 21.2 x 250 mm); solvents: acetonitrile (degassed, HPLC 
grade, Merck), H2O (degassed, Millipore); application: liquid injection in acetonitrile/MeOH 
1:1, concentration: 20 mg/mL, injection volume: 1 mL; method: gradient: H2O/acetonitrile; 
60% acetonitrile at t = 0 min, 90% acetonitrile at t = 20 min, 100% acetonitrile at t = 22 min, 
60% acetonitrile at t = 24 min, flow rate: 20 mL/min. Rf = 0.45 (SiO2, petroleum ether/EtOAc 
3:1), 0.13 (RP18, acetonitrile/H2O 3:2); 1H NMR (300 MHz, CDCl3): δ = 7.86–7.81 (m, 2H, 
CHAr), 7.61–7.56 (m, 2H, CHPh), 7.42–7.32 (m, 3H, CHPh), 7.16 (dd, J = 17.2, 10.4 Hz, 1H, 
CH=CH2), 6.97–6.92 (m, 2H, CHAr), 6.39 (dd, J = 17.2, 1.9 Hz, 1H, CH=CH2), 5.74 (dd, J = 10.4, 
1.9 Hz, 1H, CH=CH2), 3.86 (s, 3H, OCH3), 2.34 (s, 3H, CH3) ppm; 13C NMR (75 MHz, CDCl3): δ 
= 162.3 (C=O), 161.1 (CAr-OCH3), 154.2 (C=N), 139.1 (CPh), 129.2 (CH=CH2), 128.7 (CHPh), 
128.4 (CHAr), 128.2 (CHPh), 128.0 (CH=CH2), 125.8 (CHPh), 117.0 (CAr), 114.1 (CHAr), 100.5 
(N,O-C-CH3), 55.4 (OCH3), 22.9 (CH3) ppm; MS (ESI+) m/z (%): 323 [M+H]+ (100); HRMS (ESI+) 
calcd for C19H18N2O3 [M+H]+ 323.1390, found 323.1391. 
1-(2-(4-Methoxyphenyl)-2-methyl-5-(pyridin-4-yl)-1,3,4-oxadia-
zol-3(2H)-yl)prop-2-en-1-one (OXE1-OMe,(4py)’’). Hydrazone 
23c (0.150 g, 0.557 mmol, 1.0 eq.) gave with triethylamine (1.2 
eq.) and acrylic acid chloride (24a) (1.1 eq.) after 23 h OXE1-
OMe,(4py)‘‘ (53.0 mg, 0.164 mmol, 29%) as yellow oil. Rf = 0.30 
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(SiO2, petroleum ether/EtOAc 1:1): 0.49; 1H NMR (400 MHz, CDCl3): δ = 8.72 (d, J = 5.3 Hz, 
2H, CHPy), 7.71 (d, J = 5.8 Hz, 2H, CHPy), 7.49–7.45 (m, 2H, CHAr), 7.13 (dd, J = 17.2, 10.4 Hz, 
1H, CH=CH2), 6.91–6.88 (m, 2H, CHAr), 6.40 (dd, J = 17.2, 1.7 Hz, 1H, CH=CH2), 5.77 (dd, J = 
10.4, 1.6 Hz, 1H, CH=CH2), 3.78 (s, 3H, OCH3), 2.32 (s, 3H, CH3) ppm; 13C NMR (101 MHz, 
CDCl3): δ = 161.4 (C=O), 160.3 (CAr-OCH3), 152.1 (C=N), 150.3 (CHPy), 132.3 (CPy), 130.5 (CAr), 
128.8 (CH=CH2), 127.6 (CH=CH2), 127.2 (CHAr), 120.3 (CHPy), 113.8 (CHAr), 101.8 (N,O-C-CH3), 
55.2 (OCH3), 22.9 (CH3) ppm; IR (neat): 2937, 2840, 1659, 1513, 1431, 1308, 1249, 1178, 
824 cm-1; MS (ESI+) m/z (%): 324 [M+H]+ (100); HRMS (ESI+) calcd for C18H18N3O3 324.1343 
[M+H]+, found 324.1349. 
1-(2-Methyl-2-phenyl-5-(quinolin-6-yl)-1,3,4-oxadiazol-3(2H)-
yl)prop-2-en-1-one (OXE1-(6qui)’’). Hydrazone 23g (0.200 g, 
0.691 mmol, 1.0 eq.) gave with NaH (1.2 eq.) and acrylic acid chlo-
ride (24a) (1.1 eq.) after 20 h OXE1-(6qui)’’ (26.0 mg, 75.7 µmol, 
11%) as white solid. Rf = 0.47 (SiO2, petroleum ether/EtOAc 1:1); 
M.p. 117-120 °C; 1H NMR (300 MHz, CDCl3): δ = 8.99 (s, 1H, CHQui), 8.32 (d, J = 1.5 Hz, 1H, 
CHQui), 8.25 (dd, J = 8.9, 1.8 Hz, 1H, CHQui), 8.22 (d, J = 8.3 Hz, 1H, CHQui), 8.17 (d, J = 8.9 Hz, 
1H, CHQui) 7.65-7.59 (m, 2H, CHPh), 7.48 (dd, J = 8.3, 4.2 Hz, 1H, CHQui), 7.44-7.35 (m, 3H, 
CHPh), 7.22 (dd, J = 17.2, 10.4 Hz, 1H, CH=CH2), 6.43 (dd, J = 17.2, 1.8 Hz, 1H, CH=CH2), 5.80 
(dd, J = 10.4, 1.8 Hz, 1H, CH=CH2), 2.40 (s, 3H, CH3) ppm; 13C NMR (75 MHz, CDCl3): δ = 161.4 
(C=O), 153.6 (C=N), 151.9 (CHQui), 149.4 (CQui), 138.8 (CPh), 136.6 (CHQui), 130.2 (CHQui), 129.4 
(CHPh), 128.5 (2C, CHPh, CH=CH2), 127.9 (CQui), 127.7 (CHQui), 127.2 (CHQui or CH=CH2), 127.0 
(CHQui or CH=CH2), 125.8 (CHPh), 122.9 (CQui), 122.1 (CHQui), 101.3 (N,O-C-CH3), 22.9 (CH3) 
ppm; 1H NMR (300 MHz, Acetone-d6): δ = 9.00 (dd, J = 4.2, 1.7 Hz, 1H, CHQui), 8.49 (dd, J = 
8.4, 1.3 Hz, 1H, CHQui), 8.44 (d, J = 1.9 Hz, 1H, CHQui), 8.27 (dd, J = 8.9, 1.9 Hz, 1H, CHQui), 
8.15 (d, J = 8.9 Hz, 1H, CHQui) 7.69-7.64 (m, 2H, CHPh), 7.61 (dd, J = 8.3, 4.2 Hz, 1H, CHQui), 
7.48-7.38 (m, 3H, CHPh), 7.26 (dd, J = 17.2, 10.4 Hz, 1H, CH=CH2), 6.32 (dd, J = 17.2, 2.2 Hz, 
1H, CH=CH2), 5.81 (dd, J = 10.4, 2.2 Hz, 1H, CH=CH2), 2.39 (s, 3H, CH3) ppm; 13C NMR (75 
MHz, Acetone-d6): δ =161.4 (C=O), 154.2 (C=N), 153.0 (CHQui), 150.3 (CQui), 140.2 (CPh), 
137.5 (CHQui), 131.1 (CHQui), 130.1 (CHPh), 129.3 (CHPh), 129.2 (CH=CH2), 128.8 (CQui), 128.4 
(CHQui or CH=CH2), 128.2 (CHQui or CH=CH2), 127.4 (CHQui), 126.8 (CHPh), 123.5 (CQui), 123.3 
(CHQui), 102.1 (N,O-C-CH3), 23.1 (CH3) ppm; IR (neat): 3060, 2926, 2855, 1655, 1461, 1420, 
1327, 1252, 1185, 1059, 977, 883, 839, 764, 693 cm-1; MS (ESI+) m/z (%): 344 [M+H]+ (100); 
HRMS (ESI+) calcd for C21H18N3O2 [M+H]+ 344.1394, found 344.1404. 
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1-(2-(4-Nitrophenyl)-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)-
prop-2-en-1-one (OXE2-NO2,(4py)’’). Hydrazone 23h (50.0 mg, 
0.185 mmol, 1.0 eq.) gave with NaH (1.2 eq.) and acrylic acid chlo-
ride (24a) (1.1 eq.) after 2 h OXE2-NO2,(4py)’’ (27.0 mg, 83.3 µmol, 
45%) as beige solid. Rf = 0.17 (SiO2, petroleum ether/EtOAc, 1:1) 
M.p. 113-114 °C; 1H NMR (300 MHz, CDCl3): δ = 8.78 (d, J = 5.5 Hz, 2H, CHPy), 8.30–8.25 (m, 
2H, CHAr), 7.75–7.67 (m, 4H, CHAr+CHPy), 7.26 (s, 1H, N,O-C-H), 7.07 (dd, J = 17.2, 10.4 Hz, 
1H, CH=CH2), 6.50 (dd, J = 17.2, 1.6 Hz, 1H, CH=CH2), 5.89 (dd, J = 10.4, 1.6 Hz, 1H, CH=CH2) 
ppm; 13C NMR (75 MHz, CDCl3): δ = 162.6 (C=O), 154.1 (C=N), 150.6 (CHPy), 148.9 (CAr), 141.8 
(CAr-NO2), 131.4 (CPy), 130.3 (CH=CH2), 127.9 (CHAr), 126.4 (CH=CH2), 124.1 (CHAr), 120.4 
(CHPy), 91.8 (N,O-C-H) ppm; IR (neat): 2926, 2855, 1659, 1525, 1435, 1331, 1252, 984 cm-1; 
MS (ESI+) m/z (%): 325 [M+H]+ (100); HRMS (ESI+) calcd for C16H13N4O4 [M+H]+ 325.0931, 
found : 325.0934. 
1-(2-Phenyl-5-(pyridin-4-yl)-2-(trifluoromethyl)-1,3,4-oxadiazol-3-
(2H)-yl)prop-2-en-1-one (OXE3-(4py)’’). Hydrazone 23e (0.377 g, 
1.29 mmol, 1.0 eq.) gave with NaH (1.2 eq.) and acrylic acid chloride 
(24a) (1.1 eq.) after 3 h OXE3-(4py)’’ (2.34 mg, 6.74 µmol, 1%) as 
beige oil. This yield was received after column chromatography (pe-
troleum ether/EtOAc 3:1) and subsequent preparative TLC (petroleum ether/EtOAc 3:1). Rf 
= 0.45 (SiO2, petroleum ether/EtOAc 1:1); 1H NMR (300 MHz, CDCl3): δ = 8.79 (brs, 2H, CHPy), 
7.78 (d, J = 6.0 Hz, 2H, CHPy), 7.68-7.65 (m, 2H, CHPh), 7.49–7.46 (m, 3H, CHPh), 7.14 (dd, J = 
17.2, 10.4 Hz, 1H, CH=CH2), 6.50 (dd, J = 17.2, 1.6 Hz, 1H, CH=CH2), 5.90 (dd, J = 10.4, 1.6 
Hz, 1H, CH=CH2) ppm; 13C NMR (101 MHz, CDCl3) δ = 162.0 (C=O), 151.6 (C=N), 150.3 (CHPy), 
131.1 (CHPh), 131.0 (CHPh), 130.9 (CH=CH2), 130.8 (CPy), 128.8 (CH=CH2), 127.0 (CHPh), 126.8 
(q, J = 1.8 Hz, CPh), 122.1 (q, J = 290.5 Hz, CF3), 120.5 (CHPy), 98.8 (q, J = 34.4 Hz, N,O-C-CF3) 
ppm; 19F NMR (376 MHz, CDCl3): δ = -75.2 ppm; IR (neat): 2926, 2855, 1689, 1640, 1409, 
1174, 951 cm–1; MS (ESI+) m/z (%): 348 [M+H]+ (100). The 1H NMR data is in accordance 
with previous work in this group.[43] 13C NMR data have not been measured before and 
were obtained during this work with the compound prepared by Rainer Herzog in this work 
group. 
(E)-1-(2,5-Diphenyl-1,3,4-oxadiazol-3(2H)-yl)-3-(4-meth-
oxyphenyl)prop-2-en-1-one (OXE8-(OMe)‘).[45] Hydrazone 
23d (0.490 g, 2.18 mmol, 1.0 eq.) gave with triethylamine 
(10 eq.) and cinnamic acid chloride 24a (1.1 eq.) after 20 h 
OXE8-(OMe)‘ (0.341 g, 0.887 mmol, 41%) as a white solid. 
Rf = 0.5 (SiO2, petroleum ether/EtOAc 1:1); M.p. 128-130 °C; 1H NMR (400 MHz, CDCl3): δ = 
Electrophiles of the enone-type and the investigation of their reactivity and biological activity 
97 
7.98–7.96 (m, 2H, CHPh), 7.73 (d, J = 15.9 Hz, 1H, CH=CH-Ar), 7.59–7.41 (m, 10H, CHPh+CHAr), 
7.34 (d, J = 15.9 Hz, 1H, CH=CH-Ar) , 7.23 (s, 1H, N,O-C-H), 6.93 (d, J = 8.7 Hz, 2H, CHAr), 3.84 
(s, 3H, OCH3), 13C NMR (101 MHz, CDCl3): δ = 163.0 (C=O), 161.1 (CAr-OMe), 155.8 (C=N), 
142.6 (CH=CH-Ar), 136.3 (CPh), 131.6 (CAr), 129.83 (CHPh), 129.80 (CHPh), 128.7 (CHPh), 128.6 
(CHPh), 127.7 (CPh), 127.0 (CHAr), 126.6 (CHPh), 124.5 (CHPh), 114.6 (CH=CH-Ar), 114.1 (CHAr), 
92.6 (N,O-C-H), 55.3 (OCH3); IR (neat): 3012, 2915, 2840, 1648, 1603, 1513, 1431, 1238, 
1174 cm-1; MS (ESI+) m/z (%): 385 [M+H]+ (100); HRMS (ESI+) calcd for C24H21N2O3 [M+H]+ 
385.1547, found 385.1553. This compound was published by Arora et al. in 2012 with 1H 
NMR data in DMSO-d6.[45] 
(E)-1-(2-(4-Methoxyphenyl)-5-(pyridin-4-yl)-1,3,4-oxadiazol-
3(2H)-yl)-3-phenylprop-2-en-1-one (OXE8-OMe,(4py)’’). Hy-
drazone 23j (41.6 mg, 0.163 mmol, 1.0 eq.) gave with NEt3 (1.2 
eq.) and cinnamic acid chloride 24c (1.1 eq.) after 5 h OXE8-
OMe,(4py)’’ (43.5 mg, 0.113 mmol, 69%) as a yellow solid. Rf = 
0.44 (SiO2, petroleum ether/EtOAc 1:1); M.p. 156 °C; 1H NMR (400 MHz, CDCl3): δ = 8.76 (d, 
J = 5.3 Hz, 2H, CHPy), 7.78 (d, J = 6.0 Hz, 2H, CHPy), 7.75 (d, J = 16 Hz, 1H, CH=CH-Ph), 7.63–
7.61 (m, 2H, CHPh), 7.45 (d, J = 8.7 Hz, 2H, CHAr), 7.42-7.38 (m, 4H, CHPh + CH=CH-Ph), 7.20 
(s, 1H, N,O-C-H), 6.94 (d, J = 8.7 Hz, 2H, CHAr), 3.81 (s, 3H, OCH3) ppm; 13C NMR (101 MHz, 
CDCl3): δ = 162.8 (C=O), 161.0 (CAr-OCH3), 153.9 (C=N), 150.4 (CHPy), 143.6 (CH=CH-Ph), 
134.8 (CPh), 132.3 (CPy), 130.2 (CAr), 128.8 (CHPh), 128.3 (CHPh), 128.1 (CHAr), 127.9 (CHPh), 
120.5 (CHPy), 116.7 (CH=CH-Ph), 114.3 (CHAr), 93.5 (N,O-C-H), 55.3 (OCH3) ppm; IR (neat): 
3061, 3023, 1651, 1609, 1517, 1434, 1338, 1297, 1253, 1239, 1181 cm–1; MS (ESI+) m/z (%): 
386 [M+H]+ (100); HRMS (ESI+) calcd for C23H20N3O3 [M+H]+ 386.1499, found 386.1501. The 
NMR data was previously shown in DMSO-d6 in this work group.[42] 
3-Phenyl-1-(2-phenyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-
yl)propan-1-one (OXE8-(4py)’’-H2). Hydrazone 23i (0.100 g, 
0.444 mmol, 1.0 eq.) gave with NaH (1.2 eq.) and dihydrocin-
namic acid chloride (24d) (1.1 eq.) after 1 h OXE8-(4py)’’-H2 
(0.119 g, 0.334 mmol, 76%) as beige waxy solid. Rf = 0.36 (SiO2, 
petroleum ether/EtOAc 1:1); M.p. 105-110 °C; 1H NMR (300 MHz, CDCl3): δ = 8.74 (d, J = 
4.0 Hz, 2H, CHPy), 7.71 (d, J = 6.0 Hz, 2H, CHPy), 7.42 (s, 5H, CHPh), 7.30–7.20 (m, 5H, CHPh), 
7.11 (s, 1H, N,O-C-H), 3. 15–2.97 (m, 4H, CH2-CH2) ppm; 13C NMR (75 MHz, CDCl3): δ = 169.8 
(C=O), 153.7 (C=N), 150.3 (CHPy), 140.7 (CPh), 135.7 (CPh), 132.1 (CPy), 130.1 (CHPh), 128.8 
(CHPh), 128.4 (2C, CHPh), 126.5 (CHPh), 126.2 (CHPh), 120.4 (CHPy), 93.2 (N,O-C-H), 35.4 (CH2-
CH2-Ph), 30.4 (CH2-CH2-Ph) ppm; IR (neat): 3030, 2926, 1707, 1659, 1439, 1342, 1193 cm-1; 
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MS (ESI+) m/z (%): 358 [M+H]+ (100); HRMS (ESI+) calcd for C22H20N3O2 [M+H]+ 358.1549, 
found 358.1550. 
(2-Methyl-2-phenyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)(oxi-
ran-2-yl)methanone (OXEp1-(4py)’’).  A solution of tert-butylhydrop-
eroxide (5 M in decane, 0.500 mmol, 1.5 eq.) was dissolved in 1 mL 
dry THF at -78 °C and a solution of butyllithium in hexanes (1.6 M, 
586 µL, 0.366 mmol, 1.1 eq.) was added. The solution was stirred at -
78 °C for 5 min, then OXE1-(4py)’’ (0.100 mg, 0.341 mmol, 1.0 eq) in 1 mL dry THF was 
added. The reaction mixture was allowed to warm to 0 °C, stirred for 4 h, quenched by the 
addition of solid Na2SO3 (30.1 mg, 0.239 mmol, 0.7 eq.) and stirred for another 15 min. The 
mixture was diluted with 5 mL diethylether and filtered. After concentration of the solution 
under vacuum, the product was purified by column chromatography (from petroleum 
ether/DCM/EtOAc 2:1:1 to DCM/EtOAc 1:1) to yield diastereomeric OXEp1-(4py)’’ (5.0 mg, 
0.016 mmol, 5%) as pale-yellow oil. Rf = 0.41 (SiO2, DCM/EtOAc 1:1); 1H NMR (300 MHz, 
CDCl3): δ = 8.77 (d, J = 5.9 Hz, 2H, CHPy), 7.77 (d, J = 6.1 Hz, 2H, CHPy), 7.61-7.47 (m, 2H, 
CHPh), 7.43-7.36 (m, 3H, CHPh), 4.31 (dd, J = 6.7, 3.8 Hz, 1H, CH), 3.07-2.94 (m, 2H, CH2), 2.34 
(d, J = 8.2 Hz, 3H, CH3) ppm; 1H NMR (300 MHz, DMSO-d6): δ = 8.78 (dd, J = 4.5, 1.5 Hz, 2H, 
CHPy), 7.78 (dd, J = 4.5, 1.6 Hz, 2H, CHPy), 7.64-7.51 (m, 2H, CHPh), 7.50-7.36 (m, 3H, CHPh), 
4.30 (dd, J = 4.3, 2.4 Hz, 1H, CH), 3.03 (ddd, J = 8.7, 6.5, 4.3 Hz, 1H, CH2), 2.83 (ddd, J = 
19.66.5, 2.4 Hz, 1H, CH2), 2.26 (d, J = 8.4 Hz, 3H, CH3); MS (ESI+) m/z (%): 310 [M+H]+ (100). 
The 1H NMR data in CDCl3 is in accordance with the previous work in this group.[44] 
General method for the preparation of 2,3-dihydro-1,3,4-oxadiazoles with N-oxide (OXE-
(4py-N-oxides)’’)[49] 
OXE4-(4py)‘‘ or OXE8-(4py)‘‘ (1.0 eq.) was dissolved in 1.5 mL DCM and a solution of 
mCPBA (1.7 eq.) in 2 mL DCM was added. The reaction mixture was stirred at rt until com-
pletion and quenched with 5 mL aqueous NaOH (0.2 M). The organic phase was separated, 
washed with water (2 x 20 mL) and dried with MgSO4. The crude product was purified with 
column chromatography (from petroleum ether/EtOAc 1:1 to EtOAc/methanol 4:1) to yield 
N-oxidized OXEs. 
(E)-4-(4-(But-2-enoyl)-5-methyl-5-phenyl-4,5-dihydro-1,3,4-
oxadiazol-2-yl)pyridine-1-oxide (OXE4-(4py-N-oxide)‘‘). OXE4-
(4py)‘‘ (67.0 mg, 0.218 mmol, 1.0 eq.) and mCPBA (67.7 mg, 
0.392 mmol, 1.7 eq.) gave after 48 h OXE4-(4py-N-ox-
ide)‘‘ (0.0550 g, 0.170 mmol, 78%) as pale beige solid. Rf = 0.13 
(SiO2, dichloromethane/EtOAc 1:1); M.p. 174-175 °C; 1H NMR (400 MHz, CDCl3): δ = 8.20 
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(d, J = 6.9 Hz, 2H, CHPy), 7.71 (d, J = 6.9 Hz, 2H, CHPy), 7.52-7.49 (m, 2H, CHPh), 7.41-7.36 (m, 
3H, CHPh), 6.96 (dq, J = 15.4, 6.7 Hz, 1H, CH=CH-CH3), 6.79 (dd, J = 15.4, 1.4 Hz, 1H, CH=CH-
CH3), 2.31 (s, 3H, N,O-C-CH3), 1.92 (dd, J = 6.7, 1.3 Hz, 3H, CH=CH-CH3) ppm; 13C NMR (101 
MHz, CDCl3): δ = 161.9 (C=O), 150.6 (C=N), 143.2 (CH=CH-CH3), 139.4 (CHPy), 138.4 (CPh), 
129.4 (CHPh), 128.5 (CHPh), 125.6 (CHPh), 123.4 (CHPy), 121.8 (CH=CH-CH3), 121.7 (CPy), 102.2 
(N,O-C-CH3), 23.0 (CH3), 18.1 (CH=CH-CH3) ppm; MS (ESI+) m/z (%): 324 [M+H]+ (100). Spec-
tral data are in accordance with the previous work in this group.[44] 
(E)-4-(4-(Cinnamoyl-5-phenyl-4,5-dihydro-1,3,4-oxadiazol-
2-yl)pyridine-1-oxide (OXE8-(4py-N-oxide)’’). OXE8-
(4py)‘‘ (97.5 mg, 0.274 mmol, 1.0 eq.) and mCPBA (85.2 mg, 
0.494 mmol, 1.7 eq.) gave after 48 h OXE8-(4py-N-oxide)’’ 
(70.5 mg, 0.190 mmol, 69%) as pale beige solid. Rf = 0.13 
(SiO2, dichloromethane/EtOAc 1:1); M.p. 185-186 °C; 1H NMR (400 MHz, CDCl3): δ = 8.22 
(d, J = 7.1 Hz, 2H, CHPy), 7.77 (d, J = 7.1 Hz, 2H, CHPy), 7.74 (d, J = 16.1 Hz, 1H, CH=CH-Ph), 
7.61-7.57 (m, 2H, CHPh), 7.52-7.48 (m, 2H, CHPh), 7.44-7.41 (m, 3H, CHPh), 7.39–7.33 (m, 4H, 
CHPh + CH=CH-Ph), 7.22 (s, 1H, N,O-C-H) ppm; 13C NMR (101 MHz, CDCl3): δ = 162.7 (C=O), 
152.7 (C=N), 143.7 (CH=CH-Ph), 139.5 (CHPy), 135.5 (CPh), 134.6 (CPh), 130.23 (CHPh), 130.18 
(CHPh), 128.9 (CHPh), 128.8 (CHPh), 128.2 (CHPh), 126.5 (CHPh), 123.5 (CHPy), 121.1 (CPy), 116.4 
(CH=CH-Ph), 93.7 (N,O-C-H) ppm; MS (ESI+) m/z (%): 372 [M+H]+ (100). Spectral data are in 
accordance with the previous work in this group.[44] 
A 6.3 Synthesis of NO2-flavanone and precursors 
2-Isopropoxy-4-methoxybenzaldehyde (67).[77] 2-Hydroxy-4-methoxyben-
zaldehyde (65, 1.00 g, 6.60 mmol, 1 eq.) was dissolved in 10 mL dry DMF and 
2-iodopropane (66, 825 µL, 8.25 mmol, 1.25 eq.) and K2CO3 (3.96 g, 28.7 
mmol, 4.3 eq.) were added. The resulting yellow suspension was stirred at 
45 °C for 12 h, then quenched with 100 mL H2O. The aqueous phase was extracted with 
ethyl acetate (3 x 50 mL and the combined organic phase was washed with brine (3 x 
100 mL). After drying over MgSO4 and removing of the solvent, 2-Isopropoxy-4-methox-
ybenzaldehyde (67) was obtained as a pale-yellow liquid (1.15 g, 5.92 mmol, 90%). Rf = 0.43 
(SiO2, petroleum ether/EtOAc 5:1); 1H NMR (300 MHz, CDCl3): δ = 10.31 (s, 1H, O=C-H), 7.81 
(d, J = 8.7 Hz, 1H, CHAr), 6.52 (dd, J = 8.7, 2.2 Hz, 1H, CHAr), 6.44 (d, J = 2.2 Hz, 1H, CHAr), 4.63 
(hept, J = 6.0 Hz, 1H, CH-(CH3)2), 3.86 (s, 3H, OCH3), 1.40 (d, J = 6.1 Hz, 6H, CH-(CH3)2) ppm; 
13C NMR (75 MHz, CDCl3): δ = 188.7 (C=O), 166.0 (CAr-OCH3), 162.3 (CAr-OCH-(CH3)2), 130.3 
(CHAr), 119.9 (CAr-C=O), 105.8 (CHAr), 99.9 (CHAr), 71.1 (OCH-(CH3)2), 55.6 (OCH3), 21.9 (C-
(CH3)2) ppm. 
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1-(2-Isopropoxy-4-methoxyphenyl)-2-nitroethan-1-one (68).[36] 2-Iso-
propoxy-4-methoxybenzaldehyde (67, 770 mg, 3.96 mmol, 1 eq.), nitro-
methane (2.97 mL, 55.5 mmol, 14 eq.) and sodium acetate (4.55 g, 55.5 
mmol, 14 eq.) were dissolved in 20 mL ethanol and stirred at room tem-
perature for 24 h. The resulting yellow suspension was diluted with 50 mL H2O and the 
aqueous phase was extracted with ethyl acetate (3 x 30 mL). The combined organic phases 
were washed with brine (3 x 100 mL), dried over MgSO4 and the solvent was removed. A 
yellow paste was obtained which was dissolved in dichloromethane. To this solution pyri-
dinium chlorochromate (2.05 g, 9.50 mmol, 2.4 eq.) was added at 0 °C. Without removal of 
the ice bath the reaction mixture was allowed to warm to room temperature overnight and 
stirred for 24 h in total. The solvent was evaporated and after column chromatography 
(petroleum ether/ EtOAc 5:1), 1-(2-isopropoxy-4-methoxyphenyl)-2-nitroethan-1-one (68) 
was obtained as beige solid (428 mg, 1.69 mmol, 43%). Rf = 0.44 (SiO2, petroleum 
ether/EtOAc 3:1); M.p. 103 °C; 1H NMR (300 MHz, CDCl3): δ = 8.03 (d, J = 8.9 Hz, 1H, CHAr), 
6.58 (dd, J = 8.9, 2.3 Hz, 1H, CHAr), 6.42 (d, J = 2.2 Hz, 1H, CHAr), 5.74 (s, 2H, O=C-CH2), 4.71 
(hept, J = 6.1 Hz, 1H, CH-(CH3)2), 3.87 (s, 3H, OCH3), 1.44 (d, J = 6.1 Hz, 6H, CH-(CH3)2) ppm; 
13C NMR (75 MHz, CDCl3): δ = 184.2 (C=O), 166.3 (CAr-OCH3), 159.8 (CAr-OCH-(CH3)2), 133.8 
(CHAr), 117.5 (CAr-C=O), 106.2 (CHAr), 99.4 (CHAr), 85.3 (O=C-CH2), 71.4 (OCH-(CH3)2), 55.7 
(OCH3), 21.9 (C-(CH3)2) ppm; IR (neat): 3034, 2982, 2922, 2840, 1651, 1603, 1546, 1208, 
1103, 820 cm-1; MS (GC) m/z (%): 151.1 (100), 253.1 (5.83) [M ׄ]+; HRMS (GC) calcd for 
C12H15NO5 [Mׄ]+ 253.0945, found 253.0942.  
(E)-3-(3,4-Dimethoxyphenyl)-1-(2-isopropoxy-4-methoxyphe-
nyl)-2-nitroprop-2-en-1-one (70).[36] 1-(2-Isopropoxy-4-methoxy-
phenyl)-2-nitroethan-1-one (68, 339 mg, 1.34 mmol, 1 eq.) and 
3,4-dimethoxybenzaldehyde (69, 356 mg, 2.14 mmol, 1.6 eq.) 
were dissolved in 8 mL benzene and HOAc (215 µL, 3.17 mmol, 2.8 
eq.) and β-alanine (11.9 mg, 0.134 mmol, 0.1 eq.) were added. The 
resulting mixture was refluxed with a Dean-Stark apparatus for 12 h. After completion of 
the reaction, the benzene phase was washed with H2O (3 x 50 mL) and the aqueous phase 
was extracted with dichloromethane (3 x 20 mL). All organic phases were combined and 
the solvent was evaporated. After column chromatography (petroleum ether/ EtOAc 5:1), 
70 was obtained as yellow solid (376 mg, 0.937 mmol, 70%). Rf = 0.28 (SiO2, petroleum 
ether/EtOAc 3:1); M.p. 120-121 °C; 1H NMR (300 MHz, CDCl3): δ = 8.18 (d, J = 8.9 Hz, 1H, 
CHAr), 7.90 (s, 1H, NO2-C=CH), 7.06 (dd, J = 8.4, 2.1 Hz, 1H, CHAr), 6.88 (d, J = 2.1 Hz, 1H, 
CHAr), 6.81 (d, J = 8.4 Hz, 1H, CHAr), 6.60 (dd, J = 8.9, 2.3 Hz, 1H, CHAr), 6.37 (d, J = 2.2 Hz, 
1H, CHAr), 4.59 (hept, J = 6.1 Hz, 1H, CH-(CH3)2), 3.87 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.65 
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(s, 3H, OCH3), 1.21 (d, J = 6.1 Hz, 6H, CH-(CH3)2) ppm; 13C NMR (75 MHz, CDCl3): δ = 184.5 
(C=O), 166.4 (CAr-OCH3), 160.4 (CAr-OCH-(CH3)2), 152.0 (CAr-OCH3), 149.1 (CAr-OCH3), 148.1 
(C-NO2), 133.6 (CHAr), 133.1 (O2N-C=CH), 126.1 (CHAr), 122.8 (CAr), 119.2 (CAr), 112.2 (CHAr), 
111.1 (CHAr), 106.4 (CHAr), 99.3 (CHAr), 71.0 (OCH-(CH3)2), 56.0 (OCH3), 55.7 (OCH3), 55.6 
(OCH3), 21.9 (C-(CH3)2) ppm; IR (neat): 2974, 2844, 1636, 1588, 1506, 1245, 1100 cm-1; MS 
(ESI+) m/z (%): 402 (100) [M+H]+; HRMS (ESI+) calcd for C21H24NO7 [M+H]+ 402.1547, found 
402.1550. 
2-(3,4-dimethoxyphenyl)-6-methoxy-3-nitrochroman-4-one (NO2-flavanone).[78] 
 
(E)-3-(3,4-Dimethoxyphenyl)-1-(2-isopropoxy-4-methoxyphenyl)-2-nitroprop-2-en-1-one 
(70, 109 mg, 0.272 mmol, 1.0 eq.) was dissolved in 4 mL acetonitrile and a solution of AlCl3 
(362 mg, 2.17 mmol, 10 eq.) in 4 mL acetonitrile was added. The mixture was stirred at 
30 °C for 30 min, then 0.5 mL of aqueous HCl 5% was added dropwise and stirring was con-
tinued at 55 °C for another 45 min. 20 mL DCM was added and the mixture was washed 
with H2O (3 x 50 mL). After phase separation, drying over MgSO4 and evaporation of the 
solvent, a yellow oil was obtained which was purified by reversed-phase column chroma-
tography (RP-18, acetonitrile/H2O 2:1). A 1:10 mixture of α-NO2-HC and NO2-flavanone 
(44 mg, 0.122 mmol, 45%) was obtained as yellow solid. Rf = 0.63 (reversed-phase SiO2, 
acetonitrile/H2O 6:1); M.p. 128-132 °C; 1H NMR (300 MHz, CDCl3, NO2-flavanone): δ = 7.92 
(d, J = 8.9 Hz, 1H, CHAr), 7.05 (dd, J = 8.3, 2.1 Hz, 1H, CHAr), 7.00 (d, J = 2.0 Hz, 1H, CHAr), 6.90 
(d, J = 8.3 Hz, 1H, CHAr), 6.72 (dd, J = 8.9, 2.4 Hz, 1H, CHAr), 6.52 (d, J = 2.3 Hz, 1H, CHAr), 5.80 
(d, J = 11.9 Hz, 1H, O2N-CH-CH), 5.74 (d, J = 11.9 Hz, 1H, O2N-CH-CH), 3.91 (s, 3H, OCH3), 
3.90 (s, 3H, OCH3), 3.86 (s, 3H, OCH3) ppm; 1H NMR (300 MHz, CDCl3, α-NO2-HC): δ = 14.54 
(s, 0.1H, OH), 7.77 (d, J = 8.8 Hz, 0.1H, CHAr), 6.96-6.92 (m, 0.1H, CHAr), 6.83 (dd, J = 8.3, 
2.1 Hz, 0.1H, CHAr), 6.76 (s, 0.1H, O2N-C=CH), 6.65-6.61 (m, 0.2H, CHAr), 6.36 (d, J = 2.3 Hz, 
0.1H, CHAr), 3.84 (s, 0.3H, OCH3), 3.83 (s, 0.3H, OCH3), 3.81 (s, 0.3H, OCH3) ppm (); 13C NMR 
(101 MHz, CDCl3, NO2-flavanone): δ = 179.9 (C=O), 167.4 (CAr-OCH3), 162.9 (CAr-O-CH), 
152.5 (CAr-OCH3), 149.4 (CAr-OCH3), 129.8 (CHAr), 125.9 (CAr), 120.4 (CHAr), 112.3 (CAr), 111.8 
(CHAr), 111.2 (CHAr), 110.0 (CHAr), 101.1 (CHAr), 91.4 (O2N-CH-CH), 81.3 (O2N-CH-CH), 56.0 
(OCH3), 55.94 (OCH3), 55.90, (OCH3) ppm; 1H NMR (300 MHz, DMSO-d6, NO2-flavanone): δ 
= 7.82 (d, J = 8.8 Hz, 1H, CHAr), 7.35 (d, J = 1.9 Hz, 1H, CHAr), 7.16 (dd, J = 8.3, 2.0 Hz, 1H, 
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CHAr), 7.02 (d, J = 8.6 Hz, 1H, CHAr), 6.98 (d, J = 12.3 Hz, 1H, O2N-CH-CH), 6.80 (dd, J = 8.8, 
2.3 Hz, 1H, CHAr), 6.74 (d, J = 2.3 Hz, 1H, CHAr), 5.99 (d, J = 12.2 Hz, 1H, O2N-CH-CH), 3.85 (s, 
3H, OCH3), 3.78 (s, 3H, OCH3), 3.77 (s, 3H, OCH3) ppm; 13C NMR (101 MHz, DMSO-d6, NO2-
flavanone): δ = 181.2 (C=O), 167.0 (CAr-OCH3), 162.8 (CAr-O-CH), 150.0 (CAr-OCH3), 148.7 
(CAr-OCH3), 128.9 (CHAr), 126.0 (CHAr), 121.3 (CAr), 111.8 (CHAr), 111.5 (CAr), 111.4 (CHAr), 
111.3 (CHAr), 101.1 (CHAr), 90.1 (O2N-CH-CH), 80.3 (O2N-CH-CH), 56.2 (OCH3), 55.6 (OCH3), 
55.4 (OCH3) ppm; IR (neat): 2974, 2844, 1681, 1610, 1561, 1238, 1018 cm-1; MS (ESI+) m/z 
(%): 260 (100) [M+H]+; HRMS (ESI+) calcd for C18H18NO7 [M+H]+ 360.1078, found 360.1082. 
A 6.4 Synthesis of fluorescent aromatic thiol dyes 
N,N'-(disulfanediylbis(ethane-2,1-diyl))bis(5-(dime-
thylamino)naphthalene-1-sulfonamide) (DCY disul-
fide, 75).[71] (Dimethylamino)naphthalene-1-sulfonyl 
chloride (Dansyl chloride, 74, 1.00 g, 3.70 mmol, 
2.0 eq.) was dissolved in 42 mL acetone/H2O 30:1 and 
a solution of 2,2'-disulfanediylbis(ethan-1-amine) dihydrochloride (cystamine-HCl, 435 mg, 
1.90 mmol, 1.0 eq.) in 22 mL aqueous 1 M NaHCO3 was added dropwise within 15 min. The 
solution was stirred at room temperature at pH 7-8 for 2 h, poured into 30 mL DCM and 
after phase separation the aqueous phase was extracted with 30 mL DCM another two 
times. The combined organic phases were washed with 1 M NaHCO3 (3 x 200 mL), dried 
over MgSO4 and the solvent was removed. Without further purification the product 75 was 
received as bright yellow solid (1.08 g, 1.75 mmol, 92%). Rf = 0.09 (SiO2, petroleum 
ether/EtOAc 3:1); 1H-NMR (300 MHz, CDCl3): δ = 8.54 (d, J = 8.5 Hz, 2H, CHAr), 8.24-8.22 (m, 
4H, CHAr), 7.55-7.51 (m, 4H, CHAr), 7.18 (d, J = 7.6 Hz, 2H, CHAr), 5.24 (s, 2H, NH), 3.09 (brs, 
4H, CH2), 2.88 (s, 12H, CH3), 2.49 (t, J = 6.3 Hz, 4H, CH2) ppm. The NMR data is in accordance 
with the literature.[71] 
5-(Dimethylamino)-N-(2-mercaptoethyl)naphthalene-1-sulfonamide 
(DCY).[71] N,N'-(Disulfanediylbis(ethane-2,1-diyl))bis(5-(dimethylami-
no)naphthalene-1-sulfonamide) (DCY disulfide 75, 200 mg, 
0.320 mmol, 1.0 eq.) was dissolved in 13 mL degassed THF/H2O 10:1 at 
0-5 °C and NaBH4 (120 mg, 3.20 mmol, 10 eq.) was added in small por-
tions. The mixture was stirred on ice for 4 h and overnight at room temperature. THF was 
removed, the residue was taken up in 50 mL H2O and the aqueous phase was extracted 
with 3 x 10 mL diethyl ether. The combined organic phases were washed with brine, dried 
over MgSO4 and the solvent was removed. Column chromatography was performed (pe-
troleum ether/EtOAc 3:1) and the product was obtained as bright yellow solid (93.0 mg, 
Electrophiles of the enone-type and the investigation of their reactivity and biological activity 
103 
0.300 mmol, 47%). Rf = 0.38 (SiO2, petroleum ether/EtOAc 2:1); 1H-NMR (300 MHz, CDCl3): 
δ = 8.55 (d, J = 8.5 Hz, 1H, CHAr), 8.29-8.24 (m, 2H, CHAr), 7.56 (ddd, 2H, J = 16.0, 8.5, 7.5 Hz, 
CHAr), 7.19 (d, J = 7.5 Hz, 1H, CHAr), 5.24 (t, J = 6.3 Hz, 1H, NH), 3.08 (q, J = 6.4 Hz, 2H, CH2), 
2.89 (s, 6H, CH3), 2.50 (dt, J = 8.6, 6.4 Hz, 2H, CH2) ppm. The NMR data is in accordance with 
the literature.[71] 
S-(4-Formylphenyl) ethanethioate (78).[72] p-Methylthiobenzaldehyde 
(76, 0.605 g, 3.97 mmol, 1.0 eq.) was dissolved in 13 mL dry degassed 
DMF and potassium tert-butylthiolate (77, 1.02 g, 9.09 mmol, 2.3 eq.) 
was added. The reaction was stirred at 160 °C for 4.5 h and subsequently cooled to 0-5 °C. 
Acetyl chloride (793 µL, 11.1 mmol, 2.8 eq.) was added and the mixture was stirred for 2 h. 
The reaction was quenched with H2O, extracted with 3 x 100 mL diethylether and washed 
with 2 x 200 mL H2O. The combined organic phases were dried over MgSO4 and the solvent 
was evaporated. Column chromatography was performed (petroleum ether/EtOAc 5:1) to 
yield the product 78 as yellow liquid (300 mg, 1.66 mmol, 42%). Rf = 0.38 (SiO2, petroleum 
ether/EtOAc 5:1); 1H-NMR (300 MHz, CDCl3): δ = 10.03 (s, 1H, Ar-CHO), 8.01-7.82 (m, 1H, 
CHAr), 7.70-7.52 (m, 1H, CHAr), 2.46 (s, 1H, CH3) ppm; 13C-NMR (75 MHz, CDCl3): δ = 192.3 
(C=O), 191.5 (C=O), 136-7 (CAr), 135.4 (CAr), 134.5 (CHAr), 130.0 (CHAr), 30.9 (CH3) ppm. The 
NMR data is in accordance with the literature.[72] 
(E)-2-(4-(Acetylthio)styryl)-1,3,3-trimethyl-3H-indol-1-ium 
iodide (Acetyl-MSTI).[72] Tetramethylindolium iodide (79, 
123 mg, 0.410 mmol, 1.0 eq.) and NaOAc (40 mg, 
0.50 mmol, 1.2 eq.) were dissolved in 2.5 mL acetic acid an-
hydride and stirred at room temperature for 30 min. S-(4-formylphenyl) ethanethioate (78, 
74.0 mg, 0.410 mmol, 1.0 eq.) was dissolved in 2.5 mL acetic anhydride, added dropwise to 
the mixture and the reaction was stirred for 48 h. The solvent was removed via high vac-
uum. Purification was performed by mixing the crude orange solid and 5 mL diethylether 
thoroughly via ultrasonic bath in a centrifuge vial. After centrifugation the organic phase 
was decantated and the washing repeated another two times. Further 3 x 5 mL washing 
steps were performed with each toluene and petroleum ether. The product was obtained 
as orange solid (189 mg, 0.407 mmol, 99%). Rf = 0.38 (SiO2, DCM/MeOH 9:1); 1H-NMR (300 
MHz, CDCl3): δ = 8.22 (d, J = 16.5 Hz, 1H, CH=CH=C=N+), 8.19 (d, J = 8.2 Hz, 2H, CHAr), 7.82 
(d, J = 16.5 Hz, 1H, CH=CH=C=N+), 7.67-7.52 (m, 6H, CHAr), 4.45 (s, 3H, O=C-CH3), 2.45 (s, 
3H, N+-CH3), 1.86 (s, 6H, C-(CH3)2) ppm; 13C-NMR (75 MHz, CDCl3): δ = 192.7 (C=O), 182.5 
(C=N+), 152.6 (CAr), 143.1 (CAr), 141.4 (CAr), 134.7 (CAr p-subst.), 134.3 (CAr), 131.4 (CAr p-
subst.), 130.2 (CAr), 129.7 (CAr), 122.6 (CAr), 115.3 (CAr or CH=C=N+), 114.4 (CAr or CH=C=N+), 
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52.8 (C-(CH3)2, 37.6 (N+-CH3), 30.6 (O=C-CH3), 26.6 (C-(CH3)2 ppm; MS (ESI+) m/z (%): 336 
(100) [M-H]+. The NMR data is in accordance with the literature.[72] 
7-Nitrobenzo[c][1,2,5]oxadiazole-4-thiol (NBD).[73] To 4-Chloro-7-ni-
trobenzo[c][1,2,5]oxadiazole (80, 51.0 mg, 0.256 mmol, 1.0 eq.), dis-
solved in 2 mL degassed MeOH, a solution of NaSH x 1 H2O in 2 mL 
degassed MeOH was added dropwise and the mixture was stirred for 
15 min at room temperature. To remove H2S, the solution was purged with N2 for 15 min 
and the solvents were removed under high vacuum. The deep purple solid was further 
purged with N2 for 2 h. 69.2 mg (0.249 mmol, 97%) of the product containing 1 eq. NaCl 
was obtained. Rf = 0.69 (SiO2, petroleum ether/EtOAc 1:1); 1H-NMR (300 MHz, MeOD): δ = 
8.14 (d, J = 8.7 Hz, 2H, CHAr), 7.17 (d, J = 8.7 Hz, 2H, CHAr) ppm. The NMR data is in accord-
ance with the literature.[73] 
4-Chloro-6-nitrosobenzene-1,3-diol (84).[81] 4-Chlororesorcinol (87, 
5.09 g, 35.2 mmol, 1.0 eq.) was dissolved in 35 mL of EtOH/H2O 4:1 con-
taining 2.61 g (46.5 mmol, 1.32 eq.) KOH at 0-5 °C and stirred at this tem-
perature for 10 min. Isopentyl nitrite (88, 4.27 g, 36.4 mmol, 1.0 eq.) was added dropwise 
over 30 min. The mixture was warmed to room temperature and stirred for 1 h. 10 mL 37% 
aqueous HCl were added dropwise at 0-5 °C and stirred at room temperature for 10 min. 
The yellow precipitate was filtrated off and washed with 300 mL aqueous HCl solution pH 
2, 300 mL H2O and 200 mL petroleum ether. After drying under high vacuum, the product 
84 was obtained as yellow solid (5.24 g, 30.2 mmol, 86%). Rf = 0.53 (SiO2, petroleum 
ether/EtOAc 1:4, 0.1% TFA); 1H-NMR (400 MHz, DMSO-d6): δ =  13.92 (s, 1H, OH), 11.48 (s, 
1H, OH), 7.71 (s, 1H, CHAr), 5.86 (s, 1H, CHAr) ppm; 13C-NMR (101 MHz, DMSO): δ = 178.7 
(C-OH), 162.5 (C-NO), 144.3 (C-OH), 135.6 (CH), 119.4 (C-Cl), 105.6 (CH) ppm; MS (ESI-) m/z 
(%): 172 (100) [M-H]-. The NMR data is in accordance with the literature.[81] 
8-Chloro-7-hydroxy-3H-phenoxazin-3-one (86).[81] Resorcinol (85, 
1.50 g (13.6 mmol, 1.0 eq.) was dissolved in 12 mL concentrated 
sulfuric acid at 85 °C. 4-Chloro-6-nitrosobenzene-1,3-diol (84, 
2.36 g, 13.6 mmol, 1.0 eq.) was added as solid in portions over 30 min and the mixture was 
stirred at 110 °C for 24 h. After cooling to room temperature, the mixture was poured into 
200 mL of ice water. The resulting precipitate was quickly filtered off and washed with 
100 mL H2O. The product was obtained after drying under high vacuum as dark violet solid 
(3.06 g, 12.4 mmol, 91%) and used without further purification. Due to very low solubility 
no NMR data was obtained. MS (ESI-) m/z (%): 248 (100) [M-H]-. 
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10-Acetyl-2-chloro-10H-phenoxazine-3,7-diyl diacetate 
(89).[82] 8-Chloro-7-hydroxy-3H-phenoxazin-3-one (86, 
100 mg, 0.404 mmol, 1.0 eq.) and SnCl2 (230 mg, 
1.21 mmol, 3 eq.) were dissolved in 1 mL acetic acid anhy-
dride (1.08 g, 10.6 mmol) at room temperature and triethylamine (250 µL, 1.80 mmol, 
4.5 eq.) was added. The mixture was stirred at 110 °C for 18 h. After cooling to room tem-
perature acetic acid anhydride was removed by HV. The resulting solid was suspended in 
20 mL DCM and mixed thoroughly by stirring and ultrasonic treatment. The mixture was 
left standing and the solid settled, then the organic phase was decanted. This extraction 
was repeated twice and the organic phases were combined. DCM was removed by evapo-
ration and the crude product was received as viscous brown oil. Column chromatography 
was performed (petroleum ether/EtOAc 2:1) and the product was received as beige solid 
(72.0 mg, 0.192 mmol, 47%). Rf = 0.34 (SiO2, petroleum ether/EtOAc 2:1); 1H-NMR 
(300 MHz, CDCl3): δ =  7.63 (s, 1H, CHAr), 7.36 (dd, J = 8.1, 0.9 Hz, 1H, CHAr), 6.99-6.84 (m, 
3H, CHAr), 2.34 (s, 3H, CH3), 2.32 (s, 3H, CH3), 2.30 (s, 3H, CH3) ppm; 13C-NMR (75 MHz, 
CDCl3): δ = 169.0 (C=O), 168.9 (C=O), 168.2 (C=O), 150.8 (CAr-O), 149.4 (CAr-O), 149.0 (CAr-
O), 145.0 (CAr-O), 127.5 (CAr), 126.4 (CAr), 126.0 (CHAr), 125.1 (CHAr), 121.4 (CAr-Cl), 117.0 
(CHAr), 112.2 (CHAr), 110.9 (CHAr), 22.8 (CH3), 21.0 (CH3), 20.5 (CH3) ppm; MS (ESI+) m/z (%): 
376 (100) [M-H]+; HRMS (ESI+) calcd for C18H15ClNO6 [M+H]+ 376.0582, found 376.0586. 
1-(2-Chloro-3,7-dihydroxy-10H-phenoxazin-10-yl)ethan-1-one 
(90).[82] 10-Acetyl-2-chloro-10H-phenoxazine-3,7-diyl diacetate 
(89, 221 mg, 0.588 mmol, 1.0 eq.) and SnCl2 (230 mg, 1.21 mmol, 
3 eq.) were suspended in 3 mL MeOH and 2 mL aqueous KOH 
10% was added. The mixture was stirred at room temperature for 2 h, during this time it 
became a dark violet solution. 20 mL H2O and 3 M HCl (3 mL) were added and the mixture 
was stirred for approximately 10 min until it turned to a pale orange suspension. Extraction 
was performed with EtOAc (3 x 50 mL). The combined organic phases were washed with 
1 M HCl (1 x 200 mL) and brine (2 x 200 mL), dried over MgSO4 and the solvent was removed 
on the rotary evaporator. After column chromatography (petroleum ether/EtOAc 1:1) the 
product 90 was received as pale pink foamy solid (157 mg, 0.538 mmol, 92%). Rf = 0.21 
(SiO2, petroleum ether/EtOAc 2:1); 1H-NMR (300 MHz, acetone-d6): δ = 9.22 (s, 1H, OH, 
quickly decreasing due to deuterium exchange), 8.85 (s, 1H, OH, quickly decreasing due to 
deuterium exchange), 7.55 (s, 1H, CHAr), 7.30 (d, J = 8.6 Hz, 1H, CHAr), 6.75 (s, 1H, CHAr), 
6.67-6.55 (m, 2H, CHAr), 2.24 (s, 1H, CH3) pm; 13C-NMR (75 MHz, acetone-d6): δ = 170.1 
(C=O), 157.1 (CAr-O), 152.1 (CAr-OH), 152.1 (CAr-OH), 150.9 (CAr-O), 126.7 (CHAr), 126.4 
(CHAr), 123.0 (CAr), 122.0 (CAr), 114.9 (CAr-Cl), 111.2 (CHAr), 105.0 (CHAr), 104.3 (CHAr), 22.7 
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(CH3) ppm; MS (ESI+) m/z (%): 292 (100) [M-H]+; HRMS (ESI+) calcd for C14H11ClNO4 [M+H]+ 
292.0371, found 292.0378. 
10-Acetyl-2-chloro-10H-phenoxazine-3,7-diyl bis(trifluoro-
methanesulfonate) (92).[83] 11-(2-Chloro-3,7-dihydroxy-10H-
phenoxazin-10-yl)ethan-1-one (90, 272 mg, 0.932 mmol, 
1.0 eq.) was dissolved in 15 mL dry DMF and cooled to 0-5 °C. 
NaH 60% (82.0 mg, 2.05 mmol, 2.2 eq.) was added and the mixture was stirred on ice and 
allowed to warm up to room temperature after 30 min. 1,1,1-Trifluoro-N-phenyl-N-((tri-
fluoromethyl)sulfonyl)methanesulfonamide (91, 732 mg, 2.05 mmol, 2.2 eq.) was added 
and stirred for 5 min. The reaction was poured in to a separation funnel containing 100 mL 
DCM, washed with H2O (2 x 150 mL) and brine (1 x 150 mL), dried over MgSO4 and the 
solvent was removed. After column chromatography (petroleum ether/EtOAc 3:1) the 
product was received as yellow solid (317 mg, 0.570 mmol, 61%). Rf = 0.26 (SiO2, petroleum 
ether/EtOAc 4:1); 1H-NMR (300 MHz, CDCl3): δ = 7.74 (s, 1H, CHAr), 7.48 (dd, J = 3.8 Hz, 
1.9 Hz, 1H, CHAr), 7.17 (s, 1H, CHAr), 7.15-7.11 (m, 2H, CHAr), 2.36 (s, 3H, CH3); 13C-NMR 
(75 MHz, CDCl3) δ = 168.5 (C=O), 150.7 (CAr-OTf), 149.0 (CAr-O), 147.3 (CAr-O), 143.2 (CAr-
OTf), 129.2 (CAr), 128.5 (CAr), 126.9 (CHAr), 125.9 (CHAr), 122.3 (CAr-Cl), 118.5 (q, J = 320.8 Hz, 
CF3), 118.6 (q, J = 320.8 Hz, CF3), 117.3 (CHAr), 111.8 (CHAr), 111.1 (CHAr), 22.8 (CH3) ppm; 
19F-NMR (282 MHz, CDCl3): δ = -73.1, -73.7 ppm. MS (ESI+) m/z (%): 556 (100) [M-H]+; HRMS 
(ESI+) calcd for C16H9ClF6NO8S2 [M+H]+ 555.9357, found 555.9366. 
(4-Bromophenyl)(tert-butyl)sulfane (94).[84] 4-Bromothiophenol (96, 1.00 g, 
5.29 mmol, 1.0 eq.) was dissolved in 5 mL (45.4 mmol, 8.6 eq.) tert-butylchloride 
and AlCl3 (35.0 mg, 0.265 mmol, 0.05 eq.) was added in portions at room tem-
perature. The reaction was stirred for 1 h and quenched with 150 mL H2O. The 
product was extracted in hexane (3 x 50 mL), the organic phases washed with 
water (2 x 150 mL) and the solvent was removed to yield 1.02 g (4.16 mmol, 79%) of a col-
orless liquid (94). Rf = 0.63 (SiO2, petroleum ether); 1H-NMR (300 MHz, CDCl3): δ =  7.47-
7.44 (m, 2H, CHAr), 7.40-7.37 (m, 2H, CHAr), 1.27 (s, 9H, CH3) ppm; 13C-NMR (75 MHz, 
DMSO): δ = 138.9 (CHAr), 131.8 (C-S), 131.6 (CHAr), 123.4 (C-Br), 46.1 (C-(CH3)3), 30.9 
(CH3) ppm. The NMR data is in accordance with the literature.[84] 
(4-(tert-Butylthio)phenyl)boronic acid (97).[85] (4-Bromophenyl)(tert-
butyl)sulfane (94, 1.00 g, 4.08 mmol, 1.0 eq.) was dissolved in 5 mL dry THF at 
-78 °C and a solution of 4.08 mL 1.6 M n-BuLi (6.53 mmol, 1.6 eq.) was added. 
After stirring for 1 h triisopropyl borate (4.86 mL, 21.2 mmol, 5.2 eq.) was 
added. The reaction was brought to -20 °C and stirred overnight without re-
moving the cooling bath. After 24 h the solvent was removed and the residue was taken up 
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in 10 mL DCM and 20 mL 5 M aqueous HCl. The mixture was stirred vigorously for 2 h at 
room temperature. After completion of the reaction, phases were separated and the aque-
ous phase was extracted with DCM (2 x 15 mL). The combined organic phases were washed 
with 2 x 20 mL aqueous HCl 1 M, dried over MgSO4 and the solvent was removed. The crude 
product was washed with hexane, filtered off and recrystallized in hexane to yield 455 mg 
(2.17 mmol, 53%) of the product 97 as a white solid. Rf = 0.73 (SiO2, petroleum ether/EtOAc 
1:1); 1H-NMR (300 MHz, CDCl3): δ =  8.20-8.17 (m, 2H, CHAr), 7.69-7.66 (m, 2H, CHAr), 1.35 
(s, 9H, CH3) ppm; 13C-NMR (75 MHz, CDCl3): δ = 138.4 (C-S), 136.6 (CHAr), 135.5 (CHAr), 133.4 
(C-B), 46.6 (C-(CH3)3), 31.1 (CH3) ppm; MS (ESI+) m/z (%): 211 (100) [M-H]+. The NMR data 
is in accordance with the literature.[85] 
2-(3-Oxo-6-(((trifluoromethyl)sulfonyl)oxy)-3H-xanthen-9-
yl)benzoic acid (98).[86] 2-(6-Hydroxy-3-oxo-3H-xanthen-9-
yl)benzoic acid (fluorescein 95, 927 mg, 2.79 mmol, 1.0 eq.) and 
1,1,1-trifluoro-N-phenyl-N-((trifluoromethyl)sulfonyl)methane-
sulfonamide (91, 997 mg, 2.79 mmol, 1.0 eq.) were dissolved in 
7 mL dry DMF, DIPEA (1.94 mL, 11.2 mmol, 4.0 eq.) was added and the mixture was stirred 
at room temperature under exclusion of light for 60 h. A separation funnel was filled with 
a 1:1 mixture of 200 mL H2O and EtOAc and the reaction mixture was distributed within. 
After phase separation the aqueous phase was extracted with EtOAc (2 x 80 mL) and the 
combined organic phases washed with water (3 x 200 mL), dried over MgSO4 and the sol-
vent was removed. After column chromatography (petroleum ether/EtOAc 3:1) the prod-
uct 98 was obtained as bright yellow foamy solid (512 mg, 1.10 mmol, 40%). The same re-
action carried out in a microwave reactor (80 °C, 30 min) with 1.07 g (3.22 mmol) starting 
material in 20 mL DMF gave 36% yield. Rf = 0.23 (SiO2, petroleum ether/EtOAc 3:1); 1H-
NMR (300 MHz, CDCl3): δ = 8.05 (dd, J = 6.5, 1.1 Hz, 1H, CHAr), 7.74 – 7.63 (m, 2H, CHAr), 
7.24 (d, J = 2.4 Hz, 1H, CHAr), 7.19 – 7.17 (m, 1H, CHAr), 6.96 (dd, J = 8.8, 2.4 Hz, 1H, CHAr), 
6.89 (d, J = 8.8 Hz, 1H, CHAr), 6.77 (d, J = 2.4 Hz, 1H, CHAr), 6.66 (d, J = 8.7 Hz, 1H, CHAr), 6.58 
(dd, J = 8.7, 2.4 Hz, 1H, CHAr); 1H-NMR (300 MHz, DMSO-d6): 13C-NMR (75 MHz, DMSO-d6): 
168.3 (C=O), 159.8 (CAr-OH), 152.0 (O=C-O-C-CAr), 151.3 (CAr-O), 151.1 (CAr-O), 149.5 (CAr-
O), 135.9 (CHAr), 130.4 (2C, CHAr), 129.1 (CHAr), 125.5 (CAr), 124.9 (CHAr), 124.1 (CHAr), 119.8 
(CAr), 117.5 (q, J = 321.0 Hz, CF3), 117.1 (CHAr), 113.4 (CHAr), 110.6 (CHAr), 108.7 (CAr), 102.2 
(CHAr), 81.2 (O=C-O-C) ppm; 19F-NMR (282 MHz, CDCl3): δ = -73.1 ppm. The NMR data is in 
accordance with the literature.[86] 
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2-(6-(4-(tert-Butylthio)phenyl)-3-oxo-3H-xanthen-9-
yl)benzoic acid (99). 2-(3-Oxo-6-(((trifluoromethyl)-
sulfonyl)oxy)-3H-xanthen-9-yl)benzoic acid (fluorescein 
monotriflate, 98, 200 mg, 0.430 mmol, 1.0 eq.), (4-(tert-
butylthio)phenyl)boronic acid (97, 109 mg, 0.520 mmol, 
1.2 eq.), 5.0 mg (0.022 mmol, 0.05 eq.) Pd(OAc)2 and 
P(Ph)3 (23.0 mg, 0.086 mmol, 0.2 eq.) were degassed using three cycles of N2/vacuum and 
dissolved in 5 mL dioxane. K2CO3 (89.0 mg, 0.650 mmol, 1.5 eq.) in 500 µL H2O was added 
and the reaction mixture heated in a microwave reactor (120 °C, 30 min). The mixture was 
poured into 200 mL 1 M aqueous HCl and 100 mL EtOAc, the phases separated and the 
aqueous phase was extracted with EtOAc (2 x 100 mL). The combined organic phases were 
dried over MgSO4, the solvent was evaporated and column chromatography was per-
formed (petroleum ether/EtOAc 4:1) to yield the product as orange foamy solid (182 mg, 
0.379 mmol, 88%). Rf = 0.23 (SiO2, petroleum ether/EtOAc 3:1); 1H-NMR (300 MHz, CDCl3): 
δ = 8.05 (dd, J = 6.5, 1.1 Hz, 1H, CHAr), 7.72–7.53 (m, 6H, CHAr), 7.50 (d, J = 1.8 Hz, 1H, CHAr), 
7.26 (dd, J = 8.2, 1.8 Hz, 2H, CHAr), 7.22–7.18 (m, 1H, CHAr), 6.86 (d, J = 8.2 Hz, 1H, CHAr), 
6.81 (d, J = 2.3 Hz, 1H, CHAr), 6.66 (d, J = 8.7 Hz, 1H, CHAr), 6.58 (dd, J = 8.7, 2.4 Hz, 1H, CHAr), 
1.32 (s, 9H, CH3); 13C-NMR (101 MHz, CDCl3) δ = 169.8 (C=O), 158.5 (C=O), 152.5 (C-O), 151.7 
(C-O), 143.1 (CAr), 139.7 (CAr), 137.9 (2C, CHAr), 135.2 (CAr-S), 132.9 (CHAr or CAr), 129.9 (CHAr), 
129.4 (CHAr), 128.5 (CHAr), 127.3 (CAr), 127.1 (2C, CHAr), 126.6 (CAr), 125.3 (CAr), 124.1 (CHAr), 
122.5 (CHAr), 118.1 (CHAr or CAr), 115.4 (CHAr), 112.7 (CHAr), 111.0 (CAr), 103.2 (CHAr), 46.3 
(C-CH3)2), 31.0 (C-CH3)2) ppm; MS (ESI+) m/z (%): 481 (100) [M-H]+; HRMS (ESI+) calcd for 
C30H25O4S [M+H]+ 481.1468, found 481.1474. 
A 6.5 Kinetic evaluation of electrophiles 
The kinetic thiol assay for electrophiles was developed in this work group and previously 
reported.[35] Pre-kinetic UV-Vis scans and kinetic graphs can be viewed in the appendix. 
Kinetic thiol assay solvent system 
The solvent system for the kinetic thiol assay contains 100 mM Tris-HCl buffer pH 7.4, 2 mM 
EDTA/ethylene glycol 20:80 (buffer:solvent). EDTA was added to the buffer as a complexing 
agent for remaining cations in Millipore water, which are able to catalyze thiol oxidation to 
disulfides. Ethylene glycol is used as co-solvent and to slow down kinetics. The buffer was 
adjusted to pH 7.4 using a WTW-inolab pH meter with a SenTix-Mic glass electrode 
(Weilheim, Germany), mixed 20:80 with ethylene glycol, filtered through a cellulose nitrate 
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filter (pore size 0.45 µm, Sartorius Stedim, Göttingen, Germany) and degassed via ultra-
sound for 10 min. 
LC-MS studies of the compounds under kinetic thiol assay conditions 
LC-MS investigations were performed on an Agilent 1290 Infinity HPLC system coupled to 
Agilent Technologies 6540 UHD TOF/Q-TOF mass spectrometer (Agilent Technologies, 
Santa Clara, USA). The assay mixtures in kinetic thiol assay solution were applied to an Ag-
ilent Zorbax Eclipse Plus C18, 1.8 u, 50 x 2.1 mm column in volumes of 0.5 – 1 µL. Chroma-
tography was performed with an eluent system containing of H2O+0.1% HCOOH/acetoni-
trile with a gradient of 5-95% acetonitrile over 7-9 min at 40 °C. The detection wavelength 
range was 200-300 nm. Mass spectra were recorded between m/z 80 and 1400. Data was 
evaluated using the program MassHunter Workstation (Agilent, Santa Clara, USA). Com-
pounds were identified according to their HR-MS peaks, fragmentation pattern and UV 
spectra. 
Kinetic thiol assay (96-well format) for electrophiles 
All test compounds were kept as 10 mM DMSO stock solutions at -20 °C. Suitable parame-
ters were determined prior to the kinetic investigations by UV-Vis monitoring of each com-
pound with 20, 100 and/or 500-fold cysteamine and additional LC-MS measurements. For 
the assay performance, dilutions of 80 µM for OXEs and 160 µM for phenylacrylamides 
were prepared in kinetic assay buffer. Dilutions of excess cysteamine were prepared di-
rectly in kinetic thiol assay medium freshly for each experiment. All measurements were 
performed in a Thermo Scientific Multiscan Spectrum UV-Vis microplate spectrophotome-
ter (Thermo Fisher Scientific Inc., Vantaa, Finland). Both separate solutions (thiol and elec-
trophile) were incubated in the instrument for 10 min at 25 °C, measurements were per-
formed at the same temperature. 140 µL of each electrophiles and excess thiol were com-
bined in a deep-well microplate, covered with a foil and shaken thoroughly. 200 µL of each 
reaction mixture were quickly pipetted into the 96-well measurement plate (ELISA micro-
plates, F-bottom, MICROLON 200, Greiner Bio-one, Frickenhausen, Germany), covered 
with a PCR foil (Platesealer, Viewseal, transparent, 80 x 140 mm, Greiner Bio-one, Fricken-
hausen, Germany) and the measurement was started immediately. Each thiol excess con-
centration was assayed in duplicates, 380 data points were collected with varying time in-
tervals at the appropriate wavelength for each electrophilic compound. The raw data were 
analyzed by Microsoft Office Excel (Microsoft, Redmond, Washington, USA) with the help 
of a data sheet programmed by Karl Amslinger. After correction versus the blank the ob-
tained individual kinetic curves were fitted to a first-order exponential decay function with 
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the program OriginPro 9 (OriginLab Corporation, Northampton, Massachusetts, USA). The 
value t1 expresses the kobs value for each curve. K2 values were obtained from the slope of 
the linear regression function of kobs values versus their corresponding cysteamine concen-
trations. All compounds were measured in at least three independent experiments. 
Kinetic thiol assay via stopped-flow measurement for OXE3-(4py)’’ 
Measurements were performed on a SX20 stopped-flow instrument (Applied Photophysics, 
Leatherhead, UK) at 25 °C in kinetic thiol assay solution. Dilutions of 80 µM OXE3-(4py)’’ 
and 100-300-fold cysteamine in kinetic thiol assay solution were prepared freshly before 
each measurement. Equal volumes of electrophile and cysteamine solutions were mixed in 
the measurement chamber with instant monitoring of the decease of absorbance at 
330 nm over 30 s – 5 min. Five repetitions were recorded and averaged, the obtained curve 
was fitted to a first-order exponential decay function with the program Pro-Data SX 2.0 
(Applied Photophysics, Leatherhead, UK), yielding the kobs values. This experiment was in-
dividually performed for each cysteamine concentration in duplicates. K2 values were cal-
culated as described before. In total, eight measurements were performed.  
Kinetic evaluation of OXEp1-(4py)’’ and OXE4-(4py)’’ with LC-MS 
All measurements were performed in kinetic thiol assay solution. The electrophiles OXEp1-
(4py)’’ and OXE4-(4py)’’ were used in an assay concentration of 40 µM and cysteamine in 
500, 600 and 700-fold excess (20, 24 or 28 mM). Each experiment included two reactions 
in two wells of a 96-well plate: In each well one of the two electrophiles with one cysteam-
ine excess concentration each. For the electrophiles, 80 µM dilutions in kinetic thiol assay 
solution were prepared from their 10 mM DMSO stock solutions. The cysteamine dilutions 
of 40, 48 or 56 mM were directly prepared in kinetic thiol assay solution freshly for each 
experiment. Immediately before the start of the measurement, 150 µL of electrophile and 
cysteamine dilutions were mixed in a deepwell plate, covered with a foil and shaken thor-
oughly. 250 µL of the resulting mixtures were pipetted into a 96 well microplate (PS, F-
bottom, Greiner Bio-one, Frickenhausen, Germany) and covered with a foil. The reactions 
were monitored by LC-MS on an Agilent 1290 Infinity HPLC system coupled to Agilent Tech-
nologies 6540 UHD TOF/Q-TOF mass spectrometer (Agilent Technologies, Santa Clara, 
USA). The assay mixtures in kinetic thiol assay solution were applied to an Agilent Zorbax 
Eclipse Plus C18, 1.8 u, 50 x 2.1 mm column in volumes of 0.5 – 1 µL. Chromatography was 
performed with an eluent system containing of H2O+0.1% HCOOH/acetonitrile with a gra-
dient of 5-95% acetonitrile over 7-9 min at 40 °C. The detection wavelength range was 200-
300 nm. Mass spectra were recorded between m/z 80 and 1400. Data was evaluated using 
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the program MassHunter Workstation (Agilent, Santa Clara, USA). Compounds were iden-
tified according to their HR-MS peaks and UV spectra. The instrument was programmed to 
pick samples from the reaction mixtures 2, 20, 40, 60, 80, 100, 120 min as well as 2.5, 3, 
3.5, 4, 4.5, 5, 6, 8 and 24 h after pipetting. For data analysis, the decreasing electrophile 
HPLC signals (total mass counts) of each measurement were integrated with the software 
MassHunter (Agilent Technologies, Santa Clara, USA). Kobs values were determined by plot-
ting these time-dependent MS signals and fitting the resulting curves to first-order expo-
nential decay functions (software: Origin Pro 9, OriginLab Corporation, Northampton, Mas-
sachusetts, USA). K2 values were calculated by linear regression of the kobs values versus 
their corresponding thiol concentrations. For the three different thiol excess concentra-
tions, three independent single experiments were performed for each OXE4-(4py)’’ and 
OXEp1-(4py)’’. For all experimental kobs graphs and values, see appendix. 
A 6.6 In-vitro cell assays 
The MTT test for cell viability and the test for the inhibition of NO production (iNOS assay) 
were performed as reported previously by this work group.[35-36] 
Cell line and culture conditions 
Murine macrophages RAW264.7 were used which were cultured in RPMI 1640 medium 
containing 10% (v/v) heat inactivated fetal calf serum (FCS) and 2 mM glutamine (termed 
as culture medium) at 37 °C in humidified air containing 5% CO2. 
Cell viability assay (MTT assay) 
RAW264.7 cells were seeded in 96-well plates at a density of 5000 per well and cultured in 
culture medium for 24 h. Test compounds were kept as 100 mM DMSO stock solutions at -
20 °C and were diluted freshly for each experiment in culture medium to the following con-
centrations: 100, 75, 50, 25, 10, 5, 1, 0.1 µM. The cells were incubated at 37 °C with the 
different concentrations of test compounds for 20 h in culture medium. Controls were cells 
with culture medium, cells with culture medium and 0.1% DMSO and cell-free wells with 
only culture medium. The total assay volume was 100 µL and the highest DMSO concentra-
tion was 0.1%. MTT solution in a concentration of 4 mg/mL in phosphate buffered saline 
(PBS) was added in a volume of 10 µL to each well and further incubated for 4 h at 37 °C. 
The culture medium was removed from the wells and 100 µL of 10% aqueous SDS solution 
was added and incubated overnight at room temperature. The absorbance was measured 
at λ = 560 nm on a Multiscan Spectrum spectrophotometer (Thermo Fisher Scientific Inc., 
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Vantaa, Finland) at 25 °C. For each compound concentration, quadruplicates were meas-
ured. IC50 values were calculated from three to five individual performed experiments. 
Anti-inflammatory assay (NO/iNOS inhibition assay or Griess assay) 
RAW264.7 cells were seeded in 96-well plates at a density of 80,000 per well and cultured 
for 24 h. Test compounds were kept as 100 mM DMSO stock solutions at -20 °C and were 
diluted freshly for each experiment in two different culture media: one contained 10 ng/mL 
LPS, the other one without LPS. The cells were incubated with test compounds in four dif-
ferent individual concentrations according to the previously determined toxicity limits for 
24 h at 37 °C. The total assay volume was 100 µL and the highest DMSO concentration was 
0.1%. Griess reagent was prepared freshly before use by dissolving 50 mg NED (N-1-naph-
thylethylenediamine dihydrochloride), 500 mg sulfanilamide and 175 µL phosphoric acid in 
50 mL Millipore water and heating to 60-70 °C for 30-60 min. 50 µL Griess reagent was 
mixed with 50 µL culture medium at room temperature and air bubbles were removed un-
der a weak nitrogen stream. After 15 min at room temperature, the absorbance was meas-
ured at λ = 560 nm on a Multiscan Spectrum Photometer (Thermo Fisher Scientific Inc., 
Vantaa, Finland) at 25 °C. To create a calibration curve, NaNO2 solutions were prepared in 
concentrations of 0-100 µM and measured in a volume of 100 µL in a 96-well plate. For 
each compound concentration, quadruplicates were measured. IC50 values were calculated 
from three to five individual performed experiments. The statistical evaluation of the data 
using the t-test was carried out by Sabine Amslinger. 
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B Characterization of a new photoactive protein probe for 
the labeling of BTN3A4 
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B 1 Introduction 
B 1.1 The immune modulator role of HMBPP 
Phosphoantigens (PAgs) are small organic molecules, which typically contain a diphosphate 
unit (traditionally known as pyrophosphates, PPs) and are potent activators of human 
Vγ9Vδ2 T-lymphocytes. Vγ9Vδ2 T cells are an important subpopulation of γδ T cells and 
generally involved in the cross talk of the innate and adaptive immune system. The most 
potent natural phosphoantigen is (E)-4-hydroxy-3-methylbut-2-enyl diphosphate (HMBPP, 
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102, Figure 46) with an EC50 value of T-cell activation in the sub-nanomolar range[103] [104] 
[105] [106].  
 
Figure 46: Molecular structure of the phosphoantigen HMBPP (102). 
HMBPP is an intermediate of the 1-deoxy-D-xylulose 5-phosphate (DOXP) or non-mevalo-
nate pathway of isoprenoid biosynthesis that is common to many eubacteria, plants and 
apicomplexan parasites and is responsible for the massive Vγ9Vδ2 T cell expansion in some 
infectious diseases such as malaria.[106] [107] HMBPP is the immediate precursor of isopen-
tenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), which are the key com-
pounds of isoprenoid biosynthesis of all organisms and act as weak phosphoantigens with 
EC50 values in the micromolar and high nanomolar range, respectively.[105] Aminobisphos-
phonates such as zoledronate used for the therapy of tumors or osteoporosis inhibit the 
IPP-utilizing enzyme farnesyl diphosphate synthase (FPPS) and the resulting increase of IPP 
levels renders the treated cells into Vγ9Vδ2 T cell activators.[108] [109] [110] Cell surface recep-
tors mandatory for PAg-mediated Vγ9Vδ2 T cell activation are the eponymous Vγ9Vδ2 T 
cell antigen receptors (Vγ9Vδ2 TCRs) on Vγ9Vδ2 T cells (sometimes called Vγ2Vδ2 TCRs and 
Vγ2Vδ2 T cells) and butyrophilin 3A1 (BTN3A1) on the phosphoantigen-“presenting” 
cell.[111] Two mutually non-exclusive modes of interaction of phosphoantigens with the 
BTN3A1 protein have been proposed.[112] One rather debated one proposes binding of the 
PAg to a shallow binding groove in the extracellular V-domain of BTN3A1.[113] The binding 
of the resulting BTN3A1-PAg complex to the Vγ9Vδ2 TCR would then initiate the PAg-spe-
cific activation of the Vγ9Vδ2 T cells. The other one emphasizes the importance of PAg 
binding of the negatively charged diphosphate entity of the PAg to a well-defined positively 
charged pocket in the PRY/SPRY (B30.2) domain of the intracellular region of BTN3A1. This 
binding occurs at a micromolar range for HMBPP and at a millimolar range for IPP.[114] [115] 
[116] NMR studies suggest a subsequent conformational change of the membrane proximal 
parts of the intracellular domain.[115] This change would precede formation of an active 
conformation and of cell surface clusters of BTN3A1, as they were observed after treating 
cells with aminobisphosphonates.[111] [117] [118] The resulting lattice of BTN3A1 or of BTN3A1 
in conjunction with other molecules might then serve as binding partner for the Vγ9Vδ2 
TCR. The exact nature of such hypothetical additional molecules is unknown, but it is clear 
that the PAg-induced activation of Vγ9Vδ2 T cells is controlled by gene(s) encoded on hu-
man chromosome 6 encoding other components than BTN3A1.[119] 
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B 1.2 BioBP-HMBPP as a new photoactive protein probe for the labeling of 
BTN3A4 
To identify potential co-receptors or, in general, proteins involved in HMBPP binding, a 
multifunctional probe is needed. The probe was designed by connecting the three crucial 
parts:  
HMBPP high affinity ligand for the Vγ9Vδ2 T cell receptor 
benzophenone 
can be activated photochemically to make a covalent C-C bond 
with the α-carbon of amino acids of the bound protein 
biotin 
allows for detection or purification of attached proteins by 
streptavidin or avidin-based systems 
 
These three fragments were combined by two linking units, which were connected by three 
ether functionalities and an amide bond to create a high degree of hydrolytic stability for 
the probe BioBP-HMBPP (BiotinBenzoPhenone-HMBPP, 103, Figure 47). This design is 
based on prior work using the benzophenone unit as the photo-crosslinkable core unit[120] 
together with isoprenoid diphosphates including HMBPP.[121] [122] [123] [124] A biotinylated 
photoaffinity ligand very similar to this probe was recently presented.[125]  The main differ-
ence is a direct connection of HMBPP to the benzophenone unit by an ester linkage, 
whereas linker-2 and two ether bonds were used for 103.  
 
Figure 47: Structure of BioBP-HMBPP (103), a biotinylated photo-crosslinkable derivative of the PAg (E)-4-
hydroxy-3-methylbut-2-enyl diphosphate (HMBPP, 102). 
BioBP-HMBPP (103) was designed and synthesized in this work group by Sabine Amslinger 
and Andrea Mattarei. In a nine-step synthesis 103 was obtained with an overall yield of 
16%. For the complete synthesis route, reagents and conditions, yields and analytical data, 
see Mattarei et al. Chem. Eur. J. 2017, 23, 11945 – 11954.[102] 
The whole photochemical labeling strategy is based on forming radicals in 103, which react 
with proteins. More specifically, exciting the benzophenone chromophore of 103 
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transforms the carbonyl C=O double bond into biradical 104 (Scheme 30). When in close 
proximity to proteins, 104 can abstract H-atoms from α-carbons of the protein backbone 
and initiate a covalent attachment of the α-carbon of amino acids to the former carbonyl 
carbon of the benzophenone moiety.  
 
Scheme 30: Photochemically-induced covalent attachment of benzophenone-based probes to proteins.[123] 
Once covalently bound, the protein can be separated from the solution via SDS-PAGE, blot-
ted on a membrane and, if successfully labeled, detected by the streptavidin-horseradish 
peroxidase (HRPO) system. 
B 1.3 Aim of this work 
Since probe 103 was only synthesized but not investigated towards its purpose, general 
and specific protein labeling studies of 103 were performed within this work. UV-Vis spec-
troscopy was used to determine the chromophore of 103 and follow the processes during 
irradiation. Four proteins were examined: BSA and papain were used for the general label-
ing of BioBP-HMBPP towards proteins and furthermore the B30.2 domain of BTN3A1 and 
a charge reversal mutant of this protein were tested. It was tested in vitro whether 103, 
despite its increased molecular size, is still a T cell activator through the HMBPP unit (per-
formed by the work group of Prof. Herrmann, University of Würzburg). To prove the spe-
cific binding of probe 103 to the HMBPP binding pocket of the B30.2 domain of BTN3A1, 
competition experiments were performed with the natural ligand HMBPP. Conditions for 
laser irradiation, probe concentrations and sample volumes were tested and optimized. 
The labeling efficiency of BioBP-HMBPP was determined using monobiotinylated BTN3A1 
B30.2. 
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B 2 Results and Discussion 
B 2.1 Photochemical and UV-Vis evaluation, handling of proteins and 
probe solutions 
UV-Vis characterization of probe 103 without and with BSA 
To prove the applicability of 103 as a photo-crosslinkable probe, its spectroscopic and la-
beling properties were investigated. UV-Vis spectra of 103 at different concentrations in 
phosphate-buffered saline (PBS) pH 7.4 revealed an absorbance maximum of 302 nm 
caused by the benzophenone unit (Figure 48A). Thus, a 308 nm excimer laser as the light 
source was chosen for the photochemical labeling experiments. Laser irradiation allows for 
defined reaction conditions, in which the radiation is transferred very efficiently into the 
sample. Moreover, an irradiation of volumes as low as 90 mL was achieved using 1 mm 
quartz cuvettes. To establish its general properties, 103 was irradiated with an increasing 
number of 10 ns laser pulses (pulse energy 215–250 mJ, frequency 1 Hz; Figure 48C). 
Within 10 pulses, the absorbance of BioBP-HMBPP (103) decreases by 50%. This decay of 
the benzophenone chromophore reveals the formation of biradical 104, which is quenched 
by H-atom abstraction from water of the reaction medium PBS. 
Having proven its general photochemical activation, 103 was tested towards its pan reac-
tion with proteins. Bovine serum albumin (BSA) was used as a model protein to test for 
general unspecific protein labeling. Concentrations of 20 µM BSA and 30 µM (1.5-fold ex-
cess) BioBP-HMBPP 103 were chosen. First, UV-Vis spectra of 103 in PBS pH 7.4 with BSA 
were measured without irradiation. After incubation of BioBP-HMBPP (103) with BSA in 
buffer for 30 min on ice and in the dark, the radiation was performed. A control sample of 
20 µM BSA alone was also irradiated simultaneously. BSA alone proved to be stable when 
an increasing number of laser pulses for at least 50 pulses was applied (Figure 48B). Further 
prolongation of irradiation (300 or more pulses) gave a significant increase in absorption 
within the whole region scanned. This indicates radiation- or heat-related protein decom-
position. When 103 was irradiated (1–600 pulses) in presence of 20 µm BSA, a very similar 
decrease of the absorption as in Figure 48B within the first 10 pulses was observed indicat-
ing an equally efficient radical reaction (Figure 48D). Whether this effect is due to a reaction 
with water or the protein backbone cannot be determined based on this data. 
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Figure 48: UV-Vis spectra in PBS buffer pH 7.4 of A: the probe BioBP-HMBPP (103) at different concentrations 
without irradiation; B-D: Samples were irradiated with the indicated number of laser pulses at 308 nm: B: 
20 µM BSA; C: 30 µM BioBP-HMBPP (103) and D: 20 µM BSA together with 30 µM BioBP-HMBPP (103). 
Detection of BioBP-HMBPP-labeled BSA and handling of probe 103 
SDS-PAGE protein separation and subsequent Western blotting were used to prove that 
the absorbance decrease found by UV-Vis spectroscopy is due to a covalent protein labeling 
of BSA by 103. Labeling by 103 is visualized using a streptavidin-coupled HRPO (horseradish 
peroxidase) chemiluminescence detection system, which relies on binding to the biotin 
fragment in 103 after transferring the proteins on a PVDF membrane. With this method the 
successful labeling of BSA by BioBP could be proven by the detection of a strong protein 
band (Figure 49). BSA as a transporter protein is able to bind various molecules in order to 
transport them in blood plasma. Due to this general ability, probe 103 can come close 
enough to BSA to covalently bind to the protein when activated by laser energy according 
to Scheme 30. 
It is important to note that probe 103 turned out to be unstable in DMSO stock solutions 
at room temperature and daylight for extended time periods. Therefore, aliquots of the 
100 mM stock solution were kept at -20 °C and were freshly diluted when used. 
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Furthermore, inadvertent labeling of actually unirradiated control samples was frequently 
experienced during the first experiments. An example is shown in Figure 49, lanes 1 and 4 
(unirradiated). It was assumed that this phenomenon occurs when samples are incubated 
for longer than 20 min in daylight and/or artificial light. Initially, sample preparation was 
therefore performed in the darkened laboratory to avoid the effect, but later it was found 
that the source of the unwanted labeling were certain types of overhead light bulbes in 
several laboratories. Tests have shown that only a few minutes under the influence of this 
light are sufficient to induce labeling. In addition, however, the exposure to monochromatic 
light during the recording of UV-Vis spectra was not high enough in energy to produce la-
beling, not even during prolonged exposure in a kinetic experiment, which was also tested 
as an alternative to laser irradiation. Keeping non-irradiated controls with proteins and 103 
constantly in the dark and on ice secured that no artificial labeling without laser irradiation 
was found. 
 
Figure 49: Labeling of BSA by the probe BioBP-HMBPP (103) under different conditions. Protein concentration 
during irradiation in this representative experiment was 20 or 2 µM together with 100 µM BioBP-HMBPP with 
increasing laser pulses. * = Inadvertent, artificial labeling of non-laser-irradiated samples by laboratory over-
head lights is visible. 
To prove furthermore, that the gradual decrease of absorbance by increasing numbers of 
laser pulses correlates with an irradiation-dependent protein labeling of BSA, the protein 
samples of the UV-Vis experiment (Figure 48D) were also isolated and visualized. Addition-
ally, the protein load was stained with Ponceau S for the control of equal protein amounts 
in each sample. Notably, one laser pulse is enough to induce significant protein labeling by 
103 (Figure 50, lane 2). Upon prolonged irradiation, the extent of BSA labeling increased 
dramatically. Between 50 and 300 laser pulses BSA is partially destroyed; the protein deg-
radation can be seen in lane 9 and 10 (300 and 600 laser pulses) of the Ponceau S control. 
It was decided to use 10 pulses for further experiments, because significant labeling was 
observed with this small number of pulses. And, moreover, protein destruction or concen-
tration changes upon heat exposure can be avoided. This was especially important for later 
investigated BTN3A1 B30.2 which was used in small volumes of 90 µL.  
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Figure 50: Irradiation of 20 µM BSA in presence of 30 µM BioBP-HMBPP (103) in PBS pH 7.4 with an increasing 
number of laser pulses at 308 nm. Biotinylated protein bands are visualized using a streptavidin-coupled 
HRPO (horseradish peroxidase) chemiluminescence detection system. The protein load is visualized with Pon-
ceau S staining. The Western blot shown is representative of 3 independent experiments. 
Labeling of papain 
To have a second control, the enzyme papain was also checked for general protein labeling 
during the first irradiation experiments. A labeling of papain was successfully detected as 
shown in Figure 51, but to a much smaller extent than BSA (Figure 49). Papain in Figure 51 
is only barely visible even with 2.3 µg protein load on the gel for SDS-PAGE separation. Due 
to this finding BSA was later chosen as comparison protein for further labeling experiments. 
This finding can be explained by the fact that papain as an enzyme is very selective for only 
certain compounds, whereas BSA as a transport protein in the blood is specialized in bind-
ing and transporting many different types of substances, and therefore also has a higher 
affinity for probe 103. It might also be possible that papain, as a cysteine protease with 
broad activity range, is able to cleave the amide bond between biotin and linker-1 in probe 
103. Labeling may have taken place, but is no longer detectable due to the lack of biotin. 
 
Figure 51: Labeling of papain by BioBP-HMBPP (103) under different conditions. Protein concentration during 
irradiation was 20 or 2 µM together with 100 µM BioBP-HMBPP and an increasing number of laser pulses. 
B 2.2 Stimulation of γδ T cells by BioBP-HMBPP (103) 
Considering that its general applicability for protein labeling was proven, the question was 
now whether the HMBPP derivative 103 is still a Vγ9Vδ2 T cell activator. Therefore, the 
activation of Vγ9Vδ2 T cells in a titration experiment in comparison to HMBPP (102) was 
tested. Human PBMCs (peripheral blood mononuclear cells) were cultured with different 
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concentrations of BioBP-HMBPP (103) and HMBPP (102). Cultures were then analyzed for 
the activation of Vδ2+ T cells by measuring the expression of CD69 after 24 h. In addition, 
the PBMCs were analyzed for the expansion of the Vδ2+ population by determining the 
amount of Vδ2+ T cells after 7 days. Despite the fact that the HMBPP derivative 103 has a 
very large extension compared to HMBPP (102), probe 103 is still capable of activating 
Vγ9Vδ2 T cells and causing their proliferation (Figure 52). Not unexpectedly, because it is 
known that the free 4-hydroxy group is also very important[105], it is less active by a factor 
of about 3000 compared to HMBPP (102). 
The EC50 of three different donors for CD69 up-regulation after 24 h of culture with BioBP-
HMBPP 103 and HMBPP 102, resp., are summarized in Table 22, resulting in an EC50 shift 
of 2050 ± SD 1530. Looking at the proliferation response after 7 days in presence of IL-2 for 
HMBPP vs. BioBP-HMBPP, an EC50 shift of 3360 ± SD 650 was found (Table 22). 
Table 22: Individual IC50 values of the three different PBMC donors for CD69 up-regulation and proliferation 
response with natural immune modulator HMBPP 102 and label BioBP-HMBPP 103. 
CD69 up-regulation after 24 h 
Donor EC50 HMBPP [M] EC50 BioBP-HMBPP [M] 
1 1.88 x 10-9 3.14 x 10-6 
2 4.98 x 10-10 1.86 x 10-7 
3 1.69 x 10-9 1.27 x 10-6 
 
Proliferation response after 7 d in the presence of IL-2 
Donor EC50 HMBPP [M] EC50 BioBP-HMBPP [M] 
1 1.76 x 10-9 7.06 x 10-6 
2 1.09 x 10-9 2.95 x 10-7 
3 3.13 x 10-10 1.05 x 10-6 
The EC50 values obtained for each stimulation of one single donor were for BioBP-HMBPP 
4.45 x 10-6, 6.64 x   10-6, 3.50 x 10-6 M and for HMBPP 4.25 x 10-9, 3.88 x 10-9, 2.34 x 10-9 M, 
respectively, resulting in an EC50 shift of 1420 ± SD 340.  
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Figure 52: A and B: % CD69 upregulation. A: % CD69 expression of Vδ2 T cells after stimulation with BioBP-
HMBPP (59) or HMBPP (102) for 24 h. Values depict data from three donors stimulated with indicated con-
centrations of HMBPP (open symbols) or BioBP-HMBPP (full symbols) stained for CD69 and Vδ2 expression. 
Errors are SD of triplicate values from the respective donors. Curves indicate non-linear regression of depicted 
values. B: Data from A) normalized for highest and lowest value (no stimulus) for each condition. Curves 
indicate non-linear regression of depicted values. C and D: proliferation. C: % of Vδ2 T cells after 7 d stimula-
tion with BioBP-HMBPP or HMBPP. Values depict data from three donors stimulated with indicated concen-
trations of HMBPP (open symbols) or BioBP-HMBPP (full symbols) stained for CD3 and Vδ2 expression as 
described in materials and methods. Errors are SD of triplicate values. Curves indicate non-linear regression 
of depicted values. D: Data from C: normalized for highest and lowest value (no stimulus) for each condition. 
Curves indicate non-linear regression of depicted values. The experimental procedure can be viewed in the 
literature.[102] 
This data clearly indicates that despite the attachment of the large biotin-benzophenone 
moiety to the 4-hydroxyl group of HMBPP, the intact C5-diphosphate fragment is still capa-
ble of activating Vγ9Vδ2 T cells. However, its reduced activity may not only be the conse-
quence of the ether linked extension of the molecule. It might just stem from different 
pharmacokinetic properties such as a reduced uptake into the cells. This data is in agree-
ment to prior observations in which ester and ether-linked benzophenone HMBPP deriva-
tives were compared[124]. Here, Morita et al. report a 40–70-fold reduction in the activity 
of the ether-linked benzophenone HMBPP derivatives compared to the corresponding 
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esters. Figure 53 shows two examples of structures compared in those experiments. Ben-
zophenone in compound 105 is linked to HMBPP via an ether and in 106 via an ester bond. 
The esters showed indeed very similar activities as the parent compound HMBPP 102. The 
same was found in the work group of PD Dr. Sabine Amslinger when using independently 
prepared material of the ester linked benzophenone-HMBPP compound (E)-4-((4-benzo-
ylbenzoyl)oxy)-3-methylbut-2-en-1-yl diphosphate 106 (Figure 53, named BP-HMBPP in the 
Amslinger work group, previously named p-BZ-C-C5-OPP ester by Morita et al.[124]). More 
specifically, for the investigations performed in the Amslinger work group even a slightly 
higher stimulation for BP-HMBPP 106 than for HMBPP itself was obtained (data not shown). 
 
Figure 53: Structures of HMBPP combined with benzophenone by ether (105) and ester (106) linkage.[124] 
This effect could be based on a potentially higher cellular uptake of the more lipophilic BP-
HMBPP 106 combined with a release of active HMBPP (102) by ester hydrolysis within the 
cell. This effect could also explain why ester derivatives are more potent in general than 
the ether-linked compounds, which display high hydrolytic stability. Although one cannot 
completely rule out some ether hydrolysis over time, for photoaffinity probes, ether or at 
least amide bonds are preferable because phosphoantigen-specific labeling depends on an 
intact probe containing the recognition motif. 
B 2.3 Labeling of the B30.2 domain of the protein BTN3A1 by BioBP-
HMBPP (103) in the absence and presence of HMBPP (102)  
To prove whether BioBP-HMBPP (103) actually binds to the HMBPP binding site, the B30.2 
domain of the BTN3A1 protein was used.[114] Because BioBP-HMBPP (103) is about 3000 
times less active in stimulating Vγ9Vδ2 T cells, one can imagine that its binding affinity to 
the B30.2 domain is reduced compared to HMBPP. To test whether this is true and/or both 
diphosphates 102 and 103 compete for the same binding site, a titration experiment was 
set up. 
Labeling of BTN3A1 B30.2 and concentration studies 
BTN3A1 B30.2 was received as 312 and 340 µM stock solution in HEPES buffer, which were 
either stored at 4 °C or in aliquots at -20 °C as repeated freezing/thawing in -20 °C led to 
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dimerization. The protein was first tested for general labeling by BioBP-HMBPP, which was 
successful (Figure 54A). For good visibility during detection, a sufficient amount of BTN3A1-
B30.2 has to be submitted to gel electrophoresis and Western Blot. A protein amount of 
1 µg per lane was therefore determined for the further investigations after irradiation. Con-
centration experiments show strong labeling at a concentration of 60 µM and 100 µM Bi-
oBP-HMBPP but only weak and very weak labeling when irradiated solutions contained 
6/1.2 µM BTN3A1 and 1.7-fold BioBP-HMBPP. Since the 1.2 µM sample would have re-
quired a too-high sample volume for the gel loading, protein precipitation experiments 
with EtOH to obtain sufficient amounts of protein for loading were performed. As the Pon-
ceau S control (Figure 54A, lane 5 and 6) shows, this method was not successful. To have 
an optimized visualization, it was decided to use only sufficiently high protein concentra-
tions where precipitation is not necessary for further irradiation experiments. Therefore, 
further experiments were carried out initially with 60 µM protein. An HMBPP titration ex-
periment was set up using 60 µM BTN3A1 together with 100 µM BioBP-HMBPP (1.7 eq.) in 
PBS (Figure 54B). 0, 50 and 100 µM HMBPP was added to three aliquots of this solution 
each. After 30 min incubation on ice and laser irradiation (ten pulses), the labeling was de-
tected as shown and Ponceau S staining is additionally illustrated as control, showing the 
protein load for both irradiated samples and unirradiated controls. The detection shows a 
labeling gradient from the HMBPP-free sample, which shows strong protein labeling, to 
those samples with ½-molar and equimolar HMBPP concentration in comparison to probe 
103, where labeling significantly decreases. This indicates a displacement of label 103 from 
the binding pocket of BTN3A1 by the natural, 3000 times more affine ligand HMBPP. 
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Figure 54: A: Labeling experiments with different concentrations of BTN3A1 and BioBP-HMBPP (1.7-fold label 
excess each). Protein load: 1 µg per lane, * = protein was precipitated by EtOH prior to SDS-PAGE. B: Labeling 
of BTN3A1 by BioBP-HMBPP decreases in the presence of 0.5 and 1 eq. HMBPP. 
Therefore, further experiments with this protein concentration were initially carried out. 
But, since these results were not reproducible with a concentration combination of 
BTN3A1/BioBP-HMBPP 60/100 µM in all cases, experiments with lower concentrations 
were carried out for optimization. This should prevent potential protein agglomeration 
which can lead to irradiation inaccuracy. Figure 55 shows an example for such an experi-
ment. Irradiation was performed on samples with 30, 15 and 5 µM BTN3A1 and 1.5 eq. 
BioBP-HMBPP each. To study the effect of HMBPP presence on these sample mixtures, 0, 
2 and 10 eq. HMBPP (compared to label BioBP-HMBPP) were added to three aliquots of 
each sample. A displacement of the probe from the binding site leading to a reduced label-
ing of BTN3A1 is seen for the 30 and 15 µM sample, and also in the 5 µM sample, but to a 
smaller extent. Based on these experiments 20 µM protein concentration was used for fur-
ther studies. 
A 
B 
Characterization of a new photoactive protein probe for the labeling of BTN3A4 
126 
 
Figure 55: Labeling of BTN3A1 B30.2 by BioBP-HMBPP 103 in the presence and absence of 0, 2 and 20 eq. of 
HMBPP in comparison to probe 103. Different concentrations of protein BTN3A1 B30.2 and probe 103 are 
tested. 
Binding of BioBP-HMBPP to the HMBPP binding site of BTN3A1 is displaced by HMBPP, 
comparison experiments with BSA 
Thus, the following concentrations were selected as conditions for this titration experi-
ment: 20 µM protein solutions of the BTN3A1 B30.2 domain and BSA as control for unspe-
cific binding together with a 30 µM solution (1.5 equivalents compared to proteins) of Bi-
oBP-HMBPP (103), as well as different concentrations of the natural phosphoantigen 
HMBPP (0, 0.50, 1.0, 2.0, 10 equiv. compared to BioBP-HMBPP) (Figure 56 and Figure 57). 
As can be seen from the protein bands in Figure 56 and Figure 57, upon irradiation, increas-
ing amounts of HMBPP (102) strongly decreased the labeling of the B30.2 domain of 
BTN3A1 in a concentration-dependent manner, whereas for BSA, no such disruption of la-
beling was observed. Particularly, there was no significant difference between BSA alone 
and different amounts of HMBPP. Notably, the competition effect by HMBPP is not com-
plete even when HMBPP is present in a 10-times higher concentration than BioBP-HMBPP 
or even higher (up to 50 equiv., Figure 56, lane 7, 1500 µM HMBPP).  
 
Figure 56: Irradiation experiment with 20 µM BTN3A1 B30.2 and 30 µM BioBP-HMBPP 103 in competition 
with HMBPP in increasing concentrations: 0, ½, 1, 2, 10 and 50-fold excess. 
This is an indication that BioBP-HMBPP (103) has either some residual binding to the bind-
ing pocket in presence of HMBPP or, more likely, binds also in part non-specifically to 
BTN3A1 as it does to BSA. This demonstration of partial competition of labeling by the 
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original ligand (HMBPP) makes probe 103 a promising candidate tool to identify HMBPP-
binding molecules. A previously presented similar probe by Morita et al. also containing a 
biotin-linked benzophenone unit attached to HMBPP was not successful in specifically la-
beling BTN3A1 compared to BTN3A2 and chicken ovalbumin[125]. Nevertheless, this probe 
was a very active Vγ9Vδ2 T cell stimulator and most likely is more active than 103. This 
stronger bioactivity may be a consequence of attaching the HMBPP unit with an ester link-
age and a subsequent release of HMBPP. Moreover, their finding of a non-specific protein 
labeling is in agreement with our data that proves general protein labeling by such probes. 
It would also be interesting to learn to which extent it might be inhibited by competition 
with the physiological ligand HMBPP. 
Figures of the detection of all experiments with BTN3A1 and BSA used for the calculations 
depicted in Figure 57 together with additional experiments performed with 60 µM 
BTN3A1/BSA and 100 µM probe 103 can be viewed in the appendix. 
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Figure 57: Irradiation at 308 nm of 20 µM of proteins BTN3A1 B30.2 domain (BTN3A1) and BSA in presence 
of 30 µM BioBP-HMBPP (103) together with increasing concentrations of HMBPP (102) (0–300 µM). Densito-
metric evaluation of Western blot graphs from 3–4 independent experiments: A: Means with standard devi-
ations; levels of significance: * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. B: Single experiments: left (black 
symbols) BTN3A1, right (grey symbols): BSA. C: Representative Western blots of biotinylated protein bands. 
B 2.4 Labeling of a BTN3A1-B30.2 charge transfer mutant 
A charge reversal mutant of the B30.2 domain of BTN3A1 was also available for labeling 
experiments.[114] In contrast to the wild type, the mutant of BTN3A1 possesses amino acids 
with negative instead of positive charged amino acid residues which bind the diphosphate 
motif of HMBPP or PAgs resp. exactly at the HMBPP binding site of its amino acid sequence. 
This of course has dramatic effects on the function of the protein, since HMBPP is no longer 
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able to bind to this site. It also appeared that the stability of this mutant was considerably 
diminished. During the experiments with the mutant, cleavage into smaller and eventually 
undetectable fragments occurred with prolonged storage. Neither storage at 4 °C nor in 
aliquots at -20 °C had any positive effect on its stability.  
Like BSA, the mutant was also used to investigate any non-specific labeling by probe 103 
and to test the influence of increasing HMBPP concentrations on labeling. Figure 58 shows 
an experiment where labeling of the BTN3A1 mutant is visible with 60 µM protein concen-
tration and a concentration of 100 µM of probe 103. In this example, the above-mentioned 
instability is visible by the appearance of a further protein band with lower molecular 
weight in both Ponceau S staining and detection of biotinylated proteins. Experiments with 
both 60/100 µM and 20/30 µM mutant/probe were performed. An influence of HMBPP on 
the labeling is visible, but not in a concentration-dependent manner. Samples without 
HMBPP show strongest labeling with the most prominent protein band whereas in the 
presence of HMBPP labeling decreases (see Figure 58 and appendix). However, the de-
tected protein bands in the HMBPP-containing samples have different intensities which, in 
contrast to the BTN3A1 wild type, do not correlate with increasing HMBPP concentrations. 
In all tests with the mutant, the intensities appear rather randomly distributed. It can there-
fore be stated that the binding of HMBPP to BTN3A1 has deteriorated due to the reversal 
of the charge in the HMBPP binding pocket. Since otherwise no further changes were made 
to the mutant in contrast to the wild type, HMBPP can still potentially interact in a non-
ionic way with BTN3A1. Therefore, the reduction of labeling by HMBPP is less visible. 
 
Figure 58: HMBPP titration experiment performed with the charge reversal mutant of BTN3A1 B30.2, showing 
stability issues, visible by the protein fraction of 20 kDa. * = Sample contains protein ladder marker proteins. 
B 2.5 Determination of labeling efficiency by BioBP-HMBPP 
To get an idea of the efficiency of the labeling by probe 103, equal amounts of a monobi-
otinylated BTN3A1 B30.2 domain with the wild type B30.2 domain that was incubated with 
BioBP-HMBPP (103) and irradiated at 308 nm as usual were compared (Figure 59). Using 
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the typical conditions of 1.5 equivalents (30 µM) of 103 compared to BTN3A1, a strong 
protein band in the Western blot was found. The observed band is in between the signals 
of 10 and 100 ng of the monobiotinylated BTN3A1 protein. Evaluating the intensities of the 
blot by densitometry, it can be estimated that about 7% of BTN3A1 is typically labeled in 
these experiments. On the contrary, when using 0.5 equivalents of probe 103, which is a 
third of the standard concentration, a significantly lower amount of labeling of around 2% 
was detected. 
 
Figure 59: Determination of labeling efficiency. 1 µg irradiated protein samples of 20 µM of the BTN3A1 B30.2 
domain with 10 or 30 µM BioBP-HMBPP (103) were compared with different amounts of a monobiotinylated 
BTN3A1 B30.2 domain. * = two samples from independent experiments were loaded. 
B 3 Summary of Chapter B 
The general labeling ability of the new, photoactivable probe BioBP-HMBPP (103) was 
proven for all four investigated proteins BSA; papain, BTN3A1 B30.2 wild type and charge 
transfer mutant at concentrations of 2-60 µM protein. Laser irradiation at 308 nm was suc-
cessfully used for this purpose and proved to be a very effective tool. When the phospho-
antigen binding domain of BTN3A1 30.2 was challenged by adding HMBPP (102) together 
with BioBP-HMBPP (103), a clear concentration-dependent decay of labeling was observed 
proving the higher affinity of HMBPP compared to BioBP-HMBPP. This finding is in agree-
ment with the fact that 103 is a Vγ9Vδ2 T cell activator, albeit less active by about 3000 
times than natural ligand 102. However, labeling of the B30.2 domain of BTN3A1 was at 
least partially non-specific as labeling was detected even with 50-fold excess of HMBPP. 
The labeling of BSA as a random model protein was not impaired in the presence of addi-
tional HMBPP. These results demonstrate the specific binding of BioBP-HMBPP to the C5-
diphosphate binding unit, which occurs in the BTN3A1 30.2 domain. Probe 103 is a useful 
tool to discover further unknown proteins involved in Vγ9Vδ2 T cell activation.  
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B 4 Experimental 
B 4.1 General information 
HMBPP (102) was synthesized by Sabine Amslinger according to a previously published pro-
cedure.[104] BSA (Cohn fraction V, pH 5) was purchased from Biomol (Hamburg, Germany) 
and papain, extracted from Carica papaya, from Sigma Aldrich (Buchs, Switzerland). De-
scriptions of the following procedures are available in the publication:[102] The probe BioBP-
HMBPP was synthesized by Sabine Amslinger and Andrea Mattarei, University of Regens-
burg.[102] Stimulation assays were performed by Mohindar Murugesh Karunkaran, Brigitte 
Kimmel and Thomas Herrmann, University of Würzburg. 
Stock solutions of the following proteins were prepared by Siyi Gu and Erin J. Adams, De-
partment of Biochemistry and Molecular Biology, University of Chicago, USA, according to 
known procedures: BTN3A1 domain 30.2 (312 and 340 µM); [114] BTN3A1 domain 30.2 
charge reversal mutant (77.3 and 135 µM);[114] biotinylated BTN3A1 domain B30.2 
(46.8 µM).[102] 
B 4.2 Photochemical labeling of proteins with BioBP-HMBPP and Western 
Blot analysis of biotinylated proteins 
Sample preparation and irradiation 
Stock solutions of BSA (200 µM) and HMBPP (10 mM) were prepared directly in PBS buffer 
pH 7.4, while a 100 mM BioBP-HMBPP solution in DMSO was further diluted to 1 mM Bi-
oBP-HMBPP with PBS buffer pH 7.4 in a second step. Samples of 2 mL for the UV-Vis exper-
iments with BSA and 100 µL in all other cases were prepared containing proteins (either 
BSA, papain, BTN3A1 domain B30.2 or BTN3A1 reversal charge mutant) in the given final 
concentrations together with 1.5-1.7 eq. BioBP-HMBPP and increasing HMBPP concentra-
tions, where necessary. All samples were incubated on ice for 30 min in the dark prior to 
irradiation. Controls (10 µL of each sample) were not irradiated. Pipetting of small volume 
samples into the narrow cuvettes was performed with Pipettor tips Mµltiflex® tips (Carl 
Roth GmbH, Karlsruhe, Germany). Irradiation was performed at room temperature in slit 
quartz cuvettes (volume 500 µL, slit diameter 2 mm) with the excimer laser Puls-Master 
PM-840 (LightMachinery, Ottawa, Canada) at a wavelength of 308 nm. For each irradiation 
10 or the indicated number of pulses were used. The pulse duration was 10 ns, the pulse 
energy 215–250 mJ with a frequency of 1 Hz.  
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SDS-PAGE and Western Blot 
The irradiated samples as well as the non-irradiated controls were diluted (PBS buffer pH 
7.4 (10 mM Na2HPO4, 1.8 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl) pH 7.4/loading buffer 
(60 mM Tris-HCl, 5% sodium dodecyl sulfate, 30% glycerol, 10% saccharose, 3% β-mercap-
toethanol, 0.5% bromophenol blue) 1:1) to 10 µL volume that contained 1 µg or the indi-
cated amount of protein, heated at 95 °C for 5 min and separated by 15% SDS-polyacryla-
mide gel electrophoresis. Then, proteins were blotted on a PVDF membrane (0.45 mm, Mil-
lipore, Billerica, MA, USA) with a subsequent blotting control step (Ponceau S staining with 
0.1% (w/v) Ponceau S (3-hydroxy-4-(2-sulfo-4-[4-sulfophenylazo]phenylazo)-2,7-naphtha-
lenedisulfonic acid sodium salt) in 5% aqueous acetic acid). For the Ponceau S staining the 
membranes were shaken in Ponceau S solution for 5 min and the red color was subse-
quently washed off the membranes with water. After this washing step only the protein 
bands remained colored red and were photographically documented. The membranes 
were then blocked with freshly prepared 5% low fat milk suspension in TBS-T (Tris-buffered 
saline, 20 mM Tris, 140 mM NaCl with 0.1% Tween = washing buffer, 1 h, room tempera-
ture or 4 °C, overnight) and incubated with streptavidin-horseradish peroxidase (HRPO, 
Leinco Technologies Inc., Fenton, Missouri, USA) in washing buffer (0.2 mg/mL streptavi-
din-HRPO, 30 min, room temperature). After washing (4 x 15 min with washing buffer) the 
blotted proteins were detected using a chemiluminescence substrate kit (Super Signal West 
Dura Extended Duration Substrate; Thermo Fisher Scientific, Rockford, Illinois, USA) and 
the biotinylated proteins were visualized with a luminescent image analyzer (LAS 3000, Fu-
jifilm, Düsseldorf, Germany). Densitometric quantification was performed using the ImageJ 
for Windows Version: 1.45 software (Softonic International S.A., Barcelona, Spain) and den-
sities were captured from non-saturated images. Comparison between groups was made 
using a two-sided paired Student’s t test. A p value <0.05 was considered statistically sig-
nificant. Calculations were performed using Microsoft Office Excel 2010.  
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D Appendix 
D 1 NMR spectra of synthesized compounds 
1-(2-Methyl-2,5-diphenyl-1,3,4-oxadiazol-3(2H)-yl)prop-2-en-1-one (OXE1) in CDCl3 
1H NMR: 
 
13C NMR:  
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1-(5-(4-Methoxyphenyl)-2-methyl-2-phenyl-1,3,4-oxadiazol-3(2H)-yl)prop-2-en-1-one 
(OXE1-(OMe)’’) in CDCl3 
1H NMR: 
 
13C NMR: 
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1-(2-(4-methoxyphenyl)-2-methyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)prop-2-en-1-
one (OXE1-OMe,(4py)’’) in CDCl3 
1H NMR: 
 
13C NMR: 
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1-(2-Methyl-2-phenyl-5-(quinolin-6-yl)-1,3,4-oxadiazol-3(2H)-yl)prop-2-en-1-one         
(OXE1-(6qui)’’) in CDCl3 
1H-NMR: 
 
13C NMR:  
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1-(2-Methyl-2-phenyl-5-(quinolin-6-yl)-1,3,4-oxadiazol-3(2H)-yl)prop-2-en-1-one         
(OXE1-(6qui)’’) in acetone-d6 
1H-NMR: 
 
13C NMR:  
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1-(2-(4-Nitrophenyl)-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)prop-2-en-1-one             
(OXE2-NO2,(4py)’’) in CDCl3 
1H-NMR: 
 
13C NMR:  
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1-(2-Phenyl-5-(pyridin-4-yl)-2-(trifluoromethyl)-1,3,4-oxadiazol-3(2H)-yl)prop-2-en-1-on    
(OXE3-(4py)’’) in CDCl3 
1H-NMR: 
 
13C NMR:  
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19F NMR: 
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(E)-1-(2,5-Diphenyl-1,3,4-oxadiazol-3(2H)-yl)-3-(4-methoxyphenyl)prop-2-en-1-one     
(OXE8-(OMe)’) in CDCl3 
1H-NMR: 
 
13C NMR:  
  
Appendix 
148 
(E)-1-(2-(4-Methoxyphenyl)-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)-3-phenylprop-2-en-
1-one (OXE8-OMe,(4py)’’) in CDCl3 
1H-NMR: 
 
13C NMR:  
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3-Phenyl-1-(2-phenyl-5-(pyridine-4-yl)-1,3,4-oxadiazol-3(2H)-yl)propan-1-one               
(OXE8-(4py)’’-H2) in CDCl3 
1H-NMR: 
 
13C NMR:  
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(2-Methyl-2-phenyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)(oxiran-2-yl)methanone 
(OXEp1-(4py)’’) 
1H-NMR in CDCl3: 
 
1H-NMR in DMSO-d6: 
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4-(4-(But-2-enoyl)-5-methyl-5-phenyl-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridine-1-oxide 
(OXE4-(4py-N-oxide)‘‘) in CDCl3 
1H-NMR: 
 
13C NMR:  
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(E)-4-(4-(Cinnamoyl-5-phenyl-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridine-1-oxide            
(OXE8-(4py-N-oxide)’’) in CDCl3 
1H-NMR: 
 
13C NMR:  
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1-(2-Isopropoxy-4-methoxyphenyl)-2-nitroethan-1-one (68) in CDCl3 
1H-NMR: 
 
13C NMR:  
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(E)-3-(3,4-dimethoxyphenyl)-1-(2-isopropoxy-4-methoxyphenyl)-2-nitroprop-2-en-1-one 
(70) in CDCl3 
1H-NMR: 
 
13C NMR:  
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2-(3,4-Dimethoxyphenyl)-6-methoxy-3-nitrochroman-4-one (NO2-Flavanone) with approx-
imately 10% of isomer α-NO2-HC in CDCl3 
1H-NMR: 
 
13C NMR:  
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2-(3,4-Dimethoxyphenyl)-6-methoxy-3-nitrochroman-4-one (NO2-Flavanone) in DMSO-d6 
1H-NMR: 
 
13C NMR:  
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10-Acetyl-8-chloro-10,10a-dihydro-3H-phenoxazine-3,7-diyl diacetate (89) in CDCl3 
1H-NMR: 
 
13C NMR:  
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1-(8-Chloro-3,7-dihydroxy-3,10a-dihydro-10H-phenoxazin-10-yl)ethan-1-one (90) in Ace-
tone-d6 
1H-NMR: 
 
13C NMR:  
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10-Acetyl-8-chloro-10,10a-dihydro-3H-phenoxazine-3,7-diyl bis(trifluoromethanesulfo-
nate) (92) in CDCl3 
1H-NMR: 
 
13C NMR:  
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19F-NMR: 
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2-(6-(4-(tert-Butylthio)phenyl)-3-oxo-3H-xanthen-9-yl)benzoic acid (99) in CDCl3 
1H-NMR: 
 
13C NMR:  
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D 2 Pre-kinetic UV-Vis spectra of OXEs 
 
Figure 60: Pre-kinetic UV-Vis investigations: Time-dependent absorption spectra of 40 µM OXEs in 100 mM 
TRIS-HCl buffer pH 7.4, 2 mM EDTA/ethylene glycol 20:80 with and without cysteamine. A: OXE1 + 100-fold 
cysteamine, B: OXE1-(CN)’’ + 20-fold cysteamine, C: OXE1-(NO2)’’ + 20-fold cysteamine, D: OXE1-(OMe)’’ + 
20-fold cysteamine, * = abbreviated: OXE1; E: OXE1-NO2,(4py)’’ + 20-fold cysteamine, * = abbreviated: OXE1-
NO2; F: OXE1-CF3,(4py)’’ + 20-fold cysteamine, * = abbreviated: OXE1-CF3; G: OXE1-OCF3,(4py)’’ + 20-fold 
cysteamine, * = abbreviated OXE1-OCF3; H: OXE1-OMe,(4py)’’ + 20-fold cysteamine, * = abbreviated OXE1-
OMe.  
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Pre-kinetic investigations: Time dependent UV-Vis spectra of OXE1s 
 
 
Figure 61: Pre-kinetic UV-Vis investigations: Time-dependent absorption spectra of 40 µM OXEs in 100 mM 
TRIS-HCl buffer pH 7.4, 2 mM EDTA/ethylene glycol 20:80 with and without cysteamine. A: OXE1-4py,(4py)’’ 
+ 20-fold cysteamine, * = abbreviated OXE1-4py; B: OXE1-2py,(4py)’’ + 20-fold cysteamine, * = abbreviated 
OXE1-2py; C: OXE1-(4py-N-oxide)’’ + 20-fold cysteamine, * = abbreviated OXE1-Nox; D: OXE1-(6qui)’’ + 20-
fold cysteamine; E: α-OXE1-(4py)’’ + 500-fold cysteamine, * = abbreviated α-Me-OXE1. 
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Pre-kinetic investigations: Time dependent UV-Vis spectra of OXE2, OXE3, OXE4, OXE5s 
 
 
Figure 62: Pre-kinetic UV-Vis investigations: Time-dependent absorption spectra of 40 µM OXEs in 100 mM 
TRIS-HCl buffer pH 7.4, 2 mM EDTA/ethylene glycol 20:80 with and without cysteamine. A: OXE2-(4py)’’ + 20-
fold cysteamine; B: OXE2-NO2,(4py)’’ + 20-fold cysteamine, * = abbreviated OXE2-NO2; C: OXE2-OMe,(4py)’’ 
+ 20-fold cysteamine, * = abbreviated OXE2-OMe; D: OXE2-(2na)’’ + 20-fold cysteamine; E: OXE3-(4py)’’ + 
20-fold cysteamine; F: OXE4-(4py)’’ + 500-fold cysteamine; G: OXE4-(4py-N-oxide)’’ + 500-fold cysteamine, * 
= abbreviated OXE4; H: OXE5-(4py)’’ + 100-fold cysteamine.  
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Pre-kinetic investigations: Time dependent UV-Vis spectra of OXE7s and OXCE 
 
 
Figure 63: Pre-kinetic UV-Vis investigations: Time-dependent absorption spectra of 40 µM OXEs in 100 mM 
TRIS-HCl buffer pH 7.4, 2 mM EDTA/ethylene glycol 20:80 with and without cysteamine. A: OXE7 + 500-fold 
cysteamine; B: OXE7-(4py)’’ + 500-fold cysteamine, * = abbreviated OXE7; C: OXE7-OMe,(4py)’’ + 500-fold 
cysteamine, * = abbreviated OXE7; D: OXE7-(CF3)’’,(4py)’’ + 500-fold cysteamine, * = abbreviated OXE7-CF3; 
E: OXCE-(4py)’’ + 500-fold cysteamine, * = abbreviated OXCE. 
  
B 
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Pre-kinetic investigations: Time dependent UV-Vis spectra of OXE8s 
 
Figure 64: Pre-kinetic UV-Vis investigations: Time-dependent absorption spectra of 40 µM OXEs in 100 mM 
TRIS-HCl buffer pH 7.4, 2 mM EDTA/ethylene glycol 20:80 with and without cysteamine. A: OXE8-(OMe)’ + 
500-fold cysteamine; B: OXE8-(4py)’’ + 500-fold cysteamine, * = abbreviated OXE8; C: OXE8-NO2,(4py)’’ + 
500-fold cysteamine, * = abbreviated OXE8-NO2; D: OXE8-OMe,(4py)’’ + 500-fold cysteamine, * = abbrevi-
ated OXE8-OMe; E: OXE8-(OMe)2,(4py)’’ + 500-fold cysteamine, * = abbreviated OXE8-(OMe)2; F: OXE8-
(OMe)’,(4py)’’ + 500-fold cysteamine, * = abbreviated OXE-(OMe)’; G: OXE8-OMe,(OMe)’,(4py)’’ + 500-fold 
cysteamine, * = abbreviated OXE8-OMe; H: OXE8-(4py-N-oxide)’’ + 500-fold cysteamine, * = abbreviated 
OXE8-Nox.   
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D 3 Additional figures for the kinetic evaluation of OXEs and OXE 
analogues 
Decay figures of the stopped-flow assay of OXE3-(4py)’’ with cysteamine 100-300 fold 
 
Figure 65: Representative exponential decay curves for the reaction of 40 µM OXE3-(4py)’’ with 100, 150, 
200, 250 and 300 fold of cysteamine in 100 mM TRIS-HCl buffer pH 7.4, 2 mM EDTA/ethylene glycol 20:80. 
The measurement was done by stopped-flow technique. The results of the kobs values are given as k values.  
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Decay curves from plate assay of OXE1 with cysteamine (part 1) 
 
Figure 66: Representative exponential decay curves for the reaction of 40 µM OXE1 with 0, 60 and 72 fold of 
cysteamine at 330 nm in 100 mM TRIS-HCl buffer pH 7.4, 2 mM EDTA/ethylene glycol 20:80 (duplicates). 380 
data points were gained all 18 s. The results of the 1/kobs values are given in the little tables as t1 values.  
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Decay curves from plate assay of OXE1 with cysteamine (part 2) 
 
Figure 67: Representative exponential decay curves for the reaction of 40 µM OXE1 with 84, 96 and 108 fold 
of cysteamine at 330 nm in 100 mM TRIS-HCl buffer pH 7.4, 2 mM EDTA/ethylene glycol 20:80 (duplicates). 
380 data points were gained all 18 s. The results of the 1/kobs values are given in the little tables as t1 values.  
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k2 determinations of OXE1, OXE1-(CN)’’, OXE1-(NO2)’’, OXE1-(OMe)’’, OXE1-(4py)’’ and 
OXE1-NO2,(4py)’’ with cysteamine by linear regression 
 
Figure 68: Representative k2 value determinations for compounds OXE1, OXE1-(CN)’’, OXE1-(NO2)’’, OXE1-
(OMe)’’, OXE1-(4py)’’ and OXE1-NO2,(4py)’’ with cysteamine. Kobs values were plotted against cysteamine 
concentrations and a linear fit was applied to give the corresponding k2 values.  
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k2 determinations of OXE1-CF3,(4py)’’, OXE1-OCF3,(4py)’’, OXE1-OMe,(4py)’’, OXE1-
4py,(4py)’’, OXE1-2py,(4py)’’ and OXE1-(4py-N-oxide)’’ with cysteamine by linear regres-
sion 
 
Figure 69: Representative k2 value determinations for compounds OXE1-CF3,(4py)’’, OXE1-OCF3,(4py)’’, 
OXE1-OMe,(4py)’’, OXE1-4py,(4py)’’, OXE1-2py,(4py)’’ and OXE1-(4py-N-oxide)’’ with cysteamine. Kobs val-
ues were plotted against cysteamine concentrations and a linear fit was applied to give the corresponding k2 
values. 
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k2 determinations of OXE1-(6qui)’’, OXE2-(4py)’’, OXE2-NO2,(4py)’’, OXE2-OMe,(4py)’’, 
OXE2-(2na)’’ and OXE3-(4py)’’ with cysteamine by linear regression 
 
Figure 70: Representative k2 value determinations for compounds OXE1-(6qui)’’, OXE2-(4py)’’, OXE2-
NO2,(4py)’’, OXE2-OMe,(4py)’’, OXE2-(2na)’’ and OXE3-(4py)’’ with cysteamine. Kobs values were plotted 
against cysteamine concentrations and a linear fit was applied to give the corresponding k2 values. 
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k2 determinations of OXE4-(4py)’’, OXE4-(4py-N-oxide)’’, OXE5-(4py)’’, OXE7-CF3,(4py)’’, 
OXE8-(4py)’’ and OXE8-NO2,(4py)’’ with cysteamine by linear regression 
 
Figure 71: Representative k2 value determinations for compounds OXE4-(4py)’’, OXE4-(4py-N-oxide)’’, OXE5-
(4py)’’, OXE7-CF3,(4py)’’, OXE8-(4py)’’ and OXE8-NO2,(4py)’’ with cysteamine. Kobs values were plotted 
against cysteamine concentrations and a linear fit was applied to give the corresponding k2 values. 
  
Appendix 
174 
k2 determinations of OXE8-OMe,(4py)‘‘, OXE8-(OMe)2(4py)’’, OXE8-OMe,(NO2),(4py)’’, 
OXE8-(OMe)’,(4py)’’, OXE8-OMe,(OMe)’,(4py)’’ and OXE8-(4py-N-oxide)’’ with cysteam-
ine by linear regression 
 
Figure 72: Representative k2 value determinations for compounds OXE8-OMe,(4py)’’, OXE8-(OMe)2(4py)’’, 
OXE8-OMe,(NO2),(4py)’’, OXE8-(OMe)’,(4py)’’, OXE8-OMe,(OMe)’,(4py)’’ and OXE8-(4py-N-oxide)’’ with 
cysteamine. Kobs values were plotted against cysteamine concentrations and a linear fit was applied to give 
the corresponding k2 values. 
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Decay curves from MS kinetic assay of OXE4-(4py)‘‘ with cysteamine  
 
Figure 73: All exponential decay curves for the reaction of 40 µM OXE4-(4py)’’ with 500, 600 and 700 fold of 
cysteamine in 100 mM TRIS-HCl buffer pH 7.4, 2 mM EDTA/ethylene glycol 20:80 (triplicates). Data points 
were gained after 2, 20, 40, 60, 80, 100, 120 min, then 2.5, 3, 3.5, 4, 4.5, 5, 6, 8 and 24 h. In some cases, the 
2 and/or 20 min data point is missing due to detection issues: no substance detectable. The results of the 
1/kobs values are given in the little tables as t1 values. 
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Decay curves from MS kinetic assay of OXEp1-(4py)‘‘ with cysteamine 
 
Figure 74: All exponential decay curves for the reaction of 40 µM OXEp1-(4py)’’ with 500, 600 and 700 fold 
of cysteamine in 100 mM TRIS-HCl buffer pH 7.4, 2 mM EDTA/ethylene glycol 20:80 (triplicates). Data points 
were gained after 2, 20, 40, 60, 80, 100, 120 min, then 2.5, 3, 3.5, 4, 4.5, 5, 6, 8 and 24 h. In some cases, the 
2 and/or 20 min data point is missing due to detection issues: no substance detectable. The results of the 
1/kobs values are given in the little tables as t1 values. 
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D 4 LC-MS data of juglone derivatives in kinetic assay buffer 
Note: Only compounds with distinct and conclusive MS AND UV-Vis data were evaluated. 
Assay fragments and other unknown compounds which appeared only in the LC-run and/or 
in the UV-Vis detection with no evaluable MS data and/or no UV-Vis absorbance > 200 nm 
were not considered in the evaluation. 
80 µM juglon (33a) without cysteamine after 10 min – 1 h
 
80 µM juglon (33a) with 500-fold cysteamine after 10 min – 1 h
 
 
40 µM O-methyljuglon (33b) without cysteamine after 3-5 h 
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40 µM O-methyljuglon (33b) with 500-fold cysteamine after 3-5 h 
 
40 µM 3-bromojuglon (33c) without cysteamine after 3-5 h 
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40 µM 3-bromojuglon (33c) with 500-fold cysteamine after 3-5 h 
 
40 µM 3-bromo-O-methyljuglon (33d) without cysteamine after 3-5 h 
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40 µM 3-bromo-O-methyljuglon (33d) with 500-fold cysteamine after 3-5 h 
 
40 µM 3-chlorojuglon (33e) without cysteamine 
 
40 µM 3-chlorojuglon (33e) with 500-fold cysteamine after 3-5 h 
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40 µM 3-chloro-O-methyljuglon (33f) without cysteamine after 3-5 h 
 
40 µM 3-chloro-O-methyljuglon (33f) with 500-fold cysteamine after 3-5 h 
 
40 µM 3-fluoro-O-methyljuglon (33g) without cysteamine after 3-5 h 
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40 µM 3-fluoro-O-methyljuglon (33g) with 500-fold cysteamine after 3-5 h 
 
40 µM 3-azidojuglon (33h) without cysteamine after 3-5 h 
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40 µM 3-azidojuglon (33h) 500-fold cysteamine after 3-5 h 
 
40 µM 3-azido-O-methyljuglon (33i) without cysteamine after 3-5 h 
 
40 µM 3-azido-O-methyljuglon (33i) with 500-fold cysteamine after 3-5 h 
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40 µM 3-aminojuglon (33j) without cysteamine 
 
40 µM 3-aminojuglon (33j) with 500-fold cysteamine after 3-5 h 
 
40 µM 3-amino-O-methyljuglon (33k) without cysteamine after 3-5 h 
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40 µM 3-amino-O-methyljuglon (33k) with 500-fold cysteamine after 3-5 h 
 
40 µM 3-piperidinojuglon (33l) without cysteamine 
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40 µM 3-piperidinojuglon (33l) with 500-fold cysteamine after 3-5 h 
 
40 µM 2-piperidinojuglon (33m) without cysteamine 
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40 µM 2-piperidinojuglon (33m) with 500-fold cysteamine after 3-5 h 
 
40 µM 3-morpholinojuglon (33n) without cysteamine 
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40 µM 3-morpholinojuglon (33n) with 500-fold cysteamine after 3-5 h 
 
40 µM 2-morpholinojuglon (33o) without cysteamine 
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40 µM 2-morpholinojuglon (33o) with 500-fold cysteamine after 3-5 h 
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D 5 Additional figures for protein labeling experiments 
BTN3A1 B30.2: HMBPP titration experiments: 20 µM protein with 30 µM probe 
 
Figure 75: BTN3A1 B30.2 domain labeling with BioBP-HMBPP, competition with HMBPP. A-D: Four repetition 
experiments with 20 µM protein and 30 µM probe. Protein bands are stained with Ponceau S (red). 
 
BTN3A1 B30.2: HMBPP titration experiments: 60 µM protein with 100 µM probe 
 
Figure 76: Labeling experiments with the wild type of the BTN3A1 B30.2 domain and BioBP-HMBPP, compe-
tition with HMBPP. A-D: Four experiments with 60 µM protein and 100 µM probe. Protein bands are stained 
with Ponceau S (red). * = sample contains prestained protein standard.  
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BSA: HMBPP titration experiments: 20 µM protein with 30 µM probe 
 
Figure 77: Labeling experiments with BSA and BioBP-HMBPP, competition with HMBPP. A-D: Repetition ex-
periments with 20 µM protein and 30 µM probe. Protein bands are stained with Ponceau S (red). * = sample 
contains prestained protein standard. 
 
BSA: HMBPP titration experiments: 60 µM protein with 100 µM probe 
 
Figure 78: Labeling experiments with BSA and BioBP-HMBPP, competition with HMBPP. A-B: Experiments 
with 60 µM protein and 100 µM probe. Protein bands are stained with Ponceau S (red). * = sample contains 
prestained protein standard. 
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Charge Reversal Mutant of BTN3A1 B30.2: HMBPP titration experiment: 20 µM protein-
with 30 µM probe 
 
Figure 79: Labeling experiment with the BTN3A1 B30.2 charge reversal mutant and BioBP-HMBPP, competi-
tion with HMBPP, 20 µM protein and 30 µM probe. Protein bands are stained with Ponceau S (red). * = sample 
contains prestained protein standard.  
 
Charge Reversal Mutant of BTN3A1 B30.2: HMBPP titration experiments: 60 µM protein-
with 100 µM probe 
 
Figure 80: Labeling experiments with the BTN3A1 B30.2 charge reversal mutant and BioBP-HMBPP, compe-
tition with HMBPP. A-C: Three experiments with 60 µM protein and 100 µM probe. Protein bands are stained 
with Ponceau S (red). * = sample contains prestained protein standard. 
 
 
